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Background: An in-depth understanding of the fundamental principles that regulate thyroid hormone homeostasis
is critical for the development of new diagnostic and treatment approaches for patients with thyroid disease.
Summary: Important clinical practices in use today for the treatment of patients with hypothyroidism, hyper-
thyroidism, or thyroid cancer are the result of laboratory discoveries made by scientists investigating the most
basic aspects of thyroid structure and molecular biology. In this document, a panel of experts commissioned by the
American Thyroid Association makes a series of recommendations related to the study of thyroid hormone
economy and action. These recommendations are intended to promote standardization of study design, which
should in turn increase the comparability and reproducibility of experimental findings.
Conclusions: It is expected that adherence to these recommendations by investigators in the field will facilitate
progress towards a better understanding of the thyroid gland and thyroid hormone dependent processes.
INTRODUCTION
Over the past 150 years, investigators utilizing animaland cell culture–based experimental models have
achieved landmark discoveries that have shaped our under-
standing of thyroid physiology and disease. From the iden-
tification of the long-acting thyroid stimulator to the
discovery of antithyroid drugs, basic research studies have
provided the fundamentals upon which our clinical diag-
nostic and therapeutic tools are based. Tens of thousands of
publications indexed on PubMed (www.pubmed.gov) fea-
ture cells or small animals made hypothyroid or thyrotoxic.
The great similarities in multiple aspects of thyroid physi-
ology between humans and small rodents have facilitated the
rapid translation of experimental findings to the clinical
realm. At the same time, fundamental interspecies differences
do exist and must be carefully accounted for if the experi-
mental findings are to have clinical relevance.
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While certain experimental techniques have been widely
accepted and adapted following their use in papers gener-
ated by influential labs, lack of standardization has un-
doubtedly promoted heterogeneity of results. Because
certain experimental variables may have unknown biologi-
cal threshold levels, lack of standardizationmay lead to have
highly discordant results in different studies examining the
same issue.
To address this lack of standardization, the American
Thyroid Association (ATA) convened a panel of specialists in
the field of basic thyroid research to define consensus strate-
gies and approaches for thyroid studies in rodents and in cell
models. This task force was charged with reviewing the lit-
erature first to determine which experimental practices could
benefit from standardization and second to identify critical
experimental variables that demand consideration when
thyroid studies are being designed. The conclusions of the
task force are presented in this document as ‘‘American
Thyroid Association Guide to Investigating Thyroid Hor-
mone Economy and Action in Rodent and Cell Models.’’ The
70 recommendations and their accompanying commentaries
examine topics ranging from ‘‘making cells hypothyroid’’ to
‘‘how to study the thyrotoxic bone.’’ While far from exhaus-
tive, these recommendations touch on certain fundamental
aspects of thyroid research relevant for all investigators in
the field.
Each recommendation in this guide promotes a particular
experimental approach based on criteria including the
prevalence of the approach, with widely used techniques
being given precedence, and in particular whether the ap-
proach has been shown to lead to reproducible results in
studies by independent investigators. Because head-to-head
scientific comparisons of experimental methods in this field
are virtually nonexistent, these recommendations cannot be
graded on the basis of strength of evidence in the fashion of
clinical guidelines; indeed, all would be graded as ‘‘expert
opinion.’’ At the same time, unlike clinical guidelines, the
main goal of these recommendations and their accompany-
ing commentaries is not to identify the single best practice
per se, but instead to encourage investigators to choose
standard approaches; for example, avoiding random treat-
ment doses or methods of thyroid hormone administration,
which would only serve to limit comparison with previous
studies.
The practical nature of recommendations should become
readily apparent to the reader. This document is intended
to serve as a reference for investigators, assisting them in
making design choices that avoid well-known pitfalls
while increasing standardization in the field. As part of
this practical approach, reference credit is often given to
manuscripts in which the technical details are most clearly
or comprehensively explained, rather than the first publi-
cation to use a technique. In addition, emphasis was
placed on contemporary approaches, rather than historical
strategies, such that the document illustrates what is cur-
rently available for the contemporary study of thyroid
hormone homeostasis, metabolism, and action. It is the
position of the ATA that animal studies should be per-
formed in accordance with all applicable ethical standards
and research protocols approved by local institutional
animal committees.
METHODS OF DEVELOPMENT
OF RECOMMENDATIONS
Administration
TheATAExecutiveCouncil selected a chairperson to lead the
task force, and this individual (A.C.B.) identified the other 14
members of the panel in consultation with the ATA board of
directors. Membership on the panel was based on expertise and
previous contributions to the thyroid field. Panel members de-
claredwhether they had any potential conflict of interest during
the course of deliberations. Funding for the guide was derived
from the ATA and thus the task force functioned without
commercial support.
To develop a useful document, the task force first devel-
oped a list of the topics that would be most helpful and the
most important questions that scientists working in the thy-
roid field might pose when planning an experiment or inter-
preting experimental data. Each of the 10 topics was
distributed to a primary writer who used his or her knowl-
edge of the subject as well as a systematic PubMed and
Google Scholar search for primary references, reviews, and
other materials publicly available before December 2012, to
develop a set of recommendations. All drafts were reviewed
and edited by the chair for consistency and sent back to the
primary writers for review; in some cases multiple iterations
took place until the recommendation was finalized. A pre-
liminary draft of each recommendation was then reviewed by
secondary and tertiary reviewers within the group who then
prepared additional critiques. These were addressed by the
primary writer and sent back to the chair. All drafts were
merged and posted at a protected web address available only
to the task force members and ATA office. This document
remained available for periodic review by the task force at
large, with critiques and suggestions sent back to the chair
that updated the document. In a few cases the chair asked for
outside experts to critically review specific recommendations
given their expertise in a focused area. Their comments and
suggestions were then worked into the master document, and
the contributions are acknowledged at the end of this article.
The panel agreed that recommendations would be based
on consensus of the panel. Task force deliberations took place
largely through electronic communication. There were also a
few meetings of the authors and telephone conference calls.
Presentation, Approval, and Endorsement
of Recommendations
The structure of our recommendations is presented in Table
1. Specific recommendations are presented within the main
body of the text and in many cases broken down in subitems
identified by letters. The page numbers and the location
key can be used to quickly navigate to specific topics and
recommendations.
Prior to the initial submission of these guidelines, theywere
approved by the board and executive committee of the ATA
and afterwards submitted to the membership of the ATA in
early 2013 for comments and suggestions. This feedback was
considered in the further preparation of the document that
was submitted for publication. Subsequent to the document
being accepted for publication in Thyroid, it was approved by
the board and executive committee of the ATA.
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The final document was officially endorsed by the American
Academy of Otolaryngology–Head and Neck Surgery (AAO-
HNS), American Association of Endocrine Surgeons (AAES),
American College of Nuclear Medicine (ACNM), Asia and
Oceania Thyroid Association (AOTA), British Nuclear Medi-
cine Society (BNMS), British Thyroid Association (BTA),
European Thyroid Association (ETA), International Associa-
tion of Endocrine Surgeons (IAES), Italian Endocrine Society
(SIE), Japan Thyroid Association (JTA), Korean Society of
Head and Neck Surgery (KSHNS), Latin American Thyroid
Society (LATS), Korean Society of Nuclear Medicine (KSNM)
and The Endocrine Society (TES).
RESULTS
[A] Assessing the Thyroid Gland
Overview. Studies of function–structure relationship of
the thyroid gland, as well as studies of thyroid iodide kinetics
and imaging are traditionally employed to assess the thyroid
gland. Structural characterization is important to assess
functional changes such as hypo- and hyperthyroidism and
for evaluating transformation of thyroid cells into amalignant
phenotype (1–3). At the same time, the study of thyroidal
iodide economy and thyroid imaging are relevant not only to
studies of thyroid hormone synthesis but also to under-
standing the effects of environmental toxins such as perchlo-
rate or thiocyanate on thyroid economy (4–7).
[A.1] Structure–function relationships
Background. While the human thyroid consists of a left
and a right lobe that are connected by an isthmus, rodents
have two independent thyroid lobes. The thyroid gland is
divided by connective tissue septa into lobules, each one of
these containing from 20 to 40 follicles, the basic functional
unit of the thyroid gland. The follicle is a round or elongated
hollow structure lined by a single layer of polarized cuboidal
or flattened follicular cells that is filled with thyroglobulin-
containing colloid. It is surrounded by a basal membrane and
a rich capillary network with high blood flow (8). The follicles
normally vary considerable in size, and the follicular cell
morphology is usually monotonous. The height of the cells
varies according to the functional status of the gland.
& RECOMMENDATION 1a
Morphometry of thyroid follicles can be used as an index of
thyroidal activity.
Commentary. The entire gland should always be dis-
sected while attached to the trachea and immediately fixed
with 10% neutral buffered formalin for histological and im-
munohistochemical analysis. Hematoxylin and eosin (H&E)
staining is widely used to assess the thyrocytes, whereas
periodic-acid Schiff staining stains thyroglobulin avidly and is
well suited to highlight follicular protein content and follic-
ular structure (Fig. 1) (8). Structural modifications reflect
changes in secretory activity resulting from iodine deficiency
(9), chronic cold exposure (10), or treatment with antithyroid
drugs (11). Some follicular cell parameters such as height can
be measured under light microscopy using an ocular mi-
crometer grid (e.g., in a 1-month-old rat, the epithelial cell
height is about 10 lm) (12). A flat epithelium is hypoactive,
while a heightened epithelium is observed in glands in which
the thyrotropin (TSH) pathway is stimulated (10). The use of
computerized semiautomatic image analysis is more objective
and used widely (13). Such morphometric analysis should be
focused on one of the central sections of the thyroid (13) that is
representative of the whole lobe (14). The data obtained are
reduced by predefined mathematical models that assume
thyroid follicles have a spherical shape and follicular cells are
octagons with a square base. This data reduction yields the
following parameters: mean follicle circumference; surface
area and volume; total volume of epithelium and colloid;
number of epithelial cell nuclei visible in each follicle; and the
height, surface area, and volume of thyroid epithelial cell,
which can be used to estimate the functional state of the
thyroid gland. Thus, the activation index, expressed by the
epithelial volume/colloid volume ratio, increases as the thy-
roid becomes more active, reflecting an increase in the epi-
thelial volume and a decrease in the colloid volume (13).
Measurement of total cell volume in cultures of primary
thyrocytes or cell lines cultured in vitro can be performed
using confocal laser-scanning microscopy after cells are loa-
ded with octadecylrhodamine B (15,16).
FIG. 1. Microscopic structure of the mouse thyroid. (A)
Hematoxylin and eosin (H&E) staining. (B) Periodic acid
Schiff (PAS) staining. Mice were euthanized, and the thy-
roids dissected, fixed in buffered formalin, and embedded in
paraffin. Thyroid sections (5lm) were mounted on glass
slides, de-paraffinated, and hydrated. For histological anal-
ysis, sections were stained with H&E, following a standard
protocol. Glycoproteins were detected using PAS staining.
Sections were stained with 0.5% periodic acid for 30 minutes
and with Schiff’s reagent for 20 minutes and then rinsed in
running tap water for 5 minutes. Nuclei were counterstained
with hematoxylin for 3 minutes. Sections were rinsed in
running tap water, dehydrated, cleared, and mounted. Re-
produced with permission from Senou et al. (20).
INVESTIGATING THYROID HORMONE ECONOMY AND ACTION 91
& RECOMMENDATION 1b
Autoradiography can be used to quantify the overall ac-
tivity of thyroid follicles and to determine the location of
iodide within follicles.
Commentary. Thyroid follicular cells concentrate iodide
according to their activity. Although the activity of the thou-
sands of follicular cells should be similar within a given thy-
roid gland, there is a great deal of variation among cells within
the same follicle and between follicles. Thus autoradiography
provides unique insights into the activity of individual thy-
roid follicular cells.
125I is injected intravenously, typically 48 to 72 hours prior to
killing the animal. Thyroid glands are dissected and processed
for autoradiography using standard techniques (17,18). Orga-
nification of iodide can be blocked by treatment of the animals
with methimazole (MMI). Autoradiography experiments with
human, rodent, and feline goiter tissue have also been per-
formed after xenotransplantation of thyroid tissue into nude
mice. Subcutaneously implanted fragments are maintained in
recipient mice for several weeks before further analysis (19).
& RECOMMENDATION 1c
The ultrastructural distribution of iodide within thyroid
follicles can be defined with secondary ion mass spec-
trometry (SIMS).
Commentary. SIMS is a technique used to analyze the
composition of thin films by sputtering the surface of the
specimenwith a focused primary ion beam and collecting and
analyzing ejected secondary ions (Fig. 2). The mass/charge
ratios of these secondary ions are measured with a mass
spectrometer to determine the elemental, isotopic, or molec-
ular composition of the surface to a depth of 1–2 nm. SIMS is
the most sensitive surface analysis technique, with elemental
detection limits ranging from parts per million to parts per
billion. It is uniquely suited for the study of trace ions distri-
bution at the ultrastructural level (20).
Ionic images show that the early distribution of iodine is
heterogeneous from one follicle to another, from one thyr-
ocyte to another inside the same follicle, and that this dis-
tribution varies as a function of time (21). In normal thyroids
the natural 127I isotope is found predominantly in the fol-
licular lumina. The identification of lumina devoid of 127I
and/or the demonstration of significant amounts of 127I in
the cytoplasm of the epithelial cells or on the apical mem-
brane indicates impairment of the iodination pathway. To
define the ultrastructural distribution of iodide using SIMS,
thyroid lobes are processed in a similar way as for electron
microscopy, including fixation with glutaraldehyde and
preparation of semithin sections (20).
& RECOMMENDATION 1d
Confocal microscopy in conjunction with immunohisto-
chemistry (IHC) can be used for two- or three-dimensional
(2D or 3D) image reconstruction to study protein expres-
sion in thyroid follicles, the surrounding capillary network,
and the stroma.
Commentary. Antibodies are available against most key
proteins in thyrocyte biology (22,23). Thus, standard IHC
techniques are commonly used in thyroid studies (Figs. 3 and
4) (24,25). Visualization can be performed with conventional
light microscopy, immunofluorescence microscopy, or con-
focal microscopy for higher resolution and 2D or 3D image
reconstruction (26). Cell surface proteins and processes are
best investigated using scanning electron microscopy (10).
Endogenous peroxidase activity is very high in thyroid
cells and is detected by reacting fixed tissue sections with 3,3¢-
diaminobenzidine substrate; pretreatment with hydrogen
FIG. 2. Mouse thyroid transmission electron microscopy. Thyroid lobes were fixed in 2.5% glutaraldehyde in 0.1M cacodylate
buffer for 1.5 hours, post-fixed in 1% osmium tetroxide for 1 hour, and embedded in LX112 resin (Ladd Research Industries,
Burlington, VT). (A) Thin sections (0.5lm) were stained with toluidine blue and analyzed for morphology by light microscopy.
(B) Ultrathin sections were prepared and stained with uranyl acetate and lead citrate and examined with an electron microscope
Zeiss EM169 (Carl Zeiss, Oberkochen, Germany). (C) Ultrastructural distribution of 127I by secondary ion mass spectrometry
(SIMS) imaging. Semi-thin sections were prepared, and the ultrastructural distribution of the iodide natural isotope (127I) was
obtained through imaging by SIMS, using the NanoSIMS 50 system. Maps were acquired under standard analytic conditions: a
Cs+ primary beam with impact energy of 16 keV and a probe with current intensity of 1 pA. The analyzed surface was
30· 30lm. Under these conditions, a lateral resolution of 100nm is expected. All images were acquired in 256· 256 pixels with a
counting time of 20 milliseconds per pixel. White areas correspond to iodine detection. 127I is homogeneously distributed in the
follicular lumina and in a few intracytoplasmic vesicles. Reproduced with permission from Senou et al. (20).
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peroxide prior to incubation with primary antibody eliminates
endogenous peroxidase activity that will interfere in IHC
studies. The use of fluorescent-tagged proteins should be avoi-
ded if autofluorescence is a problem (as assessed by viewing
tissue sections with a fluorescence microscope before any anti-
body incubation). Fine subcellular distribution studies can
be done with IHC and confocal microscopy; immunogold
staining electron microscopy allows detection of antigens at
veryhigh resolution in studies of subcellular distribution (Fig. 5)
(20,27).
[A.2] Thyroid iodide kinetics
Background. The synthesis of thyroid hormone, its tetra-
iodinated form thyroxine (T4), and 3,3¢,5-triiodothyronine (T3)
requires a normally developed thyroid gland, an adequate io-
dide intake, and a series of regulated biochemical steps in
thyroid follicular cells, which form the spherical thyroid folli-
cles, the functional unit of the thyroid gland (28). In thyroid
epithelial cells, the sodium iodide symporter (NIS) mediates
the iodide uptake into thyroid follicular cells (29), and its ex-
pression is polarized (i.e., it is expressed only in the basolateral
membrane). At the basolateral membrane of thyrocytes, Na+/
K+ -ATPase generates a sodium gradient that permits NIS to
mediate perchlorate inhibitable, Na+ -dependent iodide uptake
(30). Iodide then translocates to the apical membrane and
reaches the follicular lumen through the apical membrane.
While it has been assumed that iodide moves across the apical
membrane primarily because of the electrochemical gradient,
studies in frozen section demonstrated that it is first accumu-
lated in the cytoplasm and only later in the lumen, and apical
iodide efflux is rapidly accelerated in polarized cells after ex-
posure to TSH (31). Electrophysiological studies using inverted
plasma membrane vesicles suggested the existence of two
apical iodide channels, but their molecular identity has not
been determined (32). The multifunctional anion exchanger
pendrin (SLC26A4/PDS), which has affinity for anions such as
iodide, chloride, and bicarbonate is thought to represent one of
these entities (33,34). Both NIS and SLC26A4 expression and
activity are increased by TSH (30, 33). While the term iodide
uptake can be used broadly for in vitro and in vivo approaches,
data interpretation should take into account the critical differ-
ences between the two settings, with the former reflecting cel-
lular iodide uptake and the latter mainly the concentration of
organified iodine in the colloid.
FIG. 4. Detection of dual oxidase
(DUOX) and thyroperoxidase in
the mouse thyroid by immunohis-
tochemistry. (A) DUOX was de-
tected on frozen sections with rabbit
polyclonal antibody diluted 1/3000
and incubated overnight. Positivity
is observed at the apical pole
(arrows, inset). (B) thyroperoxidase
was detected on paraffin sections
with rabbit antibody Load TPO
821, 4lg/mL and incubated for
3 hours. Reproduced with permis-
sion from Senou et al. (20).
FIG. 3. Detection of thyroglobulin and iodinated thyro-
globulin in the mouse thyroid by immunohistochemistry. (A)
Thyroglobulin was detected on paraffin sections using anti-
thyroglobulin rabbit polyclonal antibody (Dako) diluted 1/
1500 and incubated overnight. (B) Iodinated thyroglobulin
was detected using mouse monoclonal antibody (B1) diluted
1/3000 and incubated overnight. Negative controls included
the replacement of primary antibody by the preimmune
serum or absence of the primary antibody. Reproduced with
permission from Senou et al. (20).
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& RECOMMENDATION 2a
Basolateral cellular iodide uptake and apical efflux of iodide
can be studied in monolayers of polarized cells cultured on
semi permeablemembranes forming a two-chamber system,
or in nonpolarized cell models such as the FRTL-5 or PCCL3
rat thyroid cell lines.
Commentary. Measurement of iodide uptake and efflux in
nonpolarized cells is relatively straightforward. The establish-
ment of polarized cell systems requires isolation of primary cells
or transfection or transduction of polarized heterologous cells
and the documentation of intact monolayer formation, which
are tedious and time-consuming (31). For the iodide uptake
assays, cells are incubated in an uptake solution typically con-
taining 10- 5 M Na125I for a desired time period. Organification
can be blocked by treating the cells withMMI. The intracellular
iodide content is determined bymeasuring radiolabeled iodide
in the cell lysates using a gamma counter after cell lysis. Results
are expressed as counts per minute per well or, ideally, per
microgram of DNA. The gravimetric amount of intracellularly
accumulated iodide (pmol/lg DNA) can also be calculated
based on the specific activity of the tracer. Alternative methods
that have been used include the use of halide quenchers. A
problem with this approach is that these quenchers are not
specific for iodide, but also react to other halides. The avail-
ability of a modified enhanced yellow fluorescent protein
(EYFP) H148Q/I152L with high affinity for iodide has allowed
tracking iodide influx and efflux with relatively good accuracy
and a high degree of correlation with direct measurements of
radiolabeled iodide (35–37). Alternatively, mass spectrometry
has been used to study the uptake of perchlorate into FRTL-5
cells, which is also mediated by NIS (38).
A number of cell models and setups are available to study
NIS-mediated iodide transport (4–6,31,33,39–41), including
multiple heterologous cell lines transiently expressing NIS
(29,42). Such studies are useful for the characterization of NIS
function and the activities of naturally occurring or artificial
mutant proteins (29,42). For example, they are useful to
measure steady-state and initial rate iodide uptake as well as
kinetic parameters of NIS-mediated iodide transport. Uptake
of iodide has also been studied in cancer cell lines transfected
or transduced with constructs in which the NIS cDNA is
under the control of tissue-specific promoters with the aim to
promote uptake of 131I and to induce cell death through its
beta-emission (43,44). For studies assessing the effect of TSH,
the medium used to culture thyroid cells is changed to TSH-
deprived media for several days and then submitted to the
different experimental conditions.
& RECOMMENDATION 2b
Iodide efflux from thyrocytes can be assessed in perchlorate-
treated thyroid cell lines.
Commentary. To study iodide efflux in vitro, cells are
loaded with 125I for 1–2 hours and subsequently treated with
perchlorate in order to block iodide uptake by NIS. The efflux
can then be studied by collecting supernatants at one or
multiple time points (5). The intracellular content of iodide
should also be determined at one or multiple time points.
Another strategy is to use a two-chamber system, in which the
efflux of iodide at the apical membrane can be measured by
collecting the supernatant at one or multiple time points
(31,40). Measuring iodide directly with ion-selective elec-
trodes in supernatants or cell lysates is problematic because
these probes are not specific for iodide and also recognize
other halides such as chloride.
Efflux of radioactive iodide by the anion channel SLC26A4
(pendrin) or any other anion channels can also be studied in
multiple heterologous cell lines transiently expressing NIS that
allows for initial iodide uptake (3,40). This can be documented
bymeasuring intracellular iodide content in cells co-expressing
NIS and the channel of interest with direct comparison to cells
that only express NIS. A model system that is suited for such
experiments is the polarized Madin Darby canine kidney cell
FIG. 5. Detection of thyroglobulin in the mouse thyroid by immunogold electron microscopy. After wash with phosphate-
buffered saline–bovine serum albumin (PBS-BSA 1%), ultrathin sections (0.1 lm) were incubated overnight with a rabbit
polyclonal anti-thyroglobulin antibody (1/300, DAKO). Sections were then rinsed and incubated for 30 minutes with a 12-nm
colloidal gold affinity pure goat anti-rabbit IgG ( Jackson, 111-205-144, lot no. 71647). Sections were postfixed with 2.5%
glutaraldehyde for 5 minutes and counterstained. They were examined with a Zeiss 109 transmission electron microscope.
(A) Negative control obtained by omission of primary antibody. (B) Thyroglobulin was detected as small gold particles in the
colloid limited by flat epithelial cells. Reproduced with permission from Senou et al. (20).
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line (40). Transfection of these cells is very inefficient and this
may require establishing stably expressing cell lines or viral
transduction with appropriate vectors. Moreover, efflux can be
followed using EYFP H148Q/I152L as an indicator of the in-
tracellular iodide concentration (35–37).
& RECOMMENDATION 3a
Kinetics of thyroid gland iodide uptake can be studied via
administration of radioactive iodide. Data points can be
obtained in vivo or following en bloc resection of the tra-
chea and thyroid.
Commentary. Thyroid radioactive iodide uptake (RAIU)
and other aspects of iodine kinetics can be studied in rodents
using different iodine isotopes, most commonly 125I, which
are injected intraperitoneally (2–10lCi 125I). The thyroid
gland is subsequently studied at different time points either
with a gamma probe (used, for example, for the identification
of parathyroid tissue in minimally invasive surgery) under
anesthesia (45,46) or dissected postmortemwith the trachea en
bloc under a microscope and processed for radiometry for 1
minute in a gamma counter. The results may be expressed as a
function of 125I in the serum (47) or as percentage of the total
injected dose (46). Thyroid RAIU reaches a maximum at ap-
proximately 4 hours after administration of 125I and plateaus
at about 12 hours (48). These are approximate time points that
may vary according to the species and strain of the rodent
under investigation. Timing of the 125I injection can be coor-
dinated with the injection of bovine TSH (bTSH; 10mU) to
evaluate the TSH-induced thyroidal RAIU. In some settings it
is useful to suppress endogenous TSH by pretreating the an-
imals with T3 for 4 days prior to radioisotope administration
(48). This will minimize the possibility that endogenous TSH,
which could be different between two groups of animals, is
interfering with the response to bTSH. Notably, a compara-
tive study in rats and mice using recombinant human thyro-
tropin (rhTSH) indicates that it is far more important to
pretreat with T3 and suppress endogenous TSH in rats than in
mice (49).
& RECOMMENDATION 3b
Thyroid iodide organification can be quantified via the
perchlorate discharge test.
Commentary. The perchlorate test permits quantification
of the amount of iodide that is normally bound to thyro-
globulin (50). The test is based on the fact that iodide is
transported into thyroid cells by NIS, then released into the
follicular lumen where it is rapidly covalently bound to tyr-
osyl residues of thyroglobulin (organification). Anions such as
perchlorate inhibit NIS, and any intrathyroidal iodide that has
not been incorporated into thyroglobulin is released rapidly
into the bloodstream at the basolateral membrane and cannot
be transported back into thyrocytes. In the standard per-
chlorate test, the thyroidal counts are measured at frequent
intervals after the administration of radioiodine in order to
determine the uptake into the thyroid gland. After doc-
umenting the uptake, perchlorate is administered intrave-
nously or intraperitoneally, and the amount of intrathyroidal
radioiodine is measured at frequent intervals. Under condi-
tions of normal iodide organification, there is no significant
decrease in intrathyroidal counts. In contrast, a loss of ‡10%
indicates an organification defect, which can be partial (10%–
90%) or complete (>90%).
In mice, sodium perchlorate (NaClO4) is injected intraper-
itoneally 1 hour after injection of 125I intraperitoneally, and
animals are killed 1 hour later (47). Radioactivity remaining in
the thyroid gland of perchlorate-treated animals is then
compared with the 125I uptake measured in glands from
control mice that were not exposed to the perchlorate-induced
iodide chase. Protein-bound 125I (i.e., the total radioactive
thyroid hormones bound to serum transport proteins) is de-
termined in all blood samples after trichloroacetic acid (TCA)
precipitation (47). Others have been able to trace iodide up-
take and discharge in mice directly using gamma probes (45).
Potassium perchlorate (KClO4) has been used in rats 6–18
hours following injection of 125I and shown to reduce the 125I
thyroid/blood ratio when thyroid peroxidase is inhibited
(51,52). 124I positron emission tomography/computerized
tomography (PET/CT) has been used rarely to evaluate up-
take and discharge of iodide in rodent thyroids in vivo (53).
& RECOMMENDATION 3c
Kinetics of thyroidal secretion can be studied in vitro using
en bloc resection of the trachea and thyroid.
Commentary. This strategy is used to evaluate in vitro
TSH-induced thyroidal secretion, minimizing the interference
of other in vivo factors (20). Mice are given an intraperitoneal
injection of about 30 lCi of 125I and 24 hours later the trachea
and thyroid are removed en bloc and incubated for 3 hours in
Krebs-Ringer bicarbonate medium containing 0.5 g/L bovine
serum albumin (BSA), 8mM glucose, and 10 - 4 M NaClO4 to
avoid iodide recirculation. Radiolabeled thyroid hormone
secreted in vitro is extracted with butanol (54). The secretion is
expressed as a percentage of the total radioactivity in the tis-
sue at the beginning of the incubation. There is an approxi-
mately 10-fold induction in thyroidal secretion with the
addition of 5mU/mL TSH (20).
[A.3] Thyroid imaging
Background. Thyroid imaging in small rodents has fol-
lowed the techniques developed for humans such as scanning
with iodide isotopes, microPET, CT, and high-frequency ul-
trasound (HFUS). However, the minute size of the gland still
poses a significant challenge to obtaining high-quality high-
resolution images, which has been partially overcome by re-
cent new technology.
& RECOMMENDATION 4a
Thyroid gland functional imaging can be performed using
radioactive iodide isotopes and image acquisition in a
gamma camera or via microPET-CT.
Commentary. 123I and 131I can be used together with a
gamma camera for planar imaging as well as single photon
emission computed tomography (SPECT) studies. 131I has a
long half-life (8 days), but its high energy produces poor
quality images. In contrast, the low energy emitter 123I is ideal,
producing useful scintigrams with a low absorbed dose; the
main limitations result from its short half-life (13 hours).
Thyroid scintigraphy in anesthetized rats can also be per-
formed 1–24 hours after an intraperitoneal injection of 10 lCi
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125I using SPECT (46). Imaging is substantially improved by
placing the animals on a low-iodine diet (LID) for about 3
weeks prior to the studies (46). This enhances the 4 hour
thyroid RAIU from about 3.5% to 27% and makes thyroid
scintigraphy, at all acquisition times, brighter and more de-
tailed (46). SPECT studies in mice using 99mTc or 123I have also
been reported (55,56).
PET studies of the thyroid using 124I produce good image
quality with a reasonable half-life (4 days). The sensitivity of
PET is higher than that of a scintillation camera, as well as the
contrast and spatial resolution (53). For accurate thyroid im-
aging in rats, the combination of microPET and micro com-
puted axial tomography with 124I is necessary (Fig. 6) (57).
Anesthetized adult rats or mice are injected via tail vein with
20–540lCi of Na124I and scanned in the microPET for 40
minutes at 24, 48, and 72 hours post injection under anesthesia.
The resulting image data are then normalized to the adminis-
tered activity in terms of the percentage of the injected dose per
gram of tissues (Fig. 6B). Manually drawn 2D regions of in-
terest or 3D volumes of interest can be used to determine the
thyroidal area and volume. For example, the thyroid volume of
an adult 400–500g rat varies between 35 and 70lL (57). In
addition to the thyroid gland itself, this approach has also been
used to image metastases of thyroid cancer in mice (58).
& RECOMMENDATION 4b
Morphological microimaging of the thyroid gland can be
performed by HFUS.
Commentary. HFUS (20–100MHz) is an imaging meth-
odology that extends the in vivo visualization to microscopic
resolution (of the order of 100lm; Fig. 7) (59,60). The thyroid
gland of a mouse can be examined using a microimaging sys-
tem that has a single element probe of center frequency and a
dynamic range of 52dB. HFUS is performed under general
anesthesia (e.g., 1.5%–2% isoflurane vaporized in oxygen) on a
heated stage. Fur is removed from the area of interest (neck and
the high thorax) to obtain a direct contact of the ultrasound gel
FIG. 6. Thyroid imaging using 124I-iodide in vivo. (A) Biodistribution of 124I-iodide in thyroid of genetically modified mice in
which thyroid iodide uptake is suppressed by induction of a transgene; 1 week later suppression is relieved and iodide
uptake is normalized. Top panels: representative images of uninduced mice, 1 week on doxycyclin to induce the transgene,
followed by 1 week off doxycyclin. Positron emission tomography (PET) imaging was performed using an R4 microPET
scanner (Concorde Microsystems) with Na124I produced on the MSKCC EBCO TR 19-9 (Advanced Cyclotron Systems Inc.)
using 16MeV protons on a tellurium-124 target. Mice were injected via tail vein with 1.7–2.0MBq (45–55 lCi) of Na124I. Mice
were imaged 24, 48, and 72 hours later under inhalational isoflurane anesthesia (Forane; Baxter Healthcare) at 1 L/min. List-
mode data were acquired for 5 minutes using an energy window of 250–750 keV and a coincidence timing window of 6
nanoseconds, histogrammed into two-dimensional (2D) projected data by Fourier rebinning, and reconstructed by filter back-
projection using a cut-off frequency equal to the Nyquist frequency. The image data were normalized to correct for non-
uniformity of response of the PET, dead-time count losses, 124I positron branching ratio, and physical decay to the time of
injection, but no attenuation, scatter, or partial-volume averaging correction was applied. (B) Quantification of thyroid 124I-
iodide uptake in mice treated with the indicated conditions. ***p< 0.001. An empirically determined system calibration factor
(in units of [lCi/mL]/[cps/voxel]) was used to convert reconstructed voxel count rates to activity concentrations. The
resulting image data were then normalized to the administered activity to parameterize images in terms of the percentage of
the injected dose per gram of tissues (%ID/g). Manually drawn 2D regions of interest (ROIs) or three-dimensional (3D)
volumes of interest (VOIs) were used to determined the %ID/g (decay corrected to the time of injection) in various tissues.
Image visualization and analysis were performed using ASIPro VM software (Concorde Microsystems). (C) Representative
gross appearance of thyroid glands at the indicated times. The boundaries of the thyroid are demarcated by dashed lines.
Scale bar: 1mm. ID/g, injected dose/gram Reproduced with permission from Chakravarty et al. (58).
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to the skin of the animal, minimizing ultrasound attenuation.
Real-time imaging can be performedwith a frame rate of 20Hz
(corresponding to a temporal resolution of 50milliseconds); the
center of the mouse thyroid is placed about 6mm from the
transducer’s focal zone. The study, including measurements
and acquisition of accurate, repeatable, and high-quality im-
ages, can be completed in about 30 minutes in the hands of a
well-trained and skilled operator (61).
The volume of each lobe can be calculated using the ovoid
formula (width ·depth · length ·p/6) (61). The thyroid vol-
ume of an adult C57BL/6 mouse ranges between 2.1 and
4.9 lL. In 6-n-propyl-2-thiouracil (PTU)-treated mice there is
diffuse goiter with volumes that range between 4.1 and 8.8 lL.
Thyroid nodules can be detected via this methodology as
well, with the smallest detectable nodule exhibiting a diam-
eter of 0.46mm. Features suggestive ofmalignancy can also be
identified such as hypoechogenicity relative to adjacent nor-
mal tissue, poorly defined margins, internal microcalcifica-
tion, irregular shapes, and extraglandular extension (61). This
should be useful in the phenotypic characterization of mouse
models of thyroid cancer.
[B] Assessing Circulating
and Tissue Thyroid Hormone Levels
Overview. ‘‘Thyroid status’’ of an organism is the sum of
all thyroid hormone signaling events and depends on both
circulating thyroid hormone levels and on local factors
influencing the nuclear concentration of thyroid hormone in
specific tissues. Thyrotoxicosis is the clinical syndrome asso-
ciatedwith thyroid hormone excess, whereas hypothyroidism
results from thyroid hormone deficiency. At the same time,
individual tissues could be said to have specific thyroid sta-
tus, i.e. hypothyroid or thyrotoxic, relatively independent of
serum thyroid hormone levels; this is because of tissue-
specific deiodinase activities and/or transport mechanisms
(Fig. 8). For example, ischemia and hypoxia cause the brain
and the heart to become acutely hypothyroid in an otherwise
euthyroid animal due to induction of type III deiodinase (D3)
expression (62–65). At the same time, the brown adipose tis-
sue (BAT) exhibits localized increase in thyroid hormone
signaling shortly after rodents are moved to the cold due to
acute induction of type II deiodinase (D2) expression (66).
A common way of assessing thyroid status of an organism,
a.k.a. systemic thyroid status, is by measuring serum levels of
thyroid hormone (T4 and T3) and TSH as well; reverse T3 can
also be measured, but it is usually reserved for special situa-
tions to confirm abnormalities in thyroid hormone metabo-
lism. Tissue-specific thyroid status can be characterized via
direct measurement of tissue thyroid hormone levels. Typi-
cally, measuring the expression of T3-responsive genes (see
Section I) and/or T3-responsive biological parameters (see
Section J) is also part of the work up to define thyroid status.
As with the clinical assays developed for patients, a num-
ber of immunoassays for T4, T3 and TSH have been developed
specifically for rodents, which take into consideration differ-
ences in types and capacity of serum iodothyronine binding
proteins and species-specificity of the TSH molecule. In gen-
eral, these assays functionwell and exhibit sufficient precision
to evaluate thyroid function and systemic thyroid status in
rodents. Under experimental circumstances or specific genetic
defects, serum iodothyronine levels may not reflect thyroid
hormone signaling at the tissue or cellular level. In these cases,
thyroid status can be ascertained by measuring T3 concen-
trations in specific tissue or cells by adapting the immunoas-
says developed for serum measurements.
[B.1] Serum
Background. Serum thyroid hormone levels may vary
substantially according to sex, age, and strain of the rodent
and should be accounted for in study design. Elevated levels
FIG. 7. High-frequency ultrasonography (HFUS) of the mouse thyroid. (A) Representative image of mouse thyroid using
HFUS and its anatomic correlation with (B) histological transversal images of the subhyoid and tracheal regions. Visible
structures include: 1, tracheal cartilage ring; 2, salivary gland; 3, sternohyoideus and sternothyroideus muscles; 4, sternomas-
toideus muscle; 5, thyroid lobes; 6, common carotid arteries; 7, deep prevertebral muscles scalenus and longus colli; and 8, skin.
A Vevo 770 microimaging system (Visualsonics, Toronto, Ontario, Canada) with a single element probe of center frequency of
40MHz is used. The transducer has an active face of 3mm, a lateral resolution of 68.2lm, axial resolution of 38.5lm, focal
length of 6mm, mechanical index 0.14, and a dynamic range 52dB. A probe with lower frequency and more penetration depth
can also be used (30MHz center frequency single element with focal depth 12.7mm, lateral resolution of 115lm, axial reso-
lution of 55lm). HFUS is performed under general anesthesia. In this study, mice were anesthetized using 1.5%–2% isoflurane
vaporized in oxygen on a heated stage, with constant monitoring of their body temperature. Area of interest was shaved (neck
and the high thorax) with a depilatory cream to obtain a direct contact of the ultrasound gel to the skin of the animal minimizing
ultrasound attenuation. To provide a coupling medium for the transducer warm gel was used. An outer ring of thick gel
(Aquasonic 100; Parker Laboratories, Orange, NJ) was filled with a thinner gel (echo Gel 100; Eco-Med Pharmaceutical,
Mississauga, Canada) over the region of interest. Reproduced with permission from Mancini et al. (61).
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(as defined between adjusted normal ranges) usually indi-
cate thyrotoxicosis, while decreased serum levels are indic-
ative of hypothyroidism. Iodine deficiency, alterations in
thyroid hormone metabolism, as well as hypothalamic and
pituitary sensitivity to thyroid hormone can alter the quan-
titative reciprocal relation between serum T4, T3, and TSH as
is often the case in models of resistance to TSH or thyroid
hormone.
Immunoassays were developed decades ago and have
served as the cornerstone to measure serum iodothyronines
and TSH. However, these original assays have been largely
replaced by newer immunoassays (e.g., enzyme-linked im-
munosorbent assay [ELISA], immune radiometric assay
[IRMA]), all of which are commercially available. Using
commercially available kits to measure serum iodothyr-
onines in rodents is not straightforward because many of
these kits are developed for human serum and make use of
an artificial matrix to mimic human binding proteins with
higher affinity and capacity than those of mice or rats. These
kits utilize ‘‘displacement agents’’ to displace the iodothyr-
onines from human thyroxine binding globulin (TBG; e.g., 8
anilino naphthalen sulfonic acid, diphenylhydantoin, sal-
icylic acid) that are frequently used in excess (for mouse). In
this respect, they interfere more with T3 than T4, and par-
ticularly when serum T3 values are low. This can only
be appropriately corrected for by using iodothyronine-
deficient mouse serum as blank and constructing a standard
curve that will calibrate the assay; for example, serum from
paired box gene 8 (Pax8) knock-out (KO) mice not treated
with T4 or T3 for at least 2 months (67). Technical limitations
also require the utilization of TSH-deficient mouse serum for
blank and the preparation of a standard curve with mouse
serum TSH, not pituitary TSH, as standard (68). Liquid
chromatography/tandem mass spectrometry is also be-
coming available, although its applicability for rodents is
limited because the required serum volumes are still too
large.
& RECOMMENDATION 5a
Serum total T4 and T3 concentrations can be measured by
radioimmunoassay (RIA), or a host of other immunoas-
says such as ELISA or IRMA, provided that the standard
curves are prepared with rodent serum stripped of thyroid
hormone.
Commentary. Typical standard curves are prepared over
the range 2.5–240 ng/mL for T4 and 0.1–6 ng/mL for T3. These
assays can be developed in house by modification of kits for
human use obtained from multiple commercial sources.
Homemade RIAs have a greater sensitivity with measure-
ments over the range of 0.05–3 ng/mL (67). Clinical assays
developed for patients can be used as long as the rodent
standard curve is parallel to the standard curve provided in
the kit and an appropriate correction factor applied; the ro-
dent standard curve should be used to calculate the results
(67). Commercially available kits designed for measurement
of mouse serum T3 and T4 in 10 lL samples have been de-
veloped and used with acceptable results (69).
& RECOMMENDATION 5b
Assays for measuring circulating T4 and T3 are best per-
formed using serum rather than plasma, since fibrin for-
mation affects pipetting, and additives such as heparinmay
directly interfere with free hormone determination.
Commentary. Frequent blood samples can be obtained
during the course of an experiment if limited to approxima-
tely 10% of the total volume every 2–4 weeks and 1% every 24
hours. Serum can be stored at -20C for long time periods.
The use of anesthesia may have variable effects on thyroid
hormone levels, and each investigator should evaluate po-
tential effects in their system with the anesthetic they are
using. Serum T3 and T4 exhibit minimal circadian variations
along day–night cycles; these could be taken into account
depending on the timing of sample collection. Serum samples
FIG. 8. Supply and metabolism of thyroid hormones affect negatively and positively T3-regulated genes in the brain. To
construct this figure, the authors used individual reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)
data from T3-regulated genes to calculate the fold change relative to the wild-type (WT) values, and plotted the Log2FC (fold
change) to make the results quantitatively comparable. The data were represented in a box-and-whiskers (5%–95%) plot.
Statistical significance between each group and the WT was calculated by one-way ANOVA. For the positive genes,
F5,537= 272, p < 0.0001. For the negative genes, F5,400= 145, p < 0.0001. *p < 0.05; **p< 0.01; ***p< 0.001. Reproduced with per-
mission from Hernandez et al. (492).
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with milky aspect from lactating dams or from their pups can
give erroneous results due to their high lipid content. In these
cases extraction of the serum and removal of the lipids using
chloroform is advisable (67).
& RECOMMENDATION 5c
Determinations of free iodothyronine indexes (FT4I and
FT3I) in the serum can be achieved by measurement of the
total serum hormone concentration and the serum io-
dothyronine binding capacity using one of the resin or
charcoal methods.
Commentary. The existence of proteins in the serum
that reversibly bind thyroid hormone establishes two pools
of circulating T4 and T3 (i.e., protein-bound and free). The
major circulating high affinity thyroid hormone binding
proteins differ in rodents and humans, with transthyretin
being the major protein in the rat and TBG in humans. It is
the free thyroid hormone in the plasma that is in equilib-
rium with tissues and affects thyroid hormone signaling.
Measurement of free hormone by methods other than
equilibrium dialysis can give erroneous results, though
microfiltration of the samples has been used with reliable
results (70,71). Equilibrium dialysis of serum with labeled
iodothyronine tracer in dialysis bags has been used to
measure free T4 and T3 in the rat. The method is not used for
mice, owing to the requirement of more than 1mL of serum
for measurement in triplicate because leaks often occur.
Using diluted serum and applying correction is not advis-
able. Only 100 lL of serum is required when using micro-
filtration of the samples (70).
Alternatively, an estimate of the FT4I or FT3I can be ob-
tained using a relatively small volume of serum by using
the resin or charcoal methods (72). Serum is diluted into
phosphate-buffered saline (PBS; pH 7.4) containing [125I]T3 or
[125I]T4. Samples are allowed to equilibrate and subsequently
mixed with 0.0125% activated charcoal solution. Charcoal
pellets are obtained and then counted in a c-counter. Condi-
tions should be optimized such that approximately 20%–30%
of the tracer is bound to charcoal in sera from euthyroid
control animals. An estimate of the free T4 or T3 (FT4I or FT3I)
can be calculated by multiplying the total T4 or T3 serum
concentration by the T4 or T3 charcoal uptake.
& RECOMMENDATION 5d
Isotope dilution tandemmass spectrometric can be used to
measure T4 and T3 in biological samples.
Commentary. Immunoassays for thyroid hormone mea-
surement can suffer from poor specificity. As an alternative,
simultaneous measurement of T4 and T3 can be achieved by
using isotope dilution tandem mass spectrometry within a
single run (67,73). The method requires 100 lL of serum and
involves addition of internal standard, precipitation of pro-
teins with methanol and injection onto a C-18 column. T4 and
T3 are subsequently eluted using a methanol gradient. This
method is accurate, specific, and precise (coefficient of varia-
tion of 3.5%–9.0%). A concern is the sample volume needed
for free hormone determination, which is still relatively large
for applications involving mice, except in terminal bleeding.
Similar methodology applying liquid chromatography-
tandem mass spectrometry has been developed for measure-
ment of iodothyronamines, a decarboxylated iodothyronine
present in a number of biological fluids (74).
& RECOMMENDATION 6a
Rat and mouse serum TSH can be measured using com-
mercially available rat TSH assay kits. Alternatively,
species-specific RIAs can be performed using reagents from
the National Hormone and Peptide Program, National In-
stitute of Diabetes and Digestive and Kidney Diseases
(Bethesda, MD).
Commentary. In general, RIAs for TSH aremore sensitive
than IRMAs. Commercial assays do not provide species spe-
cific cross reference and, therefore standard curves are rarely
parallel to values obtained with actual sample dilution.
However, commercial reagents can be adapted for specific
and accurate measurements of TSH as outlined below.
TSH standard curves should be constructed using species-
specific circulating (serum, not pituitary) TSH standard,
diluted in TSH-deficient serum obtained from the same
species. Serum TSH standard is obtained from animals ren-
dered hypothyroid (see Section E.1). The content of TSH is
calibrated against a bTSH standard in a bioassay. TSH-
deficient serum is prepared by making rodents thyrotoxic
(treatment with 20 lg levothyroxine [L-T4]/100 g body
weight [BW]/day for 1 week). Sample nonparallelism with
standard curves is due to species differences and to cross-
reactivity with free TSH subunits and other pituitary gly-
coproteins in pituitary extracts. The use of lactoperoxidase to
label TSH with 125I improves the stability of the labeled TSH
and the sensitivity of the TSH assay up to thyrotoxic ranges
(68). Measurement of TSH concentration in pituitary gland
extracts can be done, however, using the same assay at a
dilution of 1:500 to 1:2000 in assay buffer. The standard
curve can also be built using buffer, instead of TSH-deficient
rodent serum, as the diluent. Running the RIAs in disequi-
librium (addition of the isotope tracer for a shorter time after
incubation of the TSH antibody with the samples) improves
the sensitivity of the assay. If no reliable rat/mouse serum
TSH measurement is available, the levels of TSHbmRNA in
the pituitary gland can be used as an indication of TSH
production (75).
& RECOMMENDATION 6b
TSH biological activity can be studied by standardized
in vitro assays as well as in vivo assays.
Commentary. TSH biological activity is modulated by a
number of factors including its structure, glycosylation or
carbohydrate branching, as well as by the TSH receptor. The
biological activity of the TSH molecule can be determined by
an in vitro bioassay using Chinese hamster ovary cells stably
expressing the TSH receptor (68,76). The subclone cl 213 of
JP2626 is particularly sensitive to low levels of TSH. About
50,000 cells are seeded in individual test tubes and incubated
with 20lL of serum, followed by cAMP extraction with 0.1M
HCl and measurement by RIA (77). Blanks are processed as
already described with TSH-depleted serum obtained from
T4-treated mice. cAMP production is a function of how much
endogenous TSH was contained in the plasma sample (68).
Dividing the cAMP generated in vitro by the TSH values in the
plasma sample provides an index of TSH biological activity.
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Of course, this can vary according to mutations in the TSH
molecule or degree and type of glycosylation or carbohydrate
branching. However, such changes may not always show
biologic differences using in vitro tests. Alteration in the pro-
tein glycosylation or the tertiary structure (carbohydrate
branching) of the sugar residue, alters the half-life of TSH
in vivo and affects its bioactivity. However, this cannot be
always demonstrated by in vitro bioassay. In some instances it
can be shown by isoelectric focusing, if a sufficient amount of
TSH can be concentrated and developed by Western blotting
or by Concanavalin-A chromatography (78). Another method
is to affinity purify the TSH being tested, inject it intrave-
nously in TSH-suppressed mice or rats (treated with high
dose of T3), and follow its half-life by RIA, or follow the bio-
logical activity of TSH by measuring T4 secretion in serum.
Decreased TSH bioactivity can also be caused by defects in the
TSH receptor or reduced number of TSH receptors expressed
in the follicular cell surface (e.g., heterozygous TTF1 KO
mice). This can be confirmed by showing intact response in an
in vitro bioassay along with alteration in the response of the
animal to injected authentic TSH (79).
& RECOMMENDATION 7
Thyrotropin releasing hormone (TRH)-induced TSH se-
cretion testing can be used to assess the capacity of the
pituitary gland to secrete TSH. TSH-induced thyroidal se-
cretion testing can be used to assess the capacity of the
thyroid gland to produce and secrete thyroid hormone.
Commentary. The TRH-TSH axis can be interrogated at
either the pituitary or thyroid glandular level via specific dy-
namic tests. The TRH stimulation test is performed with an
intravenous or intraperitoneal injection of TRH (5.0lg/kg BW).
Blood is collected 30 minutes later for measurement of serum
TSH and 2 hours later for measurement of serum T3, which
indicates the thyroidal responsiveness to TRH-induced TSH.
The expected increase in serumTSH is about threefold,whereas
an elevation of approximately 50% in serum T3 is expected (80).
The TSH stimulation test is performed with an intravenous
or intraperitoneal injection of bTSH (2–250mU/100 g BW).
Two hours later, blood is collected for measurement of serum
T3, with an expected elevation of approximately 40% com-
pared to baseline levels (79–81). An alternative approach is to
pretreat mice for 4 days with T3 (1lg/d) in order to suppress
endogenous TSH and then administer bTSH (2, 10, or 30mU)
on the morning of the fifth day. In this case, the thyroidal
response is evaluated based on the TSH-induced elevation in
serum T4 3 hours later, which is about 1 lg/dL (81) or three-
fold over baseline (82). A similar approach can be used in rats,
and the TSH-induced T4 response varies quite substantially
according to the rat strain. Still in rats, the TSH-induced T4
response plateaus at a bTSH dose of about 100mU, with an
increase of about 2lg/dL above baseline (79). Of note, a
comparative assessment of the thyroid responsiveness to
rhTSH in rats and mice indicates poor or no response in rats
that were not pretreated with T3 (49).
[B.2] Tissue
Background. While the plasma constitutes the largest
extrathyroidal pool of T4, approximately two thirds of all T3 is
found in the intracellular space and initiates thyroid hormone
action by binding to nuclear thyroid hormone receptors (TRs).
The intensity of the signaling depends on the number of oc-
cupied TRs in any given T3-responsive tissue. Because the
extracellular and intracellular compartments are in commu-
nication and thyroid hormone molecules transit in and out of
the cells via the different membrane transporters, in most
tissues measuring the serum concentration of thyroid hor-
mone provides an estimate of the intracellular T3 concentra-
tion. However, a disruption of the transport system might
prevent free access of T3 to the intracellular compartment. In
addition, intracellular metabolism of thyroid hormone, both
activation and inactivation, might affect thyroid hormone
signaling in a way that cannot be predicted from sampling the
plasma compartment. Thus, serum levels of T3 do not neces-
sarily reflect the amount of T3 in all tissues or the intensity of
thyroid hormone signaling. Direct measurement of tissue T3
content provides this additional information.
& RECOMMENDATION 8
Tissue content of T3 and T4 can be measured by immuno-
assays after tissue extraction.
Commentary. Removing blood from tissues by perfusion
is important particularly for highly vascular tissues. After
collecting a blood sample, mice are perfused with heparin
containing PBS through a needle placed in the left ventricle
(LV) of heart followed by cutting open the vena cava. Tissues
are then collected, immediately frozen on dry ice, and stored
at -80C. Iodothyronines are extracted from tissues using
methanol–chloroform (1:2). The amount of tissue to be ex-
tracted depends on thyroid hormone status of the animal and
the hormone abundance in a specific tissue. As an example,
50mg of brain and 15mg of liver of an euthyroid mouse will
generally yield satisfactory results, but the amount should be
increased in samples from hypothyroid mice or rats. Radio-
active T3 or T4 should be added to each sample to determine
efficiency of extraction; a mix of [125I]T3 and [
131I]T4 can be
used when both hormones are to be studied. Depending on
the extraction procedure, chloroform should be removed be-
cause it contains lipids and other substances that interfere in
the RIAs. This involves back-extraction in calcium chloride,
concentration of the extracts, and evaporation (83). Once ex-
traction is completed, the dried extract is dissolved, preferably
in buffer or charcoal-stripped rodent serum, and T3 content
measured by the specific immunoassay, following the given
recommendations. A highly sensitive RIA is decisive to obtain
reliable results in small samples or in samples from hypo-
thyroid animals. For determination of tissue T4 content,
commercial assays are not sensitive enough and a highly
sensitive T4 RIA in buffer should be used (83). All assays must
include appropriate blank/control tubes, containing all re-
agents except for the tissue sample, to be used to check the
assay background. Validation of the assay also includes
demonstrating parallelism between a tissue curve (multiple
points with progressively greater amounts of tissue extract)
and the standard curve over the range of interest.
[B.3] Sources of tissue T3 and TR saturation
Background. T3 present in extrathyroidal tissues may be
derived from two distinct sources: plasma T3 and T3 locally
generated from T4 (84,85). The latter mechanism is typically
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found in tissues that express D2 such as brain, pituitary, and
BAT. Estimates suggest that at least half of the T3 present in
D2-expressing tissues is produced locally from deiodination
of T4 (86–89). More recently D2 expression has been found in a
large number of tissues and cells (90–98), illustrating the im-
portance of defining its contribution to tissue-specific thyroid
hormone signaling. The determination of the sources of in-
tracellular T3 is feasible because plasma T3 equilibrates rap-
idly with most tissues (but not all). At the equilibrium time
point (Tm) one can use the plasma T3 concentration and the
nuclear/plasma ratio of tracer T3 to estimate the amount of
nuclear T3 that is derived from plasma. A similar strategy can
then be applied for T4, returning the nuclear T3 that is derived
from local conversion of T4 to T3.
& RECOMMENDATION 9a
The contribution of plasma T3 to tissue T3 can be quantified
by tissue-labeling techniques involving either single intra-
venous injections or pump-driven chronic infusion of
radiolabeled tracer T3.
Commentary. Studies have been standardized in rats but
could in theory be applied in mice as well, provided that
limitations due to body size and anesthesia are overcome.
Tissues can be studied as a whole or fractionated to isolate the
TR-containing nuclear fraction (66,86–89). After the adminis-
tration of [125I]T3, Tm is defined as the time at which the
amount of tracer [125I]T3 entering the tissue or nuclear com-
partment equals the amount of [125I]T3 exiting the same
compartment. Tm is reached within hours of the intravenous
injection or within days of the pump start. At the Tm, the
[125I]T3 plasma/tissue ratio and the plasma concentration of
T3 are used to calculate the tissue T3 concentration. Similar
calculations are used in case radiolabeled tracers are infused
via pumps (99,100). These methods have been standardized
with 125I-T3 separation by descending paper chromatography.
There is good agreement that high performance liquid chro-
matography (HPLC) and ultra performance liquid chroma-
tography (UPLC) are excellent methods for separating labeled
iodothyronines and in theory could be used as well.
& RECOMMENDATION 9b
TR maximum binding capacity in a tissue can be estimated
via saturation analysis with T3 and data reduction using the
Scatchard method.
Commentary. The combined administration of tracer
[125I]T3 with increasing amounts of cold T3 progressively
saturates the high affinity T3 binding sites (TR) (86–89,101). In
this case, nuclei are isolated and processed for [125I]T3 content.
The plasma T3 concentration and the plasma/nuclear ratio at
the Tm are then obtained for each dose of cold T3 that was
injected. Results are expressed per milligram of DNA, and the
Scatchard analysis of the data allows for the calculation of the
TR maximum binding capacity and relative affinity in any
given tissue. The plasma T3 versus nuclear T3 curve makes it
possible to calculate the TR saturation at any given level of T3,
including physiological plasma levels.
& RECOMMENDATION 9c
Dual-labeling techniques using [131I]T3 and [
125I]T4 can be
used to determine the relative contributions of plasma T3
versus locally produced T3 via T4 deiodination to tissue T3
concentration.
Commentary. The administration of [125I]T4 and subse-
quent measurement of plasma and tissue [125I]T3 allows for
the quantification of locally produced T3 in tissues as a whole
or TR-containing nuclear fraction (86–89). Even if relatively
large activities of [125I]T4 are used, the amounts of [
125I]T3
produced at the Tm are minimal in euthyroid animals. Thus,
both plasma and tissue (nuclear) [125I]T3 should be concen-
trated using an anti-T3 affinity column before separation
by chromatography. At the Tm, the plasma/tissue ratio of
[125I]T3/[
125I]T4 and the serum T4 concentration are used to
calculate the locally produced T3. Values of [
125I]T3 are mul-
tiplied by 2 given that there is only one 125I in the phenolic
(outer) ring of [125I]T4 and deiodination occurs randomly be-
tween the 3¢ and 5¢ positions. Appropriate corrections should
be used when the tracer contains radioactive iodine in both
phenolic (outer) and tyrosil (inner) rings. To account (and
discount) for the contribution of plasma [125I]T3 (exiting from
tissues) to tissue [125I]T3, administration of [
125I]T4 is coordi-
nated with the administration of [131I]T3. Because the Tm(T4)
and Tm(T3) are different, the administration of the two tracers
should be timed so that both Tms coincide at the time animals
are killed.
[C] Assessing Thyroid Hormone Transport into Cells
Overview. Based on the lipophilic structure of thyroid
hormones, it was long thought that thyroid hormone enters
the cell through passive diffusion. However, it has become
clear that thyroid hormones are transported across the plasma
membrane via carrier-mediated transport, providing the cell
with an important tool to regulate intracellular thyroid hor-
mone availability. Carrier-mediated transport of thyroid
hormones is facilitated by specific substrate–transporter in-
teractions and predominantly driven down concentration
gradients and, for some transporters, through the co-transport
of other molecules. Solute carriers known to transport thyroid
hormones include monocarboxylate transporters (MCTs),
Na+/taurocholate co-transporting polypeptide, organic anion
transporters (OATs), amino acid transporters (e.g., L-type
amino acid transporters), and organic anion transporting
polypeptides (OATPs) (102–106). The importance of thyroid
hormone transporters is illustrated by the fact that mutations
in human MCT8 cause psychomotor retardation and altered
iodothyronine levels (107,108). With the exception of
OATP1C1 (T4 and 3,3¢,5¢-triiodothyronine [rT3] transport
only), most thyroid hormone transporters transport both T4
and T3. It is important to realize that members of the MCT
family, such as MCT8 and MCT10, facilitate not only the
cellular uptake, but also the efflux of iodothyronines (109).
The physiological role of the transporters is not only depen-
dent on their relative affinities for the thyroid hormones but
also depend upon tissue- and cell-specific expression patterns.
A confounding factor in teasing out the functional role of
specific transporters is the possible expression of different
transporters on the surface of an individual cell type (e.g.,
hepatocytes and neurons). In these instances the relative
abundance of a specific family member will likely determine
the hierarchy of transport functions for a specific cell type.
Finally, several thyroid hormone transporters do not
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transport thyroid hormones exclusively. For example, the
OATPs transport a wide variety of both endobiotics and xe-
nobiotics and possess multiple substrate binding sites
(110,111). This complexity in expression and function reveals
some of the challenges associated with studying thyroid
hormone transport both in vivo and in vitro that must be
considered by the experimentalist.
[C.1] Thyroid hormone transport in vitro
Background. In vitro studies are generally considered for
the biochemical characterization of individual transporters,
study of the effects of specific mutations on transporter
function, and elucidation of the role of specific transporters
expressed in individual cell types. A primary consideration
is assurance that the experiment is properly designed and
controlled to test the function of specific transporters versus
the collective action of multiple transporters expressed in
the same cell. Kinetic studies require consideration of possible
confounding factors such as assurance of plasma membrane
localization of the expressed transporter, bidirectional sub-
strate transport, choice of experimental cell type, and typical
versus atypical kinetics.
& RECOMMENDATION 10a
Iodothyronine transport into cells can be studied in cells
transiently expressing wild-type or mutant thyroid hor-
mone transporters.
Commentary. Assessing functionality of cloned wild-
type or mutant thyroid hormone transporters is readily
achieved by conducting uptake experiments (110,112). Proper
controls include comparison to cells transfected with empty
vector and inhibition of labeled thyroid hormone uptake by
co-incubating with excess cold hormone. The latter control is
critical to ensure that the observed cell associated thyroid
hormone uptake is a saturable process and is not simply as-
sociated with nonspecific binding of labeled hormone to the
cell. For general transport assays, uptake commences with the
addition of labeled substrate to the cells and terminates at
specific time points with rapid washes with cold transport
buffer. These wash steps are essential, since iodothyronines
tend to adhere to the cell walls. Attention should be given to
the selection of transport buffer (e.g., Krebs-Henseleit buffer,
Dulbecco’s modified Eagle’s medium/F12, or regular PBS
with/or without BSA). It is important to realize that different
transport buffers can contain large amounts of amino acids,
which may also be transported by certain transporters and
thereby influence the results of uptake experiments. BSA can
be added to the medium to keep iodothyronines in solution
and prevent the adsorption to plastics. However, by de-
creasing the free iodothyronine concentration it may also limit
substrate availability.
Transport buffers preferably contain no serum at all, since
even ion-exchange resin-stripped serummay still contain low
levels of thyroid hormones interfering with the uptake assay.
As a consequence, kinetic measurements (e.g., transport
constants, maximal velocities) cannot be determined. Uptake
is calculated from the proportion of radioactivity associated
with the cell lysate compared with the total radioactivity as-
sociated with the isotopic transport buffer. Background ra-
dioactivity in cells transfected with empty vector is subtracted
from all samples. Uptake is calculated from the proportion of
radioactivity associated with the cell lysate compared with
total radioactivity associated with the isotopic transport buf-
fer and expressed in units of picomoles per minute (113,114).
Different results may be obtained in different cell types,
depending on the endogenous expression levels of thyroid
hormone transporters and/or other factors necessary for
thyroid hormone transport. When studying the function of
mutant transporters, it may be useful to compare results in
cells with high versus low endogenous expression levels.
Thyroid hormone transporters exhibit bidirectional trans-
port. For some transporters such as the OATPs, an anti-ported
substrate is thought to be required for thyroid hormone
transport across the plasma membrane and should be con-
sidered when choosing a transport buffer. Accumulation of
transported thyroid hormones in the cell is necessary for as-
sessing transport activity and can present a problem for some
bidirectional transporters because the substrate may rapidly
efflux thyroid hormones from the cell. Co-transfection with
intracellular thyroid hormone binding proteins such as mu-
crystallin provides a method for ensuring accumulation of
transported hormone (109,115,116). One caveat, however, is
that use of suchmethods precludes subsequent kinetic studies
because hormone transport will likely not ever reach steady-
state.
To study the consequences of overexpression of a specific
thyroid hormone transporter on intracellular availability of
thyroid hormone, cells can be co-transfected with an io-
dothyronine deiodinase and subsequently analyzed for me-
tabolism (114). Alternatively, Xenopus oocytes can be used for
transport studies (118).
& RECOMMENDATION 10b
Determining the substrate specificity and kinetic charac-
teristics for thyroid hormone transporters requires com-
mitment to testing various substrates at a wide range of
concentrations.
Commentary. The substrate specificity of (putative) thy-
roid hormone transporters can be investigated by incubation of
cells with different putative radioactive ligands, including the
different iodothyronines T4, T3, rT3, and 3,3¢-diiodothyronine
(T2), as well as thyroid hormone analogues such as 3,5,3¢-
triiodothyroacetic acid (tiratricol, also known as TRIAC) and/
or various amino acids such as Leu, Phe, Tyr, and Trp. Speci-
ficity of TH transport can be measured by determining the
uptake of radiolabeled iodothyronines in the presence of
putative competitors, including unlabeled iodothyronine de-
rivatives such as D- and L-iodothyronines, tiratricol, tetra-
iodothyroacetic acid (Tetrac), and amino acids.
Characterization of kinetic parameters of cloned wild-type
and mutant thyroid hormone transporters requires first de-
termining the time course of substrate influx into the trans-
fected cells. From these data a time point is identified when
substrate uptake is close to maximal but transport has not yet
reached steady-state. All further kinetic studies are then
conducted by measuring substrate accumulation in trans-
fected and control cells at this identified time point.
For analysis of transporter mutants it would be expected
that mutants may possess altered kinetic activities. Therefore,
for the time course study the investigator should assess up-
take at multiple time points over the course of 120 minutes.
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Mutants can be subjected to Michaelis–Menten kinetic anal-
ysis to quantify potential changes in thyroid hormone trans-
port kinetics.
For the subsequent kinetic studies, a time point should be
chosen prior to steady-state when maximal differences be-
tween expressed transporter versus empty vector uptake are
observed. At this time point, one can measure the uptake
using multiple different substrate concentrations spanning
the dynamic range of detection for each substrate. Since these
large experiments are difficult to perform, many investigators
choose to limit the number of data points collected, accepting
a less accurate estimation of transport kinetics. Notably, sa-
turability and apparent Km values may be influenced by
binding of iodothyronines to proteins such as BSA in the
medium.
Assessment of OATP function is even more difficult as
these transporters possess multiple substrate binding sites
and thus exhibit atypical transport kinetics (110,119). To
properly assess OATP transport kinetics gather kinetic data as
described above and use additional methods to analyze the
data (110,120–122). These transport kinetics cannot be deter-
mined for transporters with high efflux capacity, such as
MCT8 and MCT10, which may require co-transfection with
intracellular binding proteins (see previous discussion).
& RECOMMENDATION 10c
Assessing thyroid hormone transport in dissociated pri-
mary cell cultures in vitro is only of limited value if mixed
cell cultures are used.
Commentary. A caution when working with primary
cells is potential rapid down-regulation of transporter ex-
pression (123). Tracking transporter expression by Western
blot or immunocytochemistry over time in culture is therefore
critical. In addition, the presence of a mixed cell population
mandates identification of cell types expressing specific
transporters (124). However, lack of antibody specificity may
pose significant problems for tracking the expression of spe-
cific members of large transporter families with multiple
closely related members.
& RECOMMENDATION 11
Confirmation of proper plasma membrane localization is
necessary for studies utilizing cells transiently expressing
thyroid hormone transporters.
Commentary. Ensuring that the assessed transporters are
localized to the plasma membrane is of key importance for
in vitro studies. When appropriate antibodies are available
Western analysis should first be performed to ensure protein
expression followed by fluorescent immunocytochemistry to
assess subcellular protein localization. When studying trans-
fected cells, it is important to study cells with low levels of
endogenous expression of the transporter of interest. For ex-
ample, JEG3 cells are an excellent model to study plasma
membrane localization of mutated MCT8 or MCT10 because
of their low levels of endogenous expression of MCT8 and/or
MCT10. For biochemical analysis, epitope-tagged cloned
transporters provide a ready antigenic target for bothWestern
blot and immunocytochemical analysis. Subcellular localiza-
tion is preferably determined by confocal microscopy because
typical wide-field fluorescent microscopy will not readily
distinguish between cell surface and intracellular labeling.
Appropriately expressed protein is primarily localized in the
plasma membrane with limited intracellular staining. This
analysis is crucial for proper evaluation of genetic mutants as
a lack of transport observed in in vitro assays could be either
due to a lack of transport function or an inability to properly
traffic the protein to the plasma membrane. In both scenarios
the transport assay would demonstrate a loss of transporter
function, although the biochemical explanation for this result
would be markedly different. Note that these studies may be
difficult to perform in transiently transfected cells, due to a
relatively low transfection efficacy. For such studies the use of
stably transfected cells may be more useful.
[C.2] Thyroid hormone transport in vivo
Background. In vivo study of thyroid hormone transport
is considered for elucidating the physiological and patho-
physiological roles of specific transporters and for determin-
ing the kinetics of tissue influx and efflux of thyroid
hormones. Kinetic studies require consideration of possible
confounding factors such as first pass metabolism of injected
tracer hormone, the presence of multiple thyroid hormone
transporter familymembers in a single tissue or even cell type,
and developmental changes in transporter expression pat-
terns. Consequences of defective thyroid hormone transport
on thyroid hormone signaling can be analyzed using genome
wide analysis (Section I.3) on patient material such as fibro-
blasts (125), whereas consequences for different systemic
biological parameters can be analyzed using different knock-
out mouse models [see Sections I.5 and J; see Heuer and
Visser (126) for a review].
& RECOMMENDATION 12a
For in vivo studies, net thyroid hormone transport typically
represents the summation of a number of different trans-
porter activities. Assessing the contribution of a given
transporter to net transport requires examination of all
transporters expressed in the tissue.
Commentary. In vivo measures of thyroid hormone
transport are confounded by the expression of multiple thy-
roid hormone transporters in most tissues. A key consider-
ation is to determine the transporter expression profiles and
levels in specific cell types in targeted tissues. Since the affinity
for T4 and T3 is similar across most transporters, the contri-
bution of an individual transporter generally follows its
expression levels. Experimental design should take the pos-
sibility of both hormone influx and efflux into consideration
[see Heuer and Visser (126) for a review]. Consequences of
defective thyroid hormone transport for thyroid hormone
signaling can be analyzed using genome wide analysis (see
Section I.3) of patients’ material such as fibroblasts (125) or
different tissues of knock-out mice (127).
& RECOMMENDATION 12b
Metabolism of assessed thyroid hormones must be con-
sidered when measuring transport in vivo.
Commentary. Thyroid hormones are subjected to me-
tabolism in vivo including deiodination and conjugative me-
tabolism. Importantly, suchmetabolism impacts the transport
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fate of the hormones and when the thyroid hormones me-
tabolized are radiolabeled tracer substrates, interpreting ob-
tained results is difficult. Control over metabolism can be
exerted if single pass strategies are used such as direct can-
nulation of vessels leading to target tissues followed by con-
tinuous infusion of defined transport buffer and substrate.
Such strategies limit metabolism of the substrate and loss to
peripheral tissues and allow direct measurement of thyroid
hormone transport in the tissue assessed. As an example,
measurement of thyroid hormone transport across the blood–
brain barrier would be best achieved using the in situ brain
perfusion method (128). This methodology allows accurate
kinetic measurements such as transport rates and transport
affinities and can be conducted in neonatal to adult animals.
Comparison of transport kinetics in wild-type and specific
transporter null animals would allow determination of the
specific contributions of individual transporters in vivo.
[D] Assessing Thyroid Hormone Deiodination
Overview. The major circulating iodothyronine is T4.
However, T4 can be converted in the tissues to T3, the prin-
cipal thyroid hormone that binds to the nuclear receptors and
initiates thyroid hormone action (129). In extrathyroidal tis-
sues, the concentration of T3 in the intracellular and nuclear
compartments is determined in part by the rates of T4 to T3
conversion and T3 and T4 degradation in the cell (84,130–132).
The formation and degradation of T3 in tissues are depen-
dent primarily on the activities of three integral-membrane
thioredoxin-fold–containing selenoenzymes of approxima-
tely 60 kDa (dimer) that catalyze the selective removal of
iodine from iodothyronines (132–135). The type I deiodinase
(D1) and D2 enzymes are activating enzymes that catalyze
the outer-ring or 5¢-deiodination (5¢D) of T4 to T3. D3 is
an inactivating enzyme that catalyzes the inner-ring or 5-
deiodination (5D) of both T4 and T3 to their relatively inactive
derivatives, rT3 and T2, respectively. The D1 can also inacti-
vate the thyroid hormones by catalyzing the inner ring deio-
dination of sulfated iodothyronine conjugates (130–132).
Levels of activity of D1, D2, and D3 can be studied in cultured
cell preparations (136,137), tissue slices (138,139), and tissue
homogenates (140,141).
[D.1] Identification, expression, and quantification
of deiodinases
Background. The presence of the deiodinases can be
identified in a given tissue and their levels of activity quan-
tified using well-established assays for enzyme activity and
kinetic properties. In the cases of D1 and D3, tissue content of
deiodinase protein can be assessed by immunohistochemical
techniques using available antisera/antibodies (142). Levels
of expression of all three deiodinase genes can be determined
using samples of RNA prepared from the tissue of interest by
standard reverse transcriptase quantitative polymerase chain
reaction (RT-qPCR) techniques (127).
Assay of levels of deiodinase activity and/or the enzyme
reaction kinetics in broken cell/tissue preparations requires the
presence of compounds containing free sulfhydryl groups such
as dithiothreitol (DTT). Assay of D1, D2, and D3 activity levels
are generally carried out using radioactive iodothyronines as
substrates followed by quantitation of the radioactive products
generated per unit time. Alternatively, in the case of the D1 and
the D2, activity levels can be determined using nonradioactive
T4 and quantifying the T3 generated by RIA.
& RECOMMENDATION 13a
Deiodinase activities and their kinetic profiles and intrinsic
properties (e.g., Vmax, Km, activity half-life, sensitivity to
cofactors and/or inhibitors) can be determined in cell or
tissue preparations.
Commentary. There aremultiple protocols for deiodinase
assays, and they are all acceptable provided that some re-
quirements are followed. In general, release of tracer radio-
active iodide or generation of a specific deiodinase product
are the experimental endpoints measured. It is always best to
use radiolabeled iodothyronines with the highest available
specific activity. Even when they are stored in the dark at 4C,
there is spontaneous iodothyronine deiodination. Thus, in
order to minimize background levels, tracers should be pu-
rified in Sephadex LH50 at least 24 hours before the assay.
All assays should contain background controls in which there
is no deiodinase-mediated substrate deiodination. Ideally,
duplicate samples are run in parallel in tubes containing a
large excess of substrate that outcompetes the radiolabeled
iodothyronine.
Assay for D1 activity. The preferred substrate for D1 is rT3;
taking the Vmax/Km ratio as a measure of efficiency, rT3
performs as much as 700 times better than T4 as a substrate for
D1. In addition, unlike T4, rT3 it is a relatively poor substrate for
D3 and thus is the better substrate with which to assay D1 in
tissues that also contain D3 activity. At the same time, D1 ac-
tivity can also be determined using T4 as substrate. The reaction
buffer varies somewhat among laboratories but most are car-
ried out in a PBS or 2-amino-2-hydroxymethyl-1,3-propanediol
hydrochloride (Tris-HCl) buffer containing ethylenediamine-
tetraacetic acid (EDTA; 1–2mM), sucrose (0.25–0.3M), and
DTT (10–50mM). The substrate concentration is 0.1–2lM. The
amount of tissue presentmust be adjusted to ensure a relatively
low percent deiodination (<30%) in order to avoid a significant
alteration of the enzyme kinetics. With broken cell prepara-
tions, the incubation time should be 1 hour or less. When
deiodinase activity is studied in tissue slices or whole cells, the
tissue or cells should be homogenized on ice in their incubation
media prior to analysis of the products, since iodothyronines
tend to adhere to cell walls.
The iodinated products can be quantified in various ways.
Arguably the simplest method is to pass the reaction mixture
through a column of Biorad AG 50W-X8(H+) resin soaked in
10% acetic acid. The iodothyronines are adsorbed on the resin,
and the inorganic iodide passes through and can be quantified
directly. Others have used precipitation of horse serum (car-
rier) with TCA to separate the free iodide (143). Either method
requires determination that equimolar amounts of 125I and
[125I]T3 (or [
125I]T2 if [
125I]rT3 is used as a substrate) are pro-
duced, particularly if the level of enzyme activity is low or if
non-deiodinative pathways are present. This is achieved by
separating the [125I]-iodothyronines and 125I by paper des-
cending chromatography, HPLC, or UPLC. For calculating
the 5¢D activity, the percentage of product generated is mul-
tiplied by 2 because the specific activities of the labeled
products are only half that of the substrate. D1 activity is
generally expressed as picomoles or femtomoles of product
per unit of time per milligram of protein (144–147).
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Assay for D2 activity. This assay is carried out as described
for the D1 assay with the following modifications: the pre-
ferred substrate is T4 (0.5–2 nM) and if tissues that also contain
D1 activity are being used, 1mM PTU is included in the in-
cubation medium. If D3 is present, it should be saturated by
adding an appropriate excess of T3 (146–149).
Assay for D3 activity. The preferred substrate for D3 is T3
(0.5–2 nM), and since T3 is a very poor substrate for D1 and
D2, it can be successfully used to assay D3 activity in tissues
that also contain D1 and/or D2 activity. Addition of EDTA to
the assay buffer is not necessary. In this assay, since the ra-
dioactive substrates are labeled in the outer-ring only, the
iodide generated cannot be detected, and thus quantitation of
the reaction necessitates the separation of the T2 product from
the substrate T3 by HPLC or descending paper chromatog-
raphy. Since the T2 generated is also a good substrate for D3, it
is important to dilute the enzyme preparation such that the
percent deiodination is relatively low (<20%) and T2 is the
only detectable compound produced (147,150–152).
& RECOMMENDATION 13b
Studies of deiodinase activity in cell or tissue preparations
containing more than one deiodinase are feasible but spe-
cial provisions must be considered so that each deiodinase
activity is measured independently.
Commentary. Often times not only the substrate of a
given deiodinase but also the deiodination product can serve
as a substrate for another deiodinase co-expressed in the same
cell or tissue. Thus, to observe the activity of a specific deio-
dinase requires the use of enzyme-specific inhibitors and
different substrate types and/or concentrations (Fig. 9) (153–
156). For example, measuring outer-ring D1 activity in the
presence of D2 is possible if T4 or rT3 are used at their D1 Km
(i.e., approximately 1lM and 0.5 lM, respectively), which
saturates D2.Measuring inner-ring D1 activity in the presence
of D3 is possible if T3 or T3 sulfate (T3S) is used at its D1 Km
(i.e., approximately 5 lM), which saturates D3. D1 is effi-
ciently inhibited in the presence of 1mMPTU, which has only
minimal effect on D2 activity. This eliminates D1 activity from
any D2 or D3 activities, which are not affected by PTU.
No specific inhibitors are known for D2 or D3. However,
both D2 and D3 activities can be eliminated by adding a rel-
ative excess of their preferred substrate (i.e., T4 or T3, respec-
tively), saturating the enzyme and outcompeting the
radioactive tracer. For example, measuring D2 activity in the
presence of D3 is possible by using rT3 or T4 as substrate and
adding 100–1000 nMT3 in the reactionmixture. Adding the T3
excess saturates D3 binding sites but does not interfere with
the D2 activity. However, a high purity reagent is preferred
because, at high concentrations, even small amounts of a
contaminant iodothyronine will interfere with the assay.
& RECOMMENDATION 14a
The Vmax of any of the deiodinases measured under op-
timum conditions of substrate and cofactor availability can
be used as a surrogate for the amount of functional enzyme
present in a cell or tissue at any given moment.
Commentary. While D1 and D3 are expressed at levels
that can be measured by Western blotting or immunocyto/
histochemistry using commercially available antisera
(65,157,158), the combined low expression of D2 with the un-
availability of sufficiently high affinity D2 antisera has im-
paired quantification of D2 protein (159). In fact, no consensus
exists as to the validity of anti-D2 antiserum/antibodies for
measurement of endogenous protein; results need to be
evaluated on a case-by-case basis. However, an estimation of
D2 protein levels can be obtained reliably by measuring D2
Vmax, which reflects themaximal amount of active enzyme in
a cell or tissue. D1 and D3 can be assessed either via Vmax or
Western blot. The protein levels of all three deiodinases can be
quantified after labeling of deiodinase-expressing cells with
75Se, immunoprecipitation, and resolution by sodiumdodecyl
FIG. 9. Strategies to measure individualized deiodinase activity in the presence of other deiodinases. (A) Two strategies to
assess type II deiodinase (D2) activity in the presence of type I deiodinase (D1; e.g., in the human thyroid): (i) use 1mM 6-n-
propyl-2-thiouracil (PTU) to inhibit D1 or (ii) use 1–2 nM [125I]T4 in the presence or absence of 100 nM cold thyroxine (T4). (B)
To measure D2 activity in D2/D3 co-expressing tissues (e.g., the brain), use 1000 nM cold T3 to saturate D3. (C) To measure
D2 activity in D1/D2/D3 co-expressing tissues (e.g., rodent gonads, placenta, cerebrum, and skin), inhibit D1 with 1mM
PTU and saturate D3 with 1000 nM T3.
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sulfate polyacrylamide gel electrophoresis, but this takes
several weeks per assay for D2 (93). Note that biological al-
teration of Km (e.g., amino acid mutations) could alter the
relationship between Vmax and protein levels.
& RECOMMENDATION 14b
The expression of the deiodinase genes can be determined
in cells or tissues by measuring the respective mRNA
levels.
Commentary. Measuring D1 mRNA levels is straight-
forward, and given its exquisite responsiveness to T3, it con-
stitutes a sensitive marker of peripheral thyroid status in
rodents (72). D2 is a cAMP-dependent gene and its mRNA
levels can be up-regulated several-fold during sympathetic
stimulation of BAT (161). At the same time, D2 exhibits strong
posttranslational regulation via ubiquitination and proteaso-
mal degradation by different components of the endoplasmic
reticulum (162–165). Thus, mRNA levels do not necessarily
reflect protein expression or enzyme activity (162,166,167).
The Dio3 gene is intronless, and thus appropriate controls are
required given that even minimal DNA contamination could
affect the RT-qPCR results. D3 has a relatively long half-life,
and thus a high level of D3 activity can persist even after an
elevation in D3 mRNA has dissipated (168,169). In situ hy-
bridization is particularly useful in the brain given the com-
plexity in the expression patterns of D2 and D3 (170–172) (see
Sections I.2 and J.1 for technical considerations).
[D.2] Deiodination in intact cells
Background. Deiodination can be studied in intact live
cells. Essentially, established cell lines or primary cultures
expressing 5¢D and/or 5D activity are exposed to the appro-
priate [125I]-substrate (as previously discussed) and the radi-
olabeled products determined in the media and/or in cell
sonicates as already described.
& RECOMMENDATION 15
T4 and T3 metabolism via deiodination can be measured in
live cells with the advantage that studies are performed
with physiological cofactor.
Commentary. Cells are incubated with [125I]T4 or
[125I]T3 in the presence of media containing 0.1%–1.0% BSA
with added T4 and/or T3 to yield a physiological concen-
tration of free hormone in the low picomolar range (Table 2).
Metabolites in the media or in the cells are separated by
liquid or paper chromatography (as already described). The
reaction time is typically 24 hours or less. Color-free culture
media must be used due to interference with the assay. The
desired concentration of the substrate is achieved by incu-
bating cells in serum-free media containing 0.1% BSA and
including the appropriate concentration of nonradioactive
T4 and/or T3. Time courses can be established by sampling
the media followed by quantification of the products as
described above. Results are expressed as picomoles or
femtomoles of product per unit of time; correction for the
number of cells can be achieved by cell counting or by de-
termining the DNA or protein content. Studies in cells
containing more than one deiodinase are feasible and
should include appropriate controls in which one of the
deiodinative pathways is saturated with an excess of non-
labeled substrate (136,137,152).
Coculture systems with more than one cell type have been
developed in which thyroid hormone transport, metabolism,
and action can be studied simultaneously (i.e., D2-expressing
H4 human glioma cells and D3-expressing SK-N-AS human
neuroblastoma cells; Fig. 10) (173). Such a system has been
used to demonstrate that paracrine signaling by glial cell-
derived T3 activates neuronal gene expression.
[D.3] Deiodination in perfused organs
Background. Outer-ring and inner-ring deiodination can
be studied in perfused organs such as kidney and liver. Es-
sentially, freshly harvested organs expressing 5¢D and/or 5D
activities are perfusedwith buffered solutions containing BSA
and radiolabeled or cold iodothyronine substrates. The per-
fusate is collected over time and analyzed for deiodination
products using immunoassays or HPLC. This approach is
advantageous because it allows for the study of tissue-specific
deiodinative pathways under physiological or defined patho-
physiological conditions.
& RECOMMENDATION 16a
T4 to T3 conversion and the urinary iodothyronine excre-
tion can be studied in preparations of perfused rat kidney
or liver.
Commentary. In preparations of kidney perfused with T4
in BSA-containing buffer there is a liner increase in T3 pro-
duction with the increase in the perfusate FT4 concentration
that determines tissue T4 uptake. FT4 levels can be adjusted by
increasing or decreasing the concentration of total T4 or the
BSA concentration. Addition of PTU decreases renal T3 pro-
duction by about 60% without affecting tissue T4 uptake, il-
lustrating the presence of D1. In this setting there is no net
renal rT3 production from T4, and degradation and urinary
excretion of T3 are negligible (174–176).
Similar to the kidney, the perfused rat liver readily extracts
T4 from perfusionmedium and converts it to T3. Production of
T3 is a function of the size of the liver, the uptake of T4, and
Table 2. Free Fractions of T4 and T3 ( ·100
and Expressed as Percentage) for the Common
Media Types Containing Different Percentages
of Bovine Serum Albumin/Serum
Media type T3 (%) T4 (%) Reference
BSAa
4% 0.56 0.09 (648)
1% 2.18–2.3 0.29–0.32 (745,746)
0.5% 3.45–3.78 0.41 (747–749)
0.1% — 3.39–3.6 (747,748)
Bovine serum
10%b 4 0.45 (316)
10% (stripped)c 1.5–4 0.8 (750,751)
10% (Tx) 0.4–2.0 (281)
aDirect measurements by equilibrium dialysis.
bDirect measurement by ultrafiltration.
cCalculated based on total and free hormone concentrations
(equilibrium dialysis).
T4, thyroxine; BSA, bovine serum albumin; Tx, thyroidectomized.
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level of D1 expression. Production of T3, but not T4 uptake, is
decreased by PTU (177,178).
& RECOMMENDATION 16b
Placental inner-ring deiodination can be studied in situ
using a guinea pig perfusion system.
Commentary. Whereas placental D2 andD3 activities can
be measured in cell dispersions or tissue sonicates (179–182),
in situ preparations can be used to study the placental D3
pathway (183,184). In an anesthetized pregnant guinea pig, the
placenta is surgically exposed and a single umbilical artery and
the umbilical vein cannulated, while the fetus is removed. The
fetal side of the placenta is perfused through the umbilical ar-
tery with buffered solution containing BSA and [125I]T3. Pla-
centa effluent fractions are collected at timed intervals (up to 2
hours) from the umbilical vein cannula. The contents of the
perfusion buffer and the various effluent fractions are then
separated and analyzed by HPLC for their iodothyronine
content (183). In this setting outer-ring deiodination of T4 or rT3
is minimal (184) possibly because placental outer-ring deiodi-
nation is greatest in the zone immediately adjacent to the
uterine wall (185), distant from the fetal side of the organ.
[D.4] Deiodination in whole animals
Background. The study of the deiodination pathways in
the whole animal is challenging since one is dealing with three
deiodinases, each of which can deiodinate not only T4 and/or
T3, but also the products of these reactions. In addition there are
no known agents that will selectively and completely inhibit
individual deiodinases. Thus, until mice deficient in one or
more of the deiodinases became available, it was very difficult
to investigate the role of the individual deiodinases in vivo.
& RECOMMENDATION 17
Total body deiodination can be studied in live animals
following administration of radiolabeled iodothyronines
(e.g., [125I]T4 or [
125I]T3). Iodothyronines can be injected
acutely or long-term via a mini-pump. This approach
FIG. 10. In vitro modeling of thyroid hormone deiodination and transport in the brain. (A) Schematic representation of the
Transwell System in which an insert is placed on a six-well plate and cells (D2-expressing H4 glial cells) are seeded inside the
insert; D3-expressing neuroblastoma cells (SK-N-AS) are seeded at the bottom of the six-well plate. After cells are seeded, both cell
types are kept separated overnight and then placed together in the same multiwell plate as indicated. (B) At the end of the
incubation medium samples are collected, extracted and processed through a UPLC or HPLC connected to the flow gamma
counter to separate and quantify the activity of each iodothyronine. The red arrow indicates the pathway completed by the
column eluate through the gamma counter; courtesy Dr. Antonio Bianco. (C) Chromatograms of H4 cell medium at the indicated
times after addition of 125I-T4. Typical peaks of
125-T3 and
125I are shown after 24 hours. (D) Same as in (C), except that 125I-T3 was
added to cultures of SK-N-AS cells and 125I-T2 and
125I-T1 peaks are visualized. (E) Same as in (C), except that
125I-T4 was added to
H4 and SK-N-AS cocultures and the indicated peaks are visualized. UPLC, ultrahigh performance liquid chromatography; HPLC,
high performance liquid chromatography; T1, 5¢-monoiodothyronine. Reproduced with permission from Freitas et al. (173).
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allows for studies to be conducted under controlled phys-
iologic conditions. Additional information may be ob-
tained by administering more than one iodothyronine
labeled with different isotopes of iodine.
Commentary. Total body phenolic-ring deiodination can
be readily assessed in rodents following the administration of
a single dose of [125I]T4 or [
125I]T3. The rodents are then placed
in individual cages that permit the separate collection of urine
and feces. After an appropriate period of time (42–72 hours)
the fraction of the injected radioactivity excreted in the urine
can be determined, and the vast majority of this will be in-
organic iodide (186). This protocol can be used to assess the
effects of different conditions such as fasting, cold exposure,
hyper- or hypothyroidism, and the absence of one or more of
the deiodinases on total deiodination. This type of study can
be carried out using a relatively low level of radioactivity.
However, obtaining any reliable information regarding the
extent of T4 conversion to T3 or rT3 by this method is com-
plicated by the fact that both compounds are cleared from
serum at a faster rate than T4 itself.
Some information concerning the labeled products
formed from [125I]T4 or [
125I]T3 can be obtained using ani-
mals implanted with osmotic mini-pumps containing the
labeled hormones. Once the daily excretion of radioactivity
in the urine and feces becomes constant, indicating that the
animals have reached isotopic equilibrium, the animals can
be sacrificed. The serum, tissues, urine, and feces can be
obtained and the identity of their labeled compounds de-
termined, following their extraction and separation by
HPLC or chromatography. Parallel studies using mice defi-
cient in one or more of the deiodinases will shed light on the
relative importance of the different metabolic pathways.
Several extraction procedures have been published and care
must be taken to determine and correct for extraction effi-
ciency (83,187).
Results of these studies must be interpreted carefully and
alternative possibilities considered. For example, it is well-
established that both T4 and T3 can be conjugated with sulfate
in vivo, and these conjugates are excellent substrates for the
inner-ring deiodinating activity of the D1. The thyroid hor-
mones are also conjugated with glucuronic acid and most of
the T4 in the kidney is present as T4 glucuronide, which is not
detected in an RIA (137). In addition, a significant fraction of
the metabolites generated from T4 and T3, including the glu-
curonide conjugates, are to be found in the bile, the intestinal
contents, and feces.
[D.5] Non-deiodination pathways
of thyroid hormone metabolism
Background. Nonnutrient substances that reach the gas-
trointestinal system are also known as xenobiotic compounds
and are identified in the liver through specific receptors; for
example, pregnane X receptor (PXR) and constitutive an-
drostane receptor (CAR). Binding to these xenobiotic sensing
receptors, PXR and/or CAR, induces the expression of met-
abolic enzymes including Phase I (the cytochrome P450
family of enzymes) and Phase II (e.g., sulfotransferases, glu-
curonosyltransferases, and glutathione-S transferases). These
pathways modify xenobiotic molecules by introducing reac-
tive or polar groups into their molecules to increase their
water solubility, thereby facilitating their elimination. The
Phase II pathways include glucuronidation, methylation,
sulfation, acetylation, glutathione conjugation, and amino
acid conjugation.
Perhaps because of the high iodine content, the iodothyr-
onines are alsometabolized by some of the Phase II pathways;
that is, conjugation of the phenolic hydroxyl group with sul-
fate or glucuronic acid (188). In fact, a relatively small portion
of the daily thyroid hormone production is processed through
these pathways, but it can be much more if these metabolic
pathways are induced by xenobiotic compounds such as
central nervous system (CNS)-acting drugs (e.g., phenobar-
bital, benzodiazepines), calcium channel blockers (e.g.,
nicardipine, bepridil), steroids (e.g., spironolactone), reti-
noids, chlorinated hydrocarbons (e.g., chlordane, dicholoro-
diphenyltrichloro-ethane, tetrachlorodibenzo-p-dioxin, and
polyhalogenated biphenyls such as polychlorinated biphenyl
and polybrominated biphenyl, among others) (189).
Sulfated iodothyronines do not bind to the TRs, and sulfa-
tion mediates the rapid and irreversible deiodination of io-
dothyronines by D1. Therefore, the concentrations of sulfated
iodothyronines in serum are normally low. Inner-ring deiodi-
nation (inactivation) of T4 and T3 by D1 is markedly facili-
tated after sulfation, whereas outer ring deiodination of T4 is
blocked after sulfation. As expected, the D1 KOmouse exhibits
marked increase in fecal excretion of [125I]-iodothyronines
during the 48h after injection of [125I]T4 or [
125I]T3, whereas
urinary excretion of [125I]iodide was markedly diminished
(186). Notably, D2 and D3 are not capable of deiodinating
sulfated iodothyronines. Plasma levels and biliary excretion of
iodothyronine sulfates are increased in fetal and cord blood,
nonthyroidal illness (NTI), fasting, and by inhibition of D1
activity with PTU or iopanoic acid (190). Under these condi-
tions, T3Smay function as a reservoir of inactive hormone from
which active T3 may be recovered by action of tissue sulfatases
and bacterial sulfatases in the intestine (188).
Iodothyronine glucuronides are rapidly excreted in the bile.
However, this is not an irreversible pathway of hormone
disposal. After hydrolysis of the glucuronides by bacterial
b-glucuronidases in the intestine, part of the liberated io-
dothyronines are reabsorbed, resulting in an enterohepatic
cycle of iodothyronines (188). Nevertheless, about 20% of
daily T4 production appears in the feces, probably through
biliary excretion of glucuronide conjugates. Glucuronidation
is catalyzed by UDP-glucuronyltransferases (UGTs) that uti-
lize UDP-glucuronic acid (UDPGA) as the cofactor. UGTs are
localized in the endoplasmic reticulum predominantly of
liver, kidney, and intestine. Most UGTs are members of the
UGT1A and UGT2B families (191).
In general, the relation between tissue enzyme activities
for the different iodothyronines and the expression of indi-
vidual isoenzymes is hardly known, especially for the sulfo-
transfereases (SULTs). Many SULTs exhibit overlapping
substrate specificities. In addition,multiple SULTs in the same
tissue can be involved in the sulfoconjugation of the same
iodothyronines, resulting in clear redundancy [see Wu et al.
(192) for an overview]. As a consequence, the biochemical
properties of tissue SULT activity reflect the composite effect
of different isoenzymes. Expression or protein levels of the
different isoenzymes can be studied using RT-qPCR and/or
Western blotting, but do not necessarily reflect the overall
tissue sulfoconjugation activities (192,193).
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& RECOMMENDATION 18a
Sulfotransferase activities and their intrinsic properties can
be determined in cell or tissue preparations using 3¢-
phosphoadenosine-5¢-phosphosulfate (PAPS) as the sulfate
donor.
Commentary. Iodothyronine sulfation is catalyzed by
SULTs using PAPS as the sulfate donor. In humans, SULTs
show overlapping substrate specificity. In humans, they can
be subdivided into different families, SULT1, SULT2, SULT4,
and SULT6. All members of the human SULT1 family (i.e.,
hSULT1A1, -1A2, -1A3, -1B1, -1C2, -1C4, and -1E1) catalyze
the sulfation of iodothyronines (194). hSULT1A1-3, -1B1, and -
1C4 and also native enzymes in liver have a substrate pref-
erence for 3,3¢-diiodothyronine (T2), which is catalyzed much
faster than T3 and rT3, whereas T4 sulfation is negligible.
hSULT1E1 equally prefers T2 and rT3 over T3 and T4 but is the
only known SULT so far having significant T4-sulfotransfer-
ase activity (194). As a consequence, T2 is generally used to
study sulfotransferase activities in tissues homogenates under
different conditions. Different human SULTs have also been
shown to catalyze the sulfation of iodothyronamines (195).
Sulfotransferase activity assay. There are multiple accept-
able protocols for sulfotransferase assays. It is best to use
radiolabeled iodothyronines with the highest available spe-
cific activity and assays should contain background controls
and samples running in parallel in tubes without PAPS.
Due to relatively high Km values, it may be difficult to out-
compete the radiolabeled iodothyronine by a large excess of
substrate. SULT activity can be analyzed by incubation of
0.1 lM [125I]-iodothyronine of interest for 30 minutes with
tissue homogenate, cytosol, or recombinant SULT in the
presence or absence (blank) of 50lM PAPS in PBS-EDTA
buffer (194). The reaction is stopped by the addition of 0.1M
HCl and the products separated by filtration in Sephadex LH-
20 minicolumns into iodide, sulfated iodothyronines, and
nonsulfated iodothyronines (196).
& RECOMMENDATION 18b
Iodothyronine glucuronidation activities are determined in
microsomal cell or tissue preparations using UDPGA as a
cofactor.
Commentary. Glucuronidation of T4 and T3 is catalyzed
by differentmembers of the UGT1A family (197). Usually, this
involves the glucuronidation of the hydroxyl group, but
human UGT1A3 also catalyzes the glucuronidation of the
side-chain carboxyl group, with formation of so-called acyl
glucuronides. Interestingly, Tetrac and TRIAC aremuchmore
rapidly glucuronidated in human liver than T4 and T3, and
this occurs predominantly by acyl glucuronidation (198). Acyl
glucuronides are reactive compounds that may form covalent
complexes with proteins. It is unknown if this is a significant
route for the formation of covalent iodothyronine–protein
complexes.
Glucuronidation activity assay. There are multiple accept-
able protocols for glucuronyl-transferase assays. Radio-
labeled iodothyronines with the highest available specific
activity should be used and assays should contain back-
ground controls. Iodothyronine glucuronidation activity can
be analyzed by incubation of 1lM of the [125I]-iodothyronine
of interest for 60 minutes with microsomes in magnesium
chloride–containing Tris-HCl (pH 7.8) buffer, in the presence
or absence (blank) of 5mM UDPGA (197,199). When tissue
microsomes are analyzed, 1mM PTU may be added to the
reaction mixture to prevent iodothyronine deiodination
without affecting their glucuronidation. Reaction is stopped
by the addition of ice-cold ethanol and glucuronide formation
is analyzed in supernatant by chromatography on Sephadex
LH-20 minicolumns as already described.
[E] Inducing Hypothyroidism
and Thyroid Hormone Replacement
Overview. Hypothyroidism is a pathological state in
which thyroid hormone signaling is decreased systemically or
locally in one or more tissues. As a result of the depletion
of nuclear T3, there is modification in the expression of T3-
responsive genes, decreasing the biological effects of thyroid
hormone. Induction of hypothyroidism has been used tradi-
tionally to define and characterize T3-responsive processes, an
approach that can be used in animals or in cultured cells. In
rodents this is accomplished by decreasing serum levels of T3
and in cultured cells by reducing the free T3 concentration in
the medium, below physiological levels. Alternatively, TR
antagonists have been developed and used in cells.
[E.1] Hypothyroidism in animals
Background. Serum T3 concentrations in rodents can be
reduced surgically by total thyroidectomy, or medically
by treatment with antithyroid drugs or 131I. In addition, there
are a number of rodent strains in which key genes in the
hypothalamic-pituitary-thyroid (HPT) axis exhibit spontane-
ous mutations or have been genetically modified, ultimately
disrupting thyroid hormone synthesis and/or secretion. The
experimental approach for achieving hypothyroidism should
take into consideration the age of the animals (i.e., prenatal,
early postnatal, after weaning). Lastly, disruption and/
induction of deiodinases or thyroid hormone transporters
may result in tissue-specific hypothyroidism.
& RECOMMENDATION 19
Bodyweight gain should bemonitored during induction of
hypothyroidism. For cross-reference between experiments,
an observed plateau in bodyweight gain should be taken to
define a state of systemic hypothyroidism. T3-responsive
gene expression and enzyme activities, particularly liver
D1 expression or activity, can be used as additional mea-
sures of thyroid status.
Commentary. A drop in serum T4 and an elevation in
serum TSH are the first indications of a disruption in the
function of the HPT axis. More time is usually needed to re-
duce serum T3. Given that T3 is the biologically active thyroid
hormone, in theory, a state of systemic hypothyroidism could
be considered to exist after serum concentrations of T3 have
dropped below the normal range. However, given that the
drop in serum T3 might not reflect tissue T3 concentration at
early time points, most studies define systemic hypothyroid-
ism to exist when a major thyroid hormone–dependent bio-
logical effect is observed; that is, body weight gain plateaus,
or the expression level of a T3-responsive gene or the activity
of a T3-responsive enzyme is reduced. While in human
studies, TSH would be an ideal parameter to define thyroid
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status, in rodents normative data are lacking to allow for
cross-study comparison using TSH as a primary marker of
thyroid status.
Because rodents continue to grow throughout life and be-
cause growth hormone secretion is exquisitely sensitive to T3
in rats, growth, as assessed by body weight gain, is a very
sensitive marker of thyroid hormone action in rats (200,201).
An approximately 100 g rat stops putting on weight about 3
weeks after total thyroidectomy; at this time point, thyroid
hormone levels have dropped by 75% and pituitary growth
hormone content is almost undetectable (201). An absence of
growth for 2 weeks has been proposed as the gold-standard
for defining a state of severe systemic hypothyroidism (202);
shorter periods of time (e.g., 5 days of documented growth
plateau) should be acceptable as well. Notably, arrest of linear
growth (as determined by tail length), which is very sensitive
to thyroid hormone, would be an excellent and more gener-
ally applicable indicator of hypothyroidism, although pub-
lished data specifically documenting this are lacking. Less
data are available for mice, in which growth hormone is less
T3-sensitive, so a plateau in body weight gain is not a reliable
indicator of hypothyroidism.
A molecular approach to define intermediate states of
systemic hypothyroidism would involve assessment of the
expression of T3-responsive genes or the activity of T3-
responsive enzymes such as cardiac mRNA levels of myosin
heavy chain (MHC) isoforms or hepatic a-glycerophosphate
dehydrogenase (a-GPD) activity or D1 activity. While any T3-
responsive tissue could be examined, traditionally the liver
has been the organ of choice to assess systemic hypothy-
roidism given its high number of TRs and well-defined T3-
responsive pathways. Liver D1 activity is considered themost
sensitive genetic index of systemic thyroid status and thus can
assist in the characterization of very subtle states of disruption
in thyroid hormone signaling (72) (see Sections D.1 and I.2).
& RECOMMENDATION 20a
Systemic hypothyroidism can be induced by surgical total
thyroidectomy in adult rats or mice. Systemic hypothy-
roidism is achieved usually between 5 and 8 weeks after
surgery. Hemi-thyroidectomized rats develop a mild form
of systemic hypothyroidism.
Commentary. Surgical total- or hemi-thyroidectomy in
rodents is a widely used procedure given the ready access to
the thyroid gland (Fig. 11) (203). In general, when performing
total thyroidectomy on a 100 g rat or a 20 g mouse, the para-
thyroid glands are preserved. Because surgical skills and
parathyroid anatomy may vary, some investigators assume
that the procedure will result in postsurgical hypoparathy-
roidism, and thus provide animals with a solution of 2%–4%
calcium lactate in 5% dextrose ad libitum as the only fluid
source for at least 10 days postsurgery.
Thyroparathyroidectomized rats and mice can also be
purchased from commercial vendors.
& RECOMMENDATION 20b
Systemic hypothyroidism can be induced by chemical
thyroidectomy caused by the administration of antithyroid
drugs. The time frame of hypothyroidism onset is variable
and depends on the type of drug and regimen used.
Commentary. Chemical inhibition of the thyroid gland
can be induced via administration of MMI, PTU, KClO4, or
NaClO4. These drugs can be given through daily intraperi-
toneal injections (e.g., PTU 1–2mg/100 g BW, MMI 1–5mg/
100 g BW (204)), added to the chow (e.g., 0.02%–0.15% PTU or
0.01% MMI or KClO4 1.25% (205)) or the drinking water
(0.01%–0.1% MMI, 0.01%–0.1% PTU, or 0.1%–1% KClO4 or
NaClO4). A major pitfall of this strategy is that all of these
antithyroid drugs have a bitter taste and, when added to the
FIG. 11. Dissection of the rodent thyroid gland. (A) Surgical incision, (B) isolate the salivary glands, (C) dissociate the
muscles, (D) free the trachea, (E) section the lateral muscles, (F) slide a needle underneath the trachea, revealing the thyroid
gland. Modified with permission from a web posting by Prof. Emeritus Jean-Pierre Herveg and Christian Regaert.
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drinking water, consumption should be monitored. In fact,
PTU is a commonly used bitter stimulus in studies of taste
physiology (206). Empirically, it has been found that KClO4 is
less palatable than NaClO4. Because taste sensitivity varies
among inbred mice, water consumption will be variably af-
fected, and in some strains significant dehydrationmay occur.
At the same time, drug consumption may also vary because
rats and mice may stop drinking bitter fluids and can with-
stand total water deprivation for several days before hyper-
osmolality develops (207). Sucrose can be added to the water
to prevent this, but responses are variable (208). Thus, if
drinking water is the delivery method chosen, body weight
and drinking consumption should bemonitored carefully and
drug concentrations adjusted appropriately. A minor con-
sideration in rodents is that treatment with PTU or MMI ele-
vates serum calcitonin concentration and,with prolonged use,
C-cells will exhibit physiologic or reactive hyperplasia. This is
not related to the state of systemic hypothyroidism; the cause
is not known.
Serum T3 levels will fall below normal within 10–15 days
depending on the drug concentration and route used. As an
example, there was a 20-fold increase in serum TSH in rats
treated for up to 3 weeks with 0.05% MMI in drinking water
(209). Treatment with 0.1% PTU in drinking water, which
also inhibits peripheral conversion of T4 to T3, resulted in a
faster reduction in serum T3 and increase in serum TSH than
in rats treated with 0.1% MMI. However, these differences
were no longer observed after 3 weeks of treatment (209).
A state of hypothyroidism can be achieved faster if PTU or
MMI are combined with 1% KClO4 in the drinking water, a
potent NIS inhibitor (210,211). However, their combination
will also magnify the effect that these drugs have on water
consumption.
A reasonable alternative is to use 0.15% PTU-containing
low-iodine food pellets, which is commercially available and
has been used successfully (212). It has been reported that a
systemic state of hypothyroidism can be achieved after 4
weeks on this diet; a faster approach includes combining
water 0.01%MMI,which is a concentration that does not seem
to interfere with water consumption. In long-term experi-
ments (months), compensatory TSH-driven thyroid growth
can raise serum T4 back to nearly normal levels, even while
animals are on the PTU–low-iodine diet. Thus, it is important
to document a state of systemic hypothyroidism throughout
the experiment.
& RECOMMENDATION 20c
Systemic hypothyroidism can be induced by radioactive
iodide ablation of the gland. In adult animals thyroid
hormone release is markedly reduced after 1 week of 131I
administration. Growth in newborn animals plateaus after
3–4 weeks of 131I administration.
Commentary. Intraperitoneal administration of 131I in
solution results in transient or permanent hypothyroidism in
adult rats (250 g BW) depending on the dose used (213). A
progressive thyroidal degenerative process is observed after
administration of 300 or 525lCi 131I but regeneration occurs
after several months; regeneration is not seen when 875 lCi is
used (213). Other tissues may be damaged by the radiation:
fibrosis of the parathyroid glands has been observed when
525 or 875 lCi of 131I is used. There can be tracheal damage
and transient renal effects (213). No damage to the liver has
been observed (213). The earliest metabolic indicator of de-
creased glandular function is a drop in the protein bound 131I,
which is observed as early as 24 hours after the injection of
875lCi of 131I (214). This approach is also effective in newborn
rats after intraperitoneal administration of 80lCi of 131I (215).
In a 20–25 g mouse, direct ablation can be achieved with
200lCi of 131I (216).
& RECOMMENDATION 20d
A state of systemic hypothyroidism can be achieved
quickly and effectively by the use of combined approaches.
Commentary. Any combination of low-iodine diet, anti-
thyroid drugs, surgery, and radioactive iodide could be used
quickly and effectively to achieve a state of severe systemic
hypothyroidism. Typically, 131I is preceded by a low-iodine
diet. Alternatively, surgical thyroidectomy can also be fol-
lowed by a low-iodine diet for 2 weeks, followed then by
remnant ablationwith 131I; the postsurgical ablation dose for a
200–250 g rat can be *80lCi (217); for mice, 25–50 lCi has
been used successfully.
& RECOMMENDATION 21
Secondary hypothyroidism can be induced in rats by sur-
gical hypophysectomy.
Commentary. Surgical hypophysectomy in rodents re-
quires skill and experience. The parapharyngeal approach to
remove the pituitary gland in rodents has been used tradi-
tionally (218,219). This approach has been largely supplanted
by the transauricular approach (220,221). This procedure
leaves the animal deaf in one or both ears, which would affect
their performance in certain behavioral tests. Typically, an
anesthetized 50–300 g rat is immobilized in a Hoffman–Reiter
hypophysectomy instrument, which allows for the stereo-
tactic placement of the tip of a suction needle proximate to the
pituitary gland, which is then aspirated. The animal is then
removed from the instrument and provided postoperative
care. The completeness of hypophysectomy is confirmed by
the absence of weight gain over a 4 week period after surgery.
Perioperative care of these animals is critical: hypophysecto-
mized animals have difficulty regulating body temperature
and thus require constant environmental conditions; a war-
mer room (temperature between 72F and 76F) is ideal. This
procedure increases diuresis and thus cages containing con-
tact bedding must be changed frequently. Given their meta-
bolic fragility, experiments are typical conducted after the first
6 to 10 postoperative days. All hypophysectomized animals
are maintained on drinking water containing appropriate
electrolites and 5% glucose, ad libitum. Water supplements
commence on the day of surgery and should continue for 14
days. To produce animals that exhibit selective secondary
hypothyroidism, hypophysectomized animals are treated
with daily replacement doses of growth hormone, luteinizing
hormone, follicle stimulating hormone, prolactin, testosterone
propionate, 17b-estradiol benzoate, cortisone, or vehicle by
subcutaneous injections (222).
& RECOMMENDATION 22a
TheNkx2 homeobox 1 (Nkx2.1; T/ebp, TTF-1) KOmouse is
a model of thyroid dysgenesis.
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Commentary. The Nkx2.1 KO mouse lends itself for
studies of fetal thyroid gland development as well as for
studies in which fetal thyroidal secretion does not exist.
Thyroid-specific enhancer-binding protein (T/ebp)/Nkx2.1-
null mouse thyroids degenerate by embryonic day (E) 12–13
through apoptosis, whereas T/ebp/Nkx2.1-heterogyzgous
mice exhibit hypothyroidism with elevated TSH levels. The
Nkx2.1 (T/ebp, TTF-1) transcription factor regulates thyroid-
specific gene transcription but is also important for develop-
ment of pituitary, lung, and ventral brain regions (223). The
homozygous Nkx2.1 KO mouse is not suitable for postnatal
studies since these animals die at birth due to profoundly
hypoplastic lungs, a severely defective hypothalamus, and
absence of thyroid and pituitary glands. On the other hand,
Nkx2.1-heterozygous mice were shown to exhibit hypo-
thyroidism with elevated TSH levels and have a neurological
defect, although they appear to be healthy and are fertile. This
thyroid phenotype is caused by reduced expression of the
TSH receptor due to T/ebp haplo-insufficiency.
& RECOMMENDATION 22b
The Pax8 KO mouse, the TSH receptor KO mouse, and the
mouse homozygous for the autosomal recessive gene hy-
pothyroid (hyt) exhibit severe congenital hypothyroidism
of fetal onset.
Commentary. Given that the Pax8 gene governs thyroid-
specific transcription, its inactivation results in a small thyroid
gland that lacks follicle formation (224). Pax8 KO mice have
undetectable serum T4 and T3 levels, increased postnatal
mortality, and growth retardation. In contrast to the Nkx2.1
KO, the Pax8KOmouse survives birth but dies after weaning.
Postnatal treatment with T4 or T3, will rescue these animals.
Withdrawal of treatment during adult life produces a severely
hypothyroid animal that can survive for 6 months or longer.
The molecular defect in the hyt mouse is an inactivating
point mutation in the gene encoding the TSH receptor
(TSHR). Neonatal hyt/hyt mice have reduced serum T4
ranging from 1/5 to 1/6 of normal as well as significantly
delayed somatic and behavioral development. The hyt/hyt
mouse provides an ideal model for exploring the effect of
severe primary inherited hypothyroidism in utero and in the
early neonatal period (225,226). The TSHR KO mouse is
profoundly hypothyroid with no detectable thyroid hormone
in serum and elevated serum TSH, exhibiting developmental
and growth delay as well as infertility if not supplemented
with T4 (227).
& RECOMMENDATION 22c
The mouse with a missense mutation in the dual oxidase 2
(DUOX2) gene and the Cog mouse (congenital goiter) are
less severe models of congenital hypothyroidism.
Commentary. Mice with a missense mutation in the
DUOX2 gene exhibit a milder form of congenital hypothy-
roidism. The DUOX2 gene is involved in the generation of
H2O2 for thyroid peroxidase, the enzyme that catalyzes iodine
organification into thyroglobulin for thyroid hormone syn-
thesis. A valine to glycine replacement (V674G) in DUOX2
explains the thyroid dyshormonogenesis (228). The homozy-
gous DUOX2 mutant develops to adulthood but exhibits
dwarfism and suffers from hearing impairment. Serum T4
levels are 10% of wild-type levels and are associated with an
approximately 100-fold elevation in serum TSH and a dys-
plastic anterior pituitary. This mouse model of congenital
hypothyroidism can be made more severe by simultaneous
targeting of DUOXA1 and DUOXA2, which are specific
maturation factors required for targeting of functional DUOX
enzymes to the cell surface. Homozygous males and fe-
males exhibit goiter and congenital hypothyroidism with
undetectable serum T4 and 500- to 2500-fold elevated TSH
levels, respectively (45).
The cog mouse exhibits an autosomal recessive mutation
that has been mapped to the thyroglobulin gene (230,231).
Young adult cog mice exhibit reduced rate of growth, mild
anemia, lower serum T4 and T3, and elevated serum TSH.
Thyroids from mutant mice are hypertrophied, deficient in
colloid, accumulate less iodine (partially susceptible to per-
chlorate discharge), and have a marked deficiency in thyro-
globulin content (230).
& RECOMMENDATION 22d
The TRH KOmouse is a model of tertiary hypothyroidism,
in which the disruption in thyroid function is only mild.
Commentary. The TRH KO mice are viable and fertile
and exhibit normal development (80). However, they have
a marked decrease in serum T4 (about 60% of control val-
ues), elevation of serum TSH level, and diminished TSH
biological activity. The anterior pituitary has decreased
TSH immune-positive cells, which is corrected by TRH but
not thyroid hormone replacement. The TRH KO mouse
exhibits a slight growth delay by 4 weeks of age that is
normalized by 8 weeks of age or by treatment with T4 (80).
Because of the role played by TRH in the pancreatic islets,
the TRH KO mice also exhibit hyperglycemia, which is
accompanied by impaired insulin secretion in response to
glucose.
& RECOMMENDATION 23a
Cell- and tissue-specific forms of hypothyroidism related to
deiodinase activities can be studied in vivo via disruption of
the D2 pathway or induction of the D3 pathway.
Commentary. The activity of the deiodinases can modify
T3 levels in a cell-specific fashion without affecting circulating
thyroid hormone levels (84). A disruption in the D2 pathway
has been shown to decrease T3 production locally and disrupt
thyroid hormone signaling inD2-expressing cells (92,173,232–
234). This is illustrated by the approximately 50% reduction in
T3 content in the D2 KO brain (187). D2 inhibitors can be used
but with caution due to off-target effects. For example, inhi-
bition of D2 has been identified as the underlying cause in the
elevated serum TSH associated with amiodarone treatment
(235), but amiodarone also inhibits D1 and can have its own
TR effects as well. Similar concerns exist with iopanoic acid,
used to inhibit D2 and disrupt thyroid hormone signaling in
BAT (236,237). The use of the D2 KO animals constitutes the
best model to study the localized hypothyroidism due to
disruption of the D2 pathway.
Tissues expressing D3 have decreased thyroid hor-
mone signaling as a result of rapid T3 inactivation to T2
and thus constitute a model of localized hypothyroidism
(62,63,238,239). This can be exaggerated during D3
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reactivation during illness, ischemia, or hypoxia that leads to
localized disruption in thyroid hormone signaling in different
tissues such as myocardium and brain (62–65,238,241).
& RECOMMENDATION 23b
Cell- and tissue-specific hypothyroidism related to iodo-
thyronine transport can be studied in vivo via disruption of
various transporter systems.
Commentary. Inactivating mutations in the gene encod-
ing MCT8 disrupt T3 transport across plasma membrane and
decrease thyroid hormone signaling (107,108). Given that D2
is expressed in glial cells and TRmostly in neurons, the MCT8
inactivating mutation is thought to promote neuronal hypo-
thyroidism by disrupting the paracrine effects of glia-made T3
at a critical time for CNS development. In fact, the existence of
this paracrine mechanism was verified in cocultures of glia
and neuronal cell lines (173). Clinical evidence supporting this
mechanism was first obtained in patients with severe neuro-
logical phenotype exhibiting the Allan-Herndon-Dudley
syndrome (107,108).
[E.2] Thyroid hormone replacement in animals
Background. The molar ratio of T4 to T3 in rat thyroids is
8:1 (242) and the estimated T4/T3 ratio in the thyroidal se-
cretion is 5:1 (1000 pmol/d of T4 to 190pmol/d of T3), indi-
cating a small contribution of thyroidal T4-to-T3 conversion to
the daily T3 production in the rat (132). Thus, the prohormone
T4 is themajor secreted iodothyronine in iodine-sufficient rats.
While all T4 is secreted by the thyroid, about 60% of daily T3
production is via peripheral deiodination of T4, and the re-
maining 40% secreted directly from the thyroid gland. No-
tably, the human thyroid gland contributes with only about
20% of the daily T3 production (132).
In theory, thyroid hormone replacement in rodents could
be modeled on the protocols applied in humans; that is,
starting thyroid hormone replacement based on weight and
monitoring serum TSH and T4. However, in rats L-T4 mono-
therapy cannot simultaneously normalize serum T3, T4, and
TSH, presumably because of the higher thyroidal T3 produc-
tion in rodents (243,244). Thus to normalize T3 and TSH, the
serum T4 must be higher than normal in rats, and the same
applies to tissue T3 and T4 content. Historically, investigators
have used the daily T4 production rate, about 10 ng/g BW, as
a replacement dose in L-T4 monotherapy in rats because this
dose is sufficient to normalize the growth rate (200). However,
if normalization of serum TSH is desired, a higher dose (ap-
proximately 20 ng/g BW) is required. While a similar ap-
proach for L-T4 treatment has been used in hypothyroid mice
(i.e., treatment dose being equivalent to the daily production
rate) normative data are lacking to determine whether serum
thyroid function tests and tissue T3 and T4 levels respond
similarly as in rats.
& RECOMMENDATION 24a
The daily T4 replacement dose in adult rats previously
rendered hypothyroid should approximate the daily pro-
duction rate if growth rate is held as the primary endpoint
defining the euthyroid state. Higher doses of L-T4 must be
used if serum TSH is to be normalized. If other thyroid
hormone–sensitive endpoints are to be considered, the
appropriate T4 dosingmust be determined empirically on a
case-by-case basis.
Commentary. In general, normalization of serum T3 or
biological parameters such as growth, the expression of a T3-
responsive gene, or the activity of a T3-responsive enzyme in
the liver are acceptable parameters when considering thyroid
hormone replacement in rats previously rendered hypothy-
roid. Daily delivery of *8 ng/g BW to adult rats previously
rendered hypothyroid has been shown to normalize serum T3
levels, growth rate, and the activity of liver a-GPD, a very
sensitive index of systemic thyroid status in rats (202).
For practical reasons, administration of T4 is the method
used most frequently to restore euthyroidism (200,202,245,
246). However, because of the substantial direct thyroidal
secretion of T3 in rodents, the ideal thyroid hormone re-
placement regimen would feature a mixture of T4 and T3.
Some studies have established the optimal dosing for com-
bination therapy in rodents (244). When T4 is used alone for
replacement, tissue T3 content can vary across a large
number of tissues because of the role played by the deiodi-
nases as a local source of tissue T3 (via conversion from T4)
(243,244).
The calculated daily T3 production is approximately
2.7 ng/g BW (132). Notably, a slightly lower dose of T3,
2.0 ng/g BW, has been shown to restore growth and the ac-
tivity of liver a-GPD in previously rendered hypothyroid rats
(202). However, administration of T3 alone is not sufficient to
restore euthyroidism in all tissues, particularly in those with a
significant contribution of the D2 pathway (243,244).
& RECOMMENDATION 24b
The parenteral route is preferred to deliver thyroid hor-
mone to rodents; for example, intraperitoneal, subcutane-
ous, or osmotic pumps or subcutaneously implanted
pellets.
Commentary. T4 and T3 solutions are prepared in 40mM
sodium hydroxide and diluted in saline for injections. When
protected from light, stock solutions can be stored at - 20C for
a few weeks. Daily injections bypass concerns about variable
intake if the hormone is administered in food or water (see
following text). However, it should be borne in mind that in-
jections produce a rapid, supraphysiological peak in systemic
T4 or T3 levels. Alternative delivery methods for T4 or T3 ad-
ministration such as subcutaneous pumps or pellets may be
preferred if relatively constant rates of delivery are desired. T4
and T3 can be mixed with water or food, but these methods
carry the intrinsic variability of food orwater consumption that
might preclude their use in some experiments. Treatment du-
ration can span days, weeks, or months. Preferably, doses
should be divided daily (every 12 hours) given the relatively
short half-lives of T3 and T4 in rodents (2 and 8 hours, respec-
tively). Blood sampling for measurement of thyroid hormone
levels must take into account the timing of the last injection.
& RECOMMENDATION 24c
Age-appropriate regimens for T4 replacement should be
used for hypothyroid neonatal mice.
Commentary. In models of congenital or neonatal hypo-
thyroidism, T4 replacement should be started at birth (day 0)
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and continued on a daily basis through at least postnatal day
10, a critical thyroid hormone–dependent developmental
period in mice (247). Serum T4 levels in severely hypothyroid
mice can be restored to age-matched control levels via sub-
cutaneous injections of T4 on days 0–5 (4 ng/g), 6–8 (5.8 ng/g),
and 9–10 (9.1 ng/g) for the mouse (248–251). Injections can be
performed using a 0.5mL syringe with a 30-gauge saline-
treated needle.
& RECOMMENDATION 24d
Mouse embryonic stem cells can be driven to differentiate
into functional thyroid follicular cells in vitro, restoring
systemic euthyroidism when transplanted into hypo-
thyroid mice.
Commentary. Transient overexpression of the transcrip-
tion factors NKx2-1 (formerly called TTF-1) and Pax8 directs
mouse embryonic stem cells to differentiate into thyroid fol-
licular cells. When treated with TSH these cells organize into
3D follicular structures and activate thyroid functional genes
including NIS, TSH, thyroglobulin, and thyroperoxidase
genes (252,253). These in vitro derived follicles show iodide
organification activity and when grafted in vivo into athyroid
mice are able to restore serum thyroid hormone levels and
promoted subsequent symptomatic recovery (252).
[E.3] Hypothyroidism in cultured cells
Background. Culture medium generally contains animal
serum, and so cultured cells are exposed to iodothyronine
concentrations that depend on the source of the serum. For
example, if fetal bovine serum (FBS) is used to support cell
growth, the ambient T3 and T4 concentrations in the medium
will reflect the thyroid hormone levels of the calves used to
produce the serum. Historically, serum taken from thyroid-
ectomized animals or animals treated with antithyroid drugs
have been used to generate hypothyroid media (254). Because
of a lack of commercial availability of such serum, chemical
stripping has become more common, either with charcoal,
anion exchange AG1-X8 resins, or both (255,256). Depending
on the cell type being studied, using serum-free media may
also be an option, thoughmost cells propagate better inmedia
containing serum.
& RECOMMENDATION 25a
Cells in culture can be made hypothyroid using media
supplemented with either (i) charcoal-stripped serum,
(ii) resin-stripped serum, (iii) serum obtained from hypo-
thyroid animals, or (iv) medium not supplemented with
serum.
Commentary. Using ‘‘defined’’ media to induce hypo-
thyroidism has a number of caveats. While many reports in-
dicate ‘‘ > 99%’’ of T3 and T4 are removed via standard
stripping protocols, some variability exists in the degree of T3
and T4 removal achieved by the various procedures. This
variability may arise both from factors related to the type of
serum and from the method of stripping (257,258). Further-
more, current chemical strippingmethods do not allow for the
depletion of thyroid hormone without also depleting other
circulating factors. Many small molecules such as growth
factors or hormones (including sex steroids, adrenal steroids,
and vitamin D) may also be removed during stripping, and
thus the biologic changes seen over time cannot be described
as representing isolated hypothyroidism (257). Experimental
design should compare groups with thyroid hormone re-
placed (versus vehicle replaced) to enable specific attribution
of the results to thyroid hormone deficiency. If a more isolated
depletion of T3 and T4 is necessary, preparation of hypothy-
roid animal serum has been shown to be potentially cost-
effective, despite an initial appearance of impracticality (254).
Using depleted serum has been shown to induce cellular
hypothyroidism, as assessed by the expression level of T3-
responsive genes, in as little as 24 hours (259). In theory, the
time needed to achieve hypothyroidism could be shortened
by frequently changing the media (e.g., every few hours in-
stead of daily); this would accelerate the depletion of intra-
cellular T3 stores. Similarly, prolonged culture time in T3- and
T4-depleted media would be expected to induce a more pro-
found state of cellular hypothyroidism. Regardless of the
approach, the extent of hypothyroidism for each experimental
condition should be determined via measurement of T3-
responsive endpoints (e.g., expression of T3-responsive genes
or T3-responsive enzymes) to facilitate interassay comparison.
& RECOMMENDATION 25b
Cells in culture can be made hypothyroid using a TR
antagonist.
Commentary. NH-3 is a TR antagonist that strongly in-
hibits transcriptional activation by T3 (260–265). Treatment
with this compound has been shown to block thyroid hor-
mone dependent processes such as spontaneous Xenopus
laevis tadpole metamorphosis. In theory, this drug could be
used to induce hypothyroidism in other vertebrates, but this
remains to be established experimentally.
[F] Increasing Thyroid Hormone Signaling
Overview. Classically, thyrotoxicosis is thought of as a
pathophysiological state in which thyroid hormone signaling
is increased systemically (i.e., throughout all tissues of the
organism) as a result of increased T3 binding with its nuclear
receptors. Experimentally, systemic thyrotoxicosis can be
modeled in vivo via treatment of animals with thyroid hor-
mone. In vitro, cells can be treated with media supplemented
with thyroid hormone above the concentrations seen in blood.
However, in the latter case, the effects of cross-talk between
thyrotoxic tissues (i.e., the indirect, interactive effects medi-
ated via second messengers, are absent); the state of ‘‘direct
thyrotoxicosis’’ created is thus distinct from systemic thyro-
toxicosis. ‘‘Tissue-specific increase in thyroid hormone sig-
naling’’ is a more recent concept, arising as the result of local
deiodinase activity that increase nuclear T3 concentration of
certain tissues without necessarily altering plasma thyroid
hormone concentration (66).
[F.1] Thyrotoxicosis in animals
Background. Administration of thyroid hormone to an
otherwise euthyroid rodent leads to systemic thyrotoxicosis,
the intensity of which is directly related to the magnitude of
the elevation in serum T3 concentration. A number of ap-
proaches have been used to achieve systemic thyrotoxicosis,
including intraperitoneal injection of thyroid hormone,
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addition to chow or drinking water, and subcutaneous pellet
or mini-pump insertion.
& RECOMMENDATION 26a
Acute systemic thyrotoxicosis can be induced by parenteral
administration (intraperitoneal or intravenous) of 1.0 lg
T3/g BW, a TR-saturating dose of T3. Genomic effects can
be seen as early as 60 minutes and physiologic effects
starting at about 6 hours.
& RECOMMENDATION 26b
Long-term systemic thyrotoxicosis can be induced by
chronic treatment with T3 or T4 over days, weeks, or
months. Routes of administration include parenteral or
supplementation of food or water. For chronic studies, TR-
saturating doses should be avoided due to cachexia and
death. To allow comparisons between studies, T3 doses
should be given as multiples of the daily T3 or T4 replace-
ment dose.
Commentary. The half-life of T3 in rodents following in-
jection has been measured to be approximately 4 hours, and
for T4 about 11 hours (132). Given these short half-lives, in
either acute or chronic experiments, sampling for measure-
ment of T3 or T4 serum levels must take into account the
timing of the last injection, in particular for T3. Furthermore
multiple injections should be considered if biological effects
are to be measured after several half-lives have passed. After
multiple injections with classical doses of T3 (100 lg/100 g
BW), the intense state of thyrotoxicosis triggers loss of body
weight and increases mortality, such that experimental
treatment duration should not extend beyond 4–5 days. Ty-
pical doses of T4 or T3 well tolerated in long-term experiments
(2–3 months) are 10- to 25-fold the daily production rate.
While food- and water-based drug delivery methods are
subject to feeding variability, this may not be critical for
studies of chronic thyrotoxicosis; for example, powdered ro-
dent diet containing 3mg of T4 and 1mg of T3 per kilogram
has been used successfully to induce chronic thyrotoxicosis
(205). Consideration should be given to more consistent
methods such as subcutaneous pumps or pellets (243,244).
Depending on the endpoint to be studied, the choice of
iodothyronine is important, since T4 is converted to T3 via
D1 and D2. Graves’ patients can sometimes exhibit a T3-
predominant form of thyrotoxicosis, whereas thyroid cancer
patients are generally treated with pharmacologic doses of T4
to achieve TSH suppression. That being said, in studies not
focusing on the roles of the deiodinases, T3 is preferred be-
cause it does not require further activation and thus elimi-
nates the activating deiodinases as a variable.
Classically, large doses of T3 have been used in rodent ex-
periments, designed to saturate the nuclear T3 receptors rap-
idly and thus maximize the phenotypic events studied as
endpoints, whileminimizing experimental time and thus cost.
For example, a typical dose for rats or mice would be 100 lg/
100 g BW, producing measurable genomic and physiologic
changes within a few hours (266). It should be noted that the
doses of T3 classically used for rodent experiments are clearly
in the pharmacologic range and are much higher than the
pathophysiologic range seen in nature. Some authors ques-
tion whether such high doses may produce off-target artifacts
or overly enhance nongenomic effects of T3.
& RECOMMENDATION 27
In vivo activation of the D2 pathway or inactivation of the
D3 pathway can be used to study cell- and tissue-specific
increase in thyroid hormone signaling.
Commentary. cAMP-induced D2 activation in BAT leads
to rapid saturation of TR with locally generated T3 and in-
duction of T3-responsive genes and the activity of T3-
responsive enzymes, without affecting circulating thyroid
hormone levels (66,86,233,237,267–269,271). This is also ob-
served in animal models of transgenic Dio2 expression in the
heart (273,274). In contrast, D3 inactivation results in localized
increase in thyroid hormone signaling as evidenced in the D3
KO mouse (64,239,275–279).
[F.2] Thyrotoxicosis in cultured cells
Background. For cell culture–based experiments, tissue-
specific or more properly cell type–specific thyrotoxicosis can
be modeled via addition of T3 to the medium. Medium thy-
roid hormone concentrations can be determined directly, but
in most cases they are estimated based on published values
for the free fractions in a given serum.
& RECOMMENDATION 28a
Acute thyrotoxicosis can be achieved in cell culture via
addition of T3 in the media. The free fraction of T3 multi-
plied by the total concentration of T3 gives an estimate of
the free hormone concentration. If free fractions are not
determined directly, estimates of free hormone concentra-
tion can be made based on published values of the free
fractions.
Commentary. If exact thyroid hormone concentrations
within cell culture media must be known, then direct mea-
surements would be required. In most cases, however,
rough estimates are thought to suffice (Table 2). Notably,
thyroid hormones adhere to plasticware, so it is important
to add a suitable carrier protein in order to model the bound
and free thyroid hormone fractions in cell culture. Stripped
serum or fatty acid–free BSA are typically used, with T3
(and/or T4) replaced; the same caveats about loss of other
hormones still apply when this experimental approach is
used.
Few studies have reported equilibrium dialysis-based
measurement of free fractions in stripped serum, but one
study found that for FBS it is similar to the estimated range of
unstripped FBS (0.4%–4% for T3) (281). BSA with fatty acids
may have T3, thus fatty acid–free BSA should be used (282). It
should also be noted that most commercially available forms
of T4 have at least trace T3 contamination that must be con-
sidered. Importantly, recall that the free fraction of T3 (or T4)
increases as the percentage of serum in the media decreases.
Thus, the free hormone concentration stays relatively constant
as the percentage of serum decreases.
As in the case with rodents, pharmacologic dosing of T3 has
been used historically, with high concentrations designed to
achieve saturation of nuclear receptors rapidly. For example,
100 nM total T3 in 0.5% BSA would give an estimated free T3
concentration of around 3500 pM; for comparison, the free T3
concentration of euthyroid human serum would be closer to
3–8pM (about 1000 times lower). Even severely thyrotoxic
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patients would not be expected to achieve such high free T3
concentrations, only reaching values of about 20 pM (283), or
as high as 35 pM in the case of an accidental ingestion of a
massive dose of L-T4 (284). Some investigators have sug-
gested that pharmacologic dosing can artificially enhance
nongenomic and hypothetical off-target effects of T3; if these
are not a concern, the dose can be maximized for effect. Ide-
ally, T3 doses that are within or near the physiological range
should be used.
& RECOMMENDATION 28b
While inducing thyrotoxicosis in cell cultures, the possible
presence of deiodinases should be considered for each cell
type being studied.
Commentary. Knowing the deiodinase activities of a
particular cell line may be important experimentally. Unless
the effects of deiodination are of particular interest, thyro-
toxicosis should be induced via addition of T3 only, not T4.
This is because D1 activates T4 (converting it to T3), such
that cells treated with T4 will have variable media T3 con-
centrations depending on the level of D1 activity and the
volume of media and frequency of media changes. This ef-
fect is expected to be more intense in D2-expressing cells,
given its much higher catalytic efficiency. In contrast, D3
activity would lower the media concentration of T3 (con-
verting it to T2), increasing the dosing requirement to sustain
thyrotoxicosis.
[F.3] Use of thyroid hormone analogues
Background. The existence of two TR isoforms (i.e., TRa
and TRb) indicates that different signaling pathways (and
perhaps sets of biological effects) are downstream of each one
of these molecules. This is further strengthened by the ob-
servation that the distribution of TR isoforms is heteroge-
neous among different tissues/cells (285,286). For example,
bone is a predominantly TRa tissue while liver is a predomi-
nantly TRb tissue; thus the rationale for developingmolecules
that exhibit TR-isoform specificity.
Two caveats should be considered while selecting the
concentration and dose of these molecules:
(i) Pharmacokinetic data: TR selectivity depends on ligand
concentration and selective tissue uptake. For example,
eprotirome appears to have only modest selectivity for
TRb in vitro, yet its profound effects to lower lipids and
cholesterol result from selective availability to the liver,
possibly due to selective uptake. There is no information
on transporter selectivity for different ligands or whether
these ligands use the same or different transporters
compared to T3 and T4. The use of relatively high doses or
high media concentrations minimizes or eliminates TR
selectivity. There is currently no or only limited com-
prehensive pharmacokinetic studies for most analogues,
making it difficult to define concentration and doses in
comparative experiments with T3 or other analogues.
(ii) Ligand transport into the cell and cell nucleus: the
mechanisms leading to cellular uptake and nuclear
concentration of the analogues have not been defined.
Thus, even when using equimolar media concentra-
tions of two such molecules their concentration in the
nucleus, around the TR, could be different. This could
enhance or eliminate any biological advantage of TR
selectivity exhibited in vitro.
& RECOMMENDATION 29
Thyroid hormone signaling can be triggered in vivo and
in vitro by thyroid hormone analogues, some of which have
tissue selectivity or selectivity for TR isoforms (i.e., TRa1,
TRb1, TRb2). A number of highly selective TRb analogues
target tissues exhibiting predominance of TRb (e.g., liver
and pituitary gland). The utilization of equimolar doses
and concentrations of different analogues and T3 is re-
commended as a starting point in comparative studies.
Commentary. 3,5-Diiodothyropropionic acid (DITPA) is
a carboxylic acid thyroid hormone analogue that binds TRa
and TRb with nearly identical affinities (287). Studies in rats
and rabbits indicate that DITPA has positive inotropic effects
but minimal chronotropic and metabolic effects outside the
cardiovascular system (287,288). Its combined use with cap-
topril improved ventricular performance and reduced end-
diastolic pressure in the rat postinfarction model of heart
failure (289). Additional effects included attenuation of the
acute inflammatory response and reduction of myocardial
infarct size (290), and improvement of maximal perfusion
potential of the hypertrophied myocardium surviving a
myocardial infarction (291). However, other studies reported
side effects (292,293) or failed to obtain positive results with
DITPA in similar settings (294,295).
Tiratricol is an acetic acid thyroid hormone analogue that
exhibits about 3.5-fold greater in vitro affinity for TRb and 1.5-
fold greater affinity for TRa compared to T3, with an ap-
proximately threefold selectivity for TRb (296,297). However,
there is only moderate TRb selectivity in cell culture studies
(298). In rats, tiratricol has been shown to have antidepressant
effects (299), thermogenic effects in the BAT (300,301), and
some degree of organ specificity due to its enhanced liver and
skeleton effects and reduced cardiac effects (302). The use of
tiratricol in a number of settings, including patients with TSH
hypersecretion and athyrotic patients, reduced serum TSH
(303–305) and lowered serum cholesterol levels without af-
fecting heart rate but elevated biochemical markers of bone
turnover (306,307).
A new generation of highly selective TRb agonists has
much less affinity for TRa while preserving affinity for TRb
(308). The molecules in the GC family (i.e., GC-1 and GC-24)
are noniodinated compounds that were designed based on
experimental data obtained for the TR structure (309). The use
of these molecules has suggested the possible existence of a
‘‘therapeutic window’’ through which predominantly TRb-
mediated biological effects (e.g., lowering serum cholesterol
and acceleration of energy expenditure) can be triggered with
relatively little activation TRa-dependent pathways (310–
316). However, it is uncertain whether tissue specificity in vivo
is due to selectivity for TR binding or tissue concentration of
these molecules or both. For example, the TRb selective ago-
nist GC-1 concentrates preferentially in the liver as opposed to
heart, skeletal muscle, or brain (310). The KB family of mole-
cules (i.e., KB-141 and KB-2115) has been used successfully in
animals (317–320) and in hypercholesterolemic patients kept
on statins to lower serum cholesterol even further while
sparing the heart and bone (321,322). In these patients there
were only minimal alterations in thyroid function tests.
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However, clinical studies with these molecules were sus-
pended due to undesirable cartilage side effects observed in
dogs (323).
The KB general structure was subsequently used as a
scaffold to design a family of indane (hydrocarbon com-
pounds) derivatives that exhibit potent and selective thyro-
mimetic activity (324). KTA-439, a representative indane
derivative, displays the same high human TRb selectivity in a
binding assay as KB2115 and higher liver selectivity in a
cholesterol-fed rat model (324).
An alternative strategy to obtain tissue selectivity is to use
molecules that concentrate in specific tissues by virtue of
undergoing local activation such as the cytochrome P450 ac-
tivation of a prodrug that is a phosphonate-containing TR
agonist. This molecule exhibits increased TR activation in the
liver relative to extrahepatic tissues and an improved thera-
peutic index (319). MB07811 undergoes first-pass hepatic ex-
traction and cleavage, generating the TR agonist MB07344
that distributes poorly into most tissues and is rapidly elimi-
nated in the bile (319). MB07811 lowers serum cholesterol in
hypercholesterolemic rats, rabbits, monkeys, and humans
beyond what was achieved with statins alone (325), is supe-
rior to a TRb-selective agonist in the diet-induced obese
mouse model (319), and reduces hepatic steatosis in rats and
mice models (326).
Selective analogues for TRa have also been developed (327)
and shown to be effective in promoting TRa-dependent neu-
rogenesis in X. laevis (328). However, TRa selectivity was lost
when the same compound was tested in rats, with CO23 ac-
tivating thyroid hormone–responsive genes in liver and heart
(329).
[G] Iodine Deficiency and Maternal–Fetal Transfer
of Thyroid Hormone
Overview. Iodine is the major constituent of thyroid
hormone. Simply put, the most active form of thyroid hor-
mone, T3, can be viewed as three atoms of iodine attached to
a phenoxyphenyl scaffold. The unique spatial positioning of
the iodine atoms confers high affinity for the TR, a ligand-
dependent transcriptional regulator. It is remarkable that
vertebrates evolved to have a scarce environmental element,
iodine, play such an important role in embryogenesis,
growth, metabolism, cognition, and adaptation to disease
states. The sea is the main source of iodine and perhaps
the major biological role played by iodine reflects the idea
that life began to exist and evolved in the ocean. Iodine-
containing clouds are formed over the oceans and blown
inland, with rain depositing iodine over the land. Depending
on the type of soil, iodine is retained for some time or quickly
washed to the rivers and back to the oceans. Consequently,
the iodine content of plants, crops, and animals in any spe-
cific geographical region depends on the iodine content of
the soil. About 1.5 billion people live in geographic areas
of iodine insufficiency, requiring some form of iodine sup-
plementation to prevent the consequences of perinatal
hypothyroidism.
Iodide is absorbed in the small intestine and avidly taken
up by the thyroid via NIS located in the basal-lateral mem-
brane of all thyrocytes. Once inside the cells, iodide diffuses
towards the relatively positively charged lumen of the thyroid
follicle, exiting the thyrocyte via pendrin channels located in
the apical membrane. Adjacent to microvilli of the apical
membrane, iodide is oxidized and conjugated to specific ty-
rosine residues in the thyroglobulin molecule, a process cat-
alyzed by thyroid peroxidase. Subsequently, iodinated
thyroglobulin molecules are reabsorbed via pinocytosis and
digested in lysosomes, releasing T4, T3, and small amounts of
thyroglobulin as well as other iodinated molecules into the
circulation.
Iodine deficiency can pose a serious threat to the thyroidal
capacity to synthesize thyroid hormones. It is generally ac-
cepted that limited iodine availability acts as an evolutionary
pressure that favors the development of compensatory
mechanisms, which minimize the impact of iodine deficiency
on thyroid economy. Deciphering these mechanisms is critical
not only for our understanding of thyroid gland function and
thyroid hormone economy but also to formulate strategies
that can be used to treat and prevent the irreversible conse-
quences of fetal and neonatal hypothyroidism resulting from
iodine deficiency. The most severe condition is neurological
cretinism due to severe iodine deficiency and hypothyroxi-
nemia during the first half of pregnancy resulting in irre-
versible brain damage (330). Thus, experimental models of
iodine deficiency have been widely used to analyze the
adaptive mechanisms developed in animal models and the
impact of different degrees of iodine deficiency on thyroid
economy.
[G.1] Iodine deficiency in rodents
Background. The main consequences of iodine deficiency
are goiter, hypothyroxinemia (242), increased NIS expression
(331), increased monoiodotyrosine (MIT)/diiodotyrosine (DIT)
and T3/T4 ratios within the thyroglobulin (332,333), prefer-
ential T3 synthesis and secretion by the thyroid (242,332), in-
creased D1 and D2 activities in the thyroid and D2 activity in
BAT (334,335), low T4 in plasma and tissues (71,336,337), and
a TSH concentration that is slightly elevated, together with a
normal or slightly decreased T3 level in serum and several
tissues (71). Tissue uptake of T4 and T3 increases. Only some of
the endpoints of thyroid hormone action are affected but to a
lesser degree than in overt hypothyroidism (71,338). The
chow diet fed to rodents in accredited animal facilities con-
tains enough iodine (0.4–1 lg/g) to allow for a normal daily
iodine intake (*5–10 lg/d) and thyroid function. Two strat-
egies can be used, independently or in combination, to pro-
mote iodine deficiency: (i) feeding with a low iodine diet
(<0.02 lg/g) that reduces iodine intake (to 0.2–0.4 lg/d) or (ii)
treatment with drugs that inhibit NIS and thus thyroidal io-
dine uptake.
& RECOMMENDATION 30a
A state of iodine deficiency can be achieved by feeding
rodents with an LID (containing <0.02lg iodine/g). Milder
degrees of iodine deficiency can be achieved with less
stringent diets. Effects on thyroid economy can be seen as
early as 10 days, but formost parameters clear effects require
at least 1 month of LID.
& RECOMMENDATION 30b
Iodine deficiency in animals can be documented by moni-
toring urinary iodine excretion, which should be about 5- to
10-fold lower in the LID animals.
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& RECOMMENDATION 30c
Intrathyroidal iodine deficiency can be achieved via inhi-
bition of NIS following administration of 1% KClO4 in the
drinkingwater. Thyroidal iodine stores can be depleted in 1
week using this approach. Longer treatments will lead to
systemic hypothyroidism,whichmust be taken into account.
Because KClO4 is bitter, caveats apply for this strategy as
discussed previously (see Recommendation 19b).
& RECOMMENDATION 31a
The impact of iodine-deficiency on the thyroid gland itself
can be assessed by measuring gland size (at least a twofold
increase should be seen) and histologically, with LID
leading to varying degrees of hyperplasia and hypertro-
phy. The amount of colloid in the follicles is reduced, and
the epithelial cells lining the narrowed follicular spaces
consist of columnar cells instead of normal cuboidal cells.
& RECOMMENDATION 31b
The impact of iodine deficiency on thyroid economy can be
monitored by measuring serum T4, and the T3/T4 ratio in
thyroglobulin. TSH elevation is not an early finding. Si-
milarly, serum T3 is preserved until iodine deficiency is
severe.
Commentary. LID is commercially available from differ-
ent vendors, but checking the iodine content of the diet is
strongly recommended given that it is not unusual to find
higher than reported iodine content. Remington-type diet has
been used successfully; synthetic diets containing casein or
other proteins that are a source of iodine should be avoided. In
accredited animal facilities, rodents drink deionized distilled
water, which does not containing significant amounts of
iodine.
In all settings, control animals should also be fed LID but
drink water containing KI ad libitum to provide about 5–10 lg
iodine/day. The combination of LID and KClO4 results in
severe iodine deficiency, a reduction in serum T3, and overt
hypothyroidism. When KClO4 is employed it should be used
in low percentages (£ 0.005%) to avoid undesirable environ-
mental pollution (71,339).
& RECOMMENDATION 32
Gestational or neonatal iodine deficiency can be achieved
by feeding dams with the LID. Given the short duration of
gestation in rodents, dams should be pretreated with LID
so that hypothyroxinemia is achieved before the onset of
pregnancy.
Commentary. This strategy leads to profound fetal hypo-
thyroidism because maternal transfer of T4 is markedly di-
minished, and T4 is the only source of T3 for the fetal brain
(340,341). After birth, maternal T4 is concentrated in the milk
and given to the pups prior to weaning, thus resulting in
amelioration of their hypothyroidism (341).
Severe iodine deficiency before and throughout gestation
results in a rat model of neurological cretinism (330) with brain
alterations similar to those described in human affected pop-
ulations (342–344). Given that feeding on LID can potentially
decrease fertility, particularly if the state of iodine deficiency is
severe enough to reduce serum T3, LID alone might not act
quickly enough to create a state of iodine deficiency in the fetus.
In this case, KClO4 or its combination with LID can be used
successfully to promote fetal iodine deficiency.
[G.2] Placental transfer of thyroid hormone
Background. The placenta functions as an interface be-
tween the maternal and fetal circulations, allowing for the
exchange of nutrients, gases, and many other types of mole-
cules. Thyroid hormones are not only metabolized by pla-
cental cells via D2 andD3, but there is also a net flux of thyroid
hormones transport to the fetus, which ensures the presence
of T4 and T3 in the fetal circulation before the fetal thyroid is
fully developed. Thyroid hormones transport can be studied
in the rat by inhibiting the fetal thyroid withMMI given to the
mother. In this setting, different levels of both T4 and T3 are
found in fetal tissues.
& RECOMMENDATION 33
Placental transfer of thyroid hormones from mother to
fetus can be studied in MMI-treated and thyroid hormone–
replaced pregnant dams by measuring T4 and T3 content in
fetal tissues.
Commentary. Pregnant dams are given 0.02%MMI in the
drinking water, starting on the 14th day of gestation. MMI
crosses the placenta and has been shown to inhibit fetal thy-
roidal function and promote severe fetal hypothyroidism
with elevated serum TSH and low thyroid hormone levels in
blood and tissues. Mothers are treated with thyroid hormone
(T4, T3, or both) and, at any time during pregnancy or im-
mediately after delivery, fetuses are dissected and blood/
tissues obtained for extraction and determination of T4 and T3
contents (345,346). Administration of tracer [125I]T4 to preg-
nant dams and its detection in fetal tissues has also been used
to study placental transfer of thyroid hormone (347).
[H] Models of Nonthyroidal Illness
Overview. Thyroid economy is markedly affected by ill-
ness, fasting, or othermajor life-threatening conditions. This is
known as NTI syndrome, euthyroid sick syndrome, or low T3
syndrome (348). NTImay be viewed as part of the acute phase
response to illness or injury, a defense mechanism predomi-
nantly mediated by cytokines (349). A number of animal and
cell models have been developed to study the pathogenesis
and pathophysiologic consequences of NTI, including fasting,
injury or illness, and lipopolysaccharide (LPS) administration.
In general, during NTI there is a multilevel suppression of
the HPT axis and decreased thyroidal secretion (350). A drop
in serum leptin levels plays a central role in the fasting-
induced changes in thyroid economy via neuropeptide Y-
mediated TRH suppression (351), with leptin administration
restoring the fasting induced state of central hypothyroidism
(352). There are also major modifications in the metabolic
pathways of thyroid hormone, such as accelerated extra-
thyroidal inactivation of thyroid hormone via deiodination
(353), glucuronidation, and sulfation (351); it is not yet clear
whether extrathyroidal T3 production is decreased (354).
However, it is well accepted that central hypothyroidism is
the main driving force behind the changes in circulating
thyroid hormone levels and thyroid economy associated with
fasting or starvation. Also important is understanding that
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changes in thyroid economyduringNTImay be very different
in the acute versus a more chronic phase (355). Defining these
mechanisms and the pathophysiological implications of these
changes is central to our understanding of NTI, which affects
the majority of patients admitted to any general hospital.
& RECOMMENDATION 34
Fasting is widely used as amodel of NTI to study its impact
on thyroid hormone production, metabolism, and action.
Commentary. Fasting promotes central hypothyroidism,
reducing serum levels of thyroid hormone without a corre-
sponding elevation in serum TSH. Mice and rats can be fasted
for periods of hours or days depending on standards and
protocols set by the local institutional animal committee.
Usually adult rats are fasted no longer than 2–3 days and
adult mice 1 day. In rats, fasting is associated with an ap-
proximately 50%–75% drop in serum T4 and T3 that takes
place in the first 48 hours (356). Inmice, the drop in serumT3 is
about 50% and takes place by 36 hours of fasting (357). Fasting
also leads to a reduction in liver D1 and increase in D3 ac-
tivities (358,359). However, the reduction in serum T3 ob-
served in the fasted rat is mostly secondary to a reduction in
thyroidal secretion (360).
& RECOMMENDATION 35a
Major bodily insults or severe illness in rodents such as
extensive surgery, burns, inflammatory pain, bacterial in-
fection, or prolonged immobilization can be used as animal
models of NTI.
Commentary. A large number of animal models have
been developed to study NTI (361–370). Essentially, the type
and extent of the bodily insult that triggers NTI in rats, mice,
and rabbits determines the magnitude of the alterations in
thyroid economy. These different animal models display
unique characteristics as to the timeline of the fall in serum T4
and/or T3 concentrations.
Different cell models have been developed to study the
modifications in deiodinase expression and thyroid hormone
action during NTI. Basically, different deiodinase-expressing
cell types are exposed to pro-inflammatory cytokines (e.g.,
interleukin-1b) and then evaluated for the expression of dif-
ferent components of thyroid hormone signaling such as TRb,
TRa, and deiodinase activity (361).
& RECOMMENDATION 35b
The administration of bacterial LPS can be used to promote
central hypothyroidism, similar to that observed during
NTI, with reduction in hypothalamic TRH and a fall in
serum thyroid hormone levels.
Commentary. Intraperitoneal administration of LPS to
rats (371–373) or mice (173) has been used extensively to
promote central hypothyroidism and NTI (374). Despite the
drop in serum thyroid hormone levels, both TRH expression
in the paraventricular nucleus and serum TSH are decreased
in LPS-treated rats, resembling the euthyroid sick syndrome
(371,373). These LPS-induced changes are associated with an
elevation in tanycytes that may be key for the reduction in
TRH expression through feedback inhibition (373,374); this
effect is lost in the D2 KO mice (173). LPS batches vary in
efficiency; it is recommended to use a strain previously shown
to be effective; for example, O127:B8 Escherichia coli strain
in vivo in rats and mice (372–374). In vitro, treatment with LPS
increases D2 activity in human mesothelioma (MSTO-211H)
cells (375) and in cultured rat astrocytes (376).
[I] Assessing Thyroid Hormone Signaling at Tissue
and Cellular Levels
Overview. TRs mediate biological responses to thyroid
hormone by control of gene expression (377,378). TRs are nu-
clear receptors and bind specific DNA response elements in
genomic regulatory regions (enhancer elements) of target genes
(379–381). The DNA-bound TR can modify the activity of
chromatin remodeling complexes, RNA polymerase II, and the
basal transcriptional machinery to activate or suppress expres-
sion of a target gene. The transcriptional response is sensitive to
the concentration of ligand (T3) and to the duration of exposure
to T3. This can be studied in animals or in cell models usually by
contrasting expression of a T3-responsive gene between hypo-
thyroid and thyrotoxic conditions (see Sections E and F).
The three canonical TR isoforms TRa1, TRb1, and TRb2
in mammals possess broadly similar transactivation
properties on many but not all response elements in vitro.
These isoforms mediate both overlapping and distinct
biological functions in mice in vivo (286,382,383); reflecting
cell-specific expression patterns, differences in isoform
expression levels, and possible isoform-specific structural
constraints in target gene recognition or cofactor interac-
tion (Table 3) (385–389).
The analysis of T3 response genes is useful to address dif-
ferent types of research questions. T3 response genes are
useful markers, or transcriptional endpoints, of the thyroid
hormone status of a tissue in animal models or in cell culture
lines in vitro. Analyses may be relatively simple, with a focus
on a few known target genes that reliably represent the tissue
status in response to T3. Exploratory large-scale (‘‘genome-
wide’’) screens of mRNA populations may be used to search
for new T3-response genes. At the molecular level, a specific
target gene can be investigated in depth to elucidate the
transcriptional mechanisms underlying T3 action, entailing
the analysis of the DNA element that binds the TR and
functional analysis of these elements using transcriptional
assays, usually in heterologous cell culture systems. Ulti-
mately, the physiological relevance of such an element would
require in vivo evidence based, for example, on analysis of
transgenic reporter genes carrying the promoter and/or en-
hancer elements of the target gene.
Table 3. T3 Receptor Genes and General Tissue
Expression Patterns of Receptor Isoforms
Gene
T3 receptor
isoform Some main sites of expression
Thra
(Nr1a1)
TRa1 Pituitary, brain regions, heart,
intestine, bone, kidney, cartilage,
erythroid/lymphoid cells
Thrb
(Nr1a2)
TRb1 Pituitary, brain regions, heart, liver,
kidney, lung, cartilage, retina
TRb2 Pituitary, cartilage, cochlea, retina,
hypothalamus
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[I.1] Gene expression as a marker of thyroid hormone status
Background. T3 target genes can be either positively or
negatively regulated. Exploratory screens of cell lines or tis-
sues indicate that on average, approximately 50% of the T3-
responsive genes display increased mRNA levels and 50%
display decreased levels in response to T3 (127,390–394). For
the majority of these genes, it remains unknown which re-
spond directly and which indirectly to T3, since in many tis-
sues relatively few genes have been defined as direct targets
by rigorous criteria that include the identification of the
functional TR binding sites in the gene. The mRNA levels
measured also represent the net outcome of other variables
such as the developmental stage of the tissue and the mixture
of cell types in the sample (395–397). Nonetheless, even when
these limitations are taken into account, the mRNA level of
selected genes provides a useful indicator of the response
status of the tissue. Independent methods such as Western
blot analysis are used to corroborate the data at the protein
level, and in situ hybridization analysis can define more pre-
cisely the cell types in which gene expression changes occur.
Any method used to confirm gene expression data requires
appropriately controlled analyses. For example, in Western
blot analysis, evidence for the specificity and sensitivity of the
antibody used is essential. Also, as a qualitative control for the
amount and integrity of protein sample loaded, the specific
protein band detectedmay be compared to an internal control
(reference) protein such as actin or RNA polymerase II, if
these proteins themselves do not vary substantially in re-
sponse to altered T3 or TR status in the tissue being studied
(82,398). If necessary, the specific protein band detected may
also be quantified relative to the internal control protein band.
& RECOMMENDATION 36
For general assessment of the tissue status in response to T3,
the analysis of representative known response genes pro-
vides informative data.
Commentary. The following genes are examples of T3
response genes and serve as useful markers of tissue T3 status:
(i) liver: Me1, Thrsp, Dio1, Gpd2, Cyp27a, and Fasn (390); (ii)
brain: Nrgn, Mbp, Hr, and Trh (paraventricular nucleus only)
(400,401); (iii) heart: Myh6, Myh7, and Atp2a2 (402); and (iv)
BAT: UCP1 (403). Determination of mRNA levels of selected
genes is accomplished by direct methods such as Northern
blot analysis (Fig. 12) or by indirect analyses based on am-
plification of cDNAusing RT-qPCR if precautions are taken to
ascertain the specificity and quantitative validity of the PCR
assay (404). However, it should be noted that although these
genes can be useful, representative indicators of T3 status of a
tissue, different genes in the same tissue may reflect a range of
direct or indirect mechanisms of response. Other factors in-
fluence the response of a givenmRNA to T3 in a specific tissue.
For example,Me1 is responsive to thyroidal status in liver, but
not the brain. Additionally, Me1 in liver is only regulated by
thyroid hormone after postnatal day 15 (405). Such temporal
and tissue specific considerations should be taken in to ac-
count when designing experiments that quantify mRNA.
[I.2] PCR analysis of mRNA expression levels
Background. PCR analysis of mRNA levels for T3-
responsive genes follows standardmethods. PCR is extremely
sensitive and has the potential to generate ostensibly positive
signals from very few molecules of mRNA. Thus, it is im-
portant to perform negative control reactions lacking cDNA
templates. For the valid detection of mRNA transcribed from
intron-less genes, reverse transcription should be also per-
formed in the absence of the reverse transcriptase enzyme
(minus RT control) to exclude false-positive amplicons gen-
erated from a contaminating genomic DNA template. Given
these limitations, results should be supported independently
with more direct assays such as Northern blot, Western blot,
or in situ hybridization analyses.
& RECOMMENDATION 37
A current method of choice to study the expression of T3-
responsive genes is RT-qPCR, which provides precise
quantification of mRNA levels, if appropriately validated.
Care should be taken to ensure that internal control genes
(i.e., reference genes) are not themselves T3 responsive in
the system being studied.
Commentary. Care should be taken to ascertain that the
quality of the input RNA is adequate. Poor quality RNA can
limit reverse transcriptase efficiency and cDNA yields (406).
FIG. 12. Dio1 (type 1 deiodinase) is a representative T3-
responsive gene in the liver. Northern blot analysis showing
Dio1 mRNA levels in response to normal diet (ND), hypo-
thyroid (LID, low-iodine diet and antithyroid agents), and
hyperthyroid (0.5 T3) conditions. Dio1, upper panel, and
control glyceraldehyde-3-phosphate dehyrogenase (G3pdh),
lower panel. In WT mice (+/+), Dio1 mRNA is suppressed
by hypothyroid conditions and induced by hyperthyroid
conditions. Induction is defective in Thrb-deleted mice ( -/-).
Treatments: ND, normal diet; LID, hypothyroid groups
(0.05% methimazole [MMI] and 1% potassium perchlorate in
drinking water and low iodine chow, for 4 weeks); 0.5 T3,
hyperthyroid groups (same as LID but with T3 added to
drinking water at concentration of 0.5mg/mL for an addi-
tional 8 days or more). Quantitation: Dio1 mRNA level
in each condition is noted numerically below each lane rel-
ative to the level in +/+ mice on normal diet (assigned a
value = 1.0). Dio1 value is normalized to control G3pdh signal;
UD, undetectable Dio1. Signals were quantified by pho-
phorimager analysis of major bands.
120 BIANCO ET AL.
In general, standard primer design rules apply to RT-qPCR
except that amplicon size should be restricted to 50–200bp
with a preferred amplicon size around 100bp to maximize ef-
ficiency (407). When possible, primer pairs should span exon–
exon junctions in cDNA to avoid amplification of potentially
contaminating genomic DNA. Primer design websites (e.g.,
Primer3, http://frodo.wi.mit.edu or www.ncbi.nlm.nih.gov/
tools/primer-blast) and databases of validated primer sets (e.g.,
http://pga.mgh.harvard.edu/primerbank) are freely available.
Two common detection methods in RT-qPCR use the SYBR
Green DNA binding dye or 5¢-nuclease (i.e., TaqMan probe)
assays (Fig. 13). In the unbound state, SYBR fluorescence is
negligible, but upon binding to double-stranded DNA its
fluorescence increases. The 5¢-nuclease assay takes advantage
of the intrinsic 5¢-exonuclease activity ofmanyTaqpolymerases
to degrade a fluorescence resonance energy transfer–linked
oligonucleotide probe designed to anneal within the amplicon.
Probe cleavage separates the 3¢-quencher fluorophore from the
5¢-reporter fluorophore. A real-time PCR machine measures
the accumulation of released fluorescent reporter product. The
5¢-nuclease assay offers possibly increased specificity over
SYBRGreen detection as it avoids potential complications with
primer dimer formation (408). To validate the assay it is also
necessary to confirm the size of PCR band and/or the presence
of a single peak in the dissociation curve (Fig. 13C).
Quantification of mRNA by RT-qPCR usually requires
normalization to an internal control reference gene. Care
should be taken in selecting reference genes for thyroid re-
search because several reports have indicated that commonly
utilized reference genes (e.g., Actb, Gapdh) are somewhat
responsive to thyroid hormone in some specific tissues (409–
412). The genesRn18S andPpia (cyclophillin A) appear suitable
for several tissues including brain, pituitary, and liver (351,413).
The abundance of a target mRNA is calculated by either rel-
ative or absolute quantification (406,414). In relative quantifica-
tion, the PCR critical threshold (Ct) of a test RNA sample (e.g.,
treated with T3) is compared to a reference sample (i.e., vehicle
control). Two methods of relative quantification are widely
used: DDCt-method and the relative standard curve method.
The DDCt-method of normalization makes use of a refer-
ence gene, such as a house keeping (Actb, Gapdh) or other
suitable forms of reference gene, that is expressed similarly
across all samples with minimal variation. The DDCt is cal-
culated as follows:
DCtcontrol¼CttargetCtreference
DCttest¼CttargetCtreference
DDCt¼DCtcontrolDCttest
Relative Expression¼ 2DDCt
where Ct is the PCR cycle number at which the reporter
fluorescence is greater than the background signal (414).
In the relative standard curve method, cDNA from an in-
dependent sample is used to create a relative standard curve
utilizing the known mass of input RNA against which
FIG. 13. An example of using RT-qPCR to analyze a T3-responsive gene. The qPCR amplification plots indicate change in
the mRNA level for the T3-responsive gene OPN1LW/MW (red/green opsin) in the human retinoblastoma cell line WERI
following treatment with increasing T3 concentrations spanning the physiological range. The increased SYBER Green de-
tection (DRn; SYBER Green fluorescence [reporter] normalized to background) following each PCR cycle demonstrates the
accumulation of a PCR amplicon. (A) Amplification plots of the internal control (reference) gene GAPDH (glyceraldehyde-3-
phosphate dehydrogenase). Note that at the critical threshold (Ct, dotted line across graph) no difference is detected between
the T3 doses for GAPDH indicating that this reference gene is not responsive to T3 treatment. (B) Amplification plots of the T3
target gene OPN1LW/MW. Note that as the T3 concentration increases, the PCR cycle needed to reach the threshold decreases
indicating the presence of higher levels of mRNA induced by T3. A plateau in T3-induced expression of OPN1LW/MW is
reached at 50 nM T3. (C) Melting curve analysis of OPN1LW/MW qPCR amplifications. Note that a single melt peak is
observed in a plot of the first negative derivative (-R; fluorescence over time; i.e., the change rate) against temperature
indicating that the increase in SYBER Green fluorescence detected is likely derived from a single PCR amplicon. Data are
unpublished observations from D.S. Sharlin and D. Forrest and are consistent with previous reports (752).
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unknown samples, such as reference and test samples, can be
quantified. To control for potential variation in RT input
RNA, calculated masses can be normalized by the calculated
mass of an endogenous control (408).
In absolute quantification, the Ct for the mRNA of a given
gene is fitted to the Ct from a standard curve generated using
serial dilutions of samples that contain known quantities of the
target gene (i.e., plasmidDNAor in vitro transcribedRNA) (406).
The abundance of an mRNAmay also be determined by the
so-called semiquantitative, or end-point RT-PCR, in which
amplicons are visualized by agarose gel electrophoresis after a
predefined, arbitrary number of PCR cycles (404). Although
arbitrary end-point RT-PCR can detect obvious changes in gene
expression, it suffers from low precision, and often involves
visualization of PCR products at the plateau phase of the
reaction, when the data do not accurately reflect the quantity of
initial starting mRNA material (407).
[I.3] Genome-wide analysis
of thyroid hormone–responsive mRNA
Background. Microarrays or genome-wide analyses by
othermethods, such as next-generation sequencing of expressed
RNA populations (i.e., RNA sequences [RNAseq]), generate
large datasets that demand major computational investigation
to extract meaningful data for relevant genes. Typically, thou-
sands of mRNA sequences display some degree of change in
levels. Follow-up analysis by other methods is required to de-
termine if candidate genes are direct targets of T3 action.
& RECOMMENDATION 38a
Microarray or other methods of genome-wide screening for
mRNA expression patterns can be used for large-scale
analysis of gene expression changes in response to ma-
nipulations of thyroid hormone signaling pathways. Can-
didate transcripts of interest must be corroborated by
independent methods, such as RT-qPCR, Western blot, or
in situ hybridization analysis.
Commentary. Many studies have been published featur-
ing microarray analysis of a given tissue or cell line following
T3 treatment of an intact organism or cultured cells. Specific
techniques for genome-wide expression analysis are evolving
rapidly, and multiple microarray systems and data mining
software packages exist and can be used as desired. Most
post-array analytical software platforms allow for manipula-
tion of the stringency parameters that set a threshold for sig-
nificantly changed genes, such as fold-change, false discovery
rate (to correct for multiple comparisons), and p-value. In
general, at least three biological replicates per treatment
group (e.g., T3 exposure) and control group (e.g., vehicle) are
required for ‘‘statistically significant’’ differences to be de-
tected if statistical significance is taken to mean a p value of
<0.05, false discovery rate of <0.05, and fold-change >2 (417).
Given the high likelihood of false-positive differences, results
of microarray studies should best be viewed as ‘‘hypothesis-
generating data’’ in nature, and changes in key transcripts
must be confirmed via PCR and other methods.
& RECOMMENDATION 38b
RNAseq uses deep-sequencing technology and can pro-
vide a more precise measurement of mRNA and variant
mRNA isoform levels compared to microarrays as data
derived from RNAseq is not biased by analysis using pre-
determined genes and probes.
Commentary. RNAseq requires major bioinformatics
analysis of sequence reads (418). The inclusion of extrane-
ous cell types in a tissue sample should be minimized, as
qualitative variations between samples will increase experi-
mental ‘‘noise’’ and reduce the resolution of analysis. Tissue
samplingmay be refined using laser microdissection to isolate
defined pieces of tissue from histological sections or fluores-
cence-activated cell sorting to isolate enriched cell popula-
tions based on specific cell markers (419,420). Observed
changes in mRNA expression patterns might represent indi-
rect alteration in mixed cell populations in tissues (421,422). A
cell line in culture, although not a physiological sample, may
provide a more homogeneous cell population for certain an-
alyses.
[I.4] Mechanisms of gene regulation by thyroid hormone
Background. The TR binds to DNA elements known as T3
responsive elements (T3REs) (423). In general, TR binds the
T3RE as a homodimer or heterodimer with retinoid X recep-
tors (RXRs). These receptor complexes attract co-repressors or
co-activators depending onwhether the TR is in a T3-bound or
unbound state (424–426). Analyses of TR–DNA interactions
often use two broad approaches: (i) transcription response
(‘‘transactivation’’) assays, typically in transfected cells in
culture, and (ii) assays to investigate TR binding to DNA on
isolated DNA response elements (electrophoretic mobility
shift assay [EMSA]) or on genomic DNA in a chromatin state
(chromatin immunoprecipitation [ChIP]).
& RECOMMENDATION 39
The regulation of a target gene by TR can be investigated in
tissue culture cells co-transfected with a reporter gene
plasmid plus a TR-expressing plasmid. Transactivation of
the reporter is assessed in response to added T3 at varying
doses over a physiological range and can be tested in dif-
ferent cell lines since responses may be influenced by host
cell-specific factors.
Commentary. The candidate T3RE or enhancer region of
the target gene with its natural promoter or an artificial pro-
moter is ligated to a readily detectable reporter gene, usually
firefly luciferase. Luciferase activity generates light, which is
detected using a luminometer (427). Promoter-less and
enhancer-less luciferase reporters are used as controls to ex-
clude the possibility of spurious responses originating from
‘‘stealth sequences’’ fortuitously present in the luciferase gene
or vector backbone (428).
Transfection efficiency is assessed by co-transfection of an
internal control reporter plasmid usually with Renilla lucif-
erase driven by a constitutively active promoter. The specific
readout of a reporter assay is normalized as firefly luciferase
activity (test gene) over Renilla luciferase activity (internal
control gene). It is imperative to establish that internal control
reporters do not respond to the experimental conditions be-
cause this can inappropriately distort the readout ratio (429).
Consideration should be given to whether the reporter
vector is chromatin-forming or non–chromatin-forming.
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Standard or ‘‘naked DNA’’ reporter plasmids such as pGL4
often yield useful data in transiently transfected cells. Alter-
natively, vectors that carry an episomal replication origin,
such as pREP4, can form chromatin in transiently transfected
cells. Some DNA response elements require a chromatin-
forming vector to display activity (430).
The location of the promoter for a given target gene of
interest should be verified. Not all genes represented in the
genome databases depict an accurate 5¢ gene structure, which
requires experimental mapping of 5¢ ends of mRNAs from
different tissues. The most upstream exons of a gene (trans-
lated or untranslated) can be identified by RNAse protection
assays or 5¢-rapid amplification of cDNA ends analysis
(431,432). The function of a presumptive promoter should be
demonstrated using luciferase assays in transfected cells or
reporter transgenes in an animal model. The preconception
should be avoided that relevant enhancers reside only up-
stream of the promoter of a target gene. Many enhancers re-
side within introns or downstream of the gene (433).
& RECOMMENDATION 40a
EMSA can demonstrate direct binding of the TR to a DNA
element thereby providing evidence that a gene is a direct
target of TR. EMSA is based on the observation that
protein-bound DNA migrates at a slower rate than un-
bound DNA when subjected to electrophoresis. The DNA
element (the probe) is usually radiolabeled to allow sensi-
tive detection of protein:DNA probe complexes.
Commentary. TR binding sites are typically related to the
consensus motif for a nuclear receptor binding site, 5¢-
AGGTCA-3¢ and often occur in dimeric repeat configurations
(423,434). Optimal EMSA probes are short double-stranded
oligonucleotides (*20–30 bp). Longer probes (or degraded
probes) may increase nonspecific binding, which appears as
indistinct, smeared signals after EMSA. Radioactively end-
labeled probes offer great sensitivity and allow detection of
protein–DNA complexes using x-ray film or phosphorima-
ging. Alternatively, probes can be labeled nonradioactively
(e.g., with biotin), followed by secondary detection with
streptavidin and enzymatic substrates similar to those used
for Western blotting (435).
Nuclear or whole cell extracts from the tissue or cell line of
interest provide a source of TR protein. Lysates of cultured
cells transfected with a TR-expressing plasmid are another
common source of TR protein (381). Alternatively, TR protein
can be generated using a cell-free in vitro translation system
(436,437).
The specificity of the TR–DNA probe interaction is con-
firmed by two standard control tests: (i) the use of an anti-TR
antibody that supershifts or disrupts the retarded band (a
parallel negative control using a nonspecific antibody should
not disrupt the specific TR–DNA probe complex), and (ii) the
specificity of the TR binding to the labeled DNA probe should
be confirmed by competition in the presence of an excess of
unlabeled ‘‘cold’’ oligonucleotide probe. Two types of com-
petitor oligonucleotide probe are used in parallel samples:
wild-type probe and probe containing point mutations within
the proposed TR binding site. A dose-dependent reduction in
the intensity of the shifted band signal is expected when using
cold wild-type probe but not mutant probe (436). Typically,
each cold competitor is added in two or three doses, re-
presenting a range of approximately 2- to 100-fold excess over
the labeled probe.
& RECOMMENDATION 40b
ChIP can be used to indicate that the TR associates with a
target gene in its natural context in the genome in a tissue or
cell line. The most critical requirement for ChIP is a high-
quality specific antibody for immunoprecipitation, with the
specificity being established by control experiments.
Commentary. ChIP is used for testing binding of tran-
scription factors to known target genes or for exploration of
previously undefined binding sites. A positive ChIP result
indicates an association with a region of chromatin DNA but
does not differentiate between direct binding to DNA and
indirect binding to a complex of other factors that bind DNA.
Currently, there is little evidence that available antibodies
against TR generate consistently reproducible ChIP results for
mammalian tissues, although some ChIP data have been re-
ported for cell lines and amphibian tissues (438–442). The
difficulties in generating ChIP data on natural tissues may be
a consequence of relatively low concentration of TR in
mammalian tissues compared to other types of more abun-
dantly expressed transcription factors.
Optimal conditions for cross-linking and sonicating chro-
matin should be established empirically for any tissue or cell
line (443). A negative control for ChIP utilizes purified non-
specific IgG, pre-immune serum, or antibodies against foreign
proteins not present in the tissue. Genomic DNA fragments
isolated by ChIP are identified by PCR using a series of primer
sets that span the genomic region of interest as well as nega-
tive regions of the gene or distant genomic regions (444). All
negative controls can generate a background signal and
should be tested empirically.
& RECOMMENDATION 40c
More advanced applications of ChIP, demanding stringent
technique and computational analysis, involve the combi-
nation of ChIP with microarray (ChIP-chip) or next-
generation sequencing to identify genome-wide binding
sites for a nuclear factor.
[I.5] Mouse models for indicating thyroid hormone
and TR signaling in tissues
Background. Numerous KO and knockin mouse strains
derived by genetic manipulation have yielded a wealth of
information on the physiological functions of TR isoforms
in vivo. Genetic manipulation has also been used to generate
models that yield insights into where and when T3 or specific
TR proteins are present in tissues in vivo. There is scope for
further development of such approaches, to elucidate at the
cellular level, the basis of T3 actions in vivo.
It should be borne in mind that the lack of receptor in KO
mice may produce certain differences in phenotype compared
to a lack of hormone. For example, mice lacking all T3 receptors
(TRa1, TRb1, TRb2) display multiple tissue phenotypes but are
not as small or as retarded as mice with severe, congenital hy-
pothyroidism (75). There may be several explanations for these
differences.An explanation that has been supported by study of
the cerebellum in vivo, is that in hypothyroidism, the TR exerts
chronic ligand-independent dysregulation of gene expression
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to produce a more severe outcome than the absence of a TR. In
the absence of TR, this ligand-independent dysregulation of
gene expression could not occur such that the phenotype is less
severe (445). However, few tissues and few target genes have
been studied in detail to indicate how widely this explanation
may apply. In summary, the deletion of TR isoforms yields
precise information on the tissue-specific functions of TR iso-
forms.However, the phenotypesmay not always be reflected in
hypothyroid models. Conversely, hypothyroid phenotypes
may not be fully reflected in TR-deficient models.
& RECOMMENDATION 41a
Mouse strains with targeted KO or knockin mutations in
the endogenous Thra and Thrb genes provide models to
study TR functions in vivo.
Commentary. Numerous mutations in the Thra and Thrb
genes (also known as Nr1a1 and Nr1a2, respectively) have
been derived but only a brief mention of phenotypes is given
here. For more detailed reviews on Thra and Thrb mutations,
readers are referred elsewhere (286,382,383) and to the Mouse
Genome Informatics website (www.informatics.jax.org). An-
other useful online resource is the Nuclear Receptor Signaling
Atlas (www.nursa.org).
The initial gene targeting studies established that Thrb is pri-
marily responsible for the regulation of the HPT axis (446,447),
the development of the auditory and color visual systems
(448,449), and the majority of T3 actions in liver (390,393,450).
The Thra gene is primarily responsible for determining thermo-
genic and cardiac functions (386,451) and the maturation of the
intestine (452), bone (453), and certain brain tissues (445,454).
In contrast to KO models, knockin mutations in the coding
sequence of the Thra or Thrb genes have generated mouse
models that express dominant negative TRa1 and TRb pro-
teins with little or no response to T3 (456). These mutations
create models of localized ‘‘tissue-restricted’’ hypothyroidism
selective for tissues in which TRa1 or TRb is the predominant
T3 receptor isoform expressed.
& RECOMMENDATION 41b
Mice devoid of known T3 receptors (TRa1, TRb1, and TRb2)
can be used to model the complete absence of TR-mediated
signaling.
Commentary. Mice lacking specifically TRa1, TRb1, and
TRb are viable but have cellular and functional defects in mul-
tiple organ systems, indicating that in many tissues, TRa1 and
TRb isoforms serve additional, common functions that were not
evident in models with single receptor gene mutations (75,457).
& RECOMMENDATION 41c
Coding sequence changes introduced into both Thrb and
Thra genes have provided mouse models for the human
syndromes of resistance to thyroid hormone.
Commentary. The human syndrome of resistance to
thyroid hormone is typically caused by heterozygous coding
mutations in the THRB gene that generate dominant negative
proteins with little or no response to T3 (458). Recently, similar
mutations in the human THRA gene have been identified that
generate dominant negative TRa1 proteins (459,460). The Thrb
and Thra knockin mouse models display a range of tissue-
selective phenotypes and offer the opportunity to investigate
the cellular and molecular defects underlying the disease
symptoms in specific tissues (456,461–465).
& RECOMMENDATION 41d
Transgenic reporter mice that express a T3-responsive chi-
meric protein provide an in vivo model that allows for
monitoring of the presence of T3 in various tissues.
Commentary. It has traditionally been difficult to detect T3
at the cellular level in natural tissues, especially in specialized
cell populations. RIAs performed on tissue homogenates
provide no information on which cell types contain T3. The
transgenic FINDT3 mouse model offers the advantage of
detection of T3 in localized regions within complex tissues
(278,467). These mice express a chimeric protein consisting of a
yeast Gal4 DNA binding domain fused to a TRa1 ligand-
binding domain. The expression of the reporter does not
require endogenous TR. The presence of T3 is detected visually
on tissue sections based upon activation by the chimeric pro-
tein of a Gal4-responsive promoter-fused to a LacZ reporter
gene (Fig. 14).
This approach can be used to detect T3 activity in several
tissues, but reportedly has limited sensitivity in certain brain
regions (278). Using beta-gal as the readout in transgenic
mice, T3 signaling was absent in the early embryo and was
then detected at around E11.5–E12.5 in different primordia
(i.e., CNS, intestine, etc.). Since at this time, fetal thyroid
function in the mouse is still inactive, and these early signals
may reflect maternal T4 or T3 activity. Early T3 signaling was
observed in the brain (i.e., diencephalic primordia, medulla
oblongata) and sense organs primordia (otic vescicle, olfac-
tory epithelium, retina), whereas at late stages (E15.5–E17.5)
beta-gal expression was localized in other primordia (i.e., in
the bones, follicular nerves of the vibrissae, as well as in the
small intestine primordia, but also in the medulla oblongata)
(468).
& RECOMMENDATION 41e
Targeted insertions in the endogenous Thra and Thrb genes
generate TR proteins fused to protein tags that can be used
to monitor expression of TR isoforms in specific cell pop-
ulations in vivo.
Commentary. The fused tag allows detection of TR iso-
form expression by immunohistochemistry (IHC) or immu-
nofluorescence in tissue sections or whole-mount preparations
and offers the possibility of detection at single cell resolution.
Thra1gfp mice carry green fluorescent protein (GFP) fused
in-frame at the C-terminus of the intact TRa1 protein (469).
Detection of TRa1-GFP protein has been reported in specific
brain tissues and cell types. LacZ inserted into the Thrb gene
allows detection of TRb isoforms (430,449,457) and has re-
vealed TRb2 expression in restricted cell populations in the
cochlea, pituitary gland, and cone photoreceptors.
[J] Assessing Thyroid Hormone Signaling
by Way of Systemic Biological Parameters
Overview. Thyroid hormones exert diverse actions in
virtually all tissues during development, infancy, adoles-
cence, and adulthood in areas such as growth, cognition,
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skeletal-muscle homeostasis, cardio-circulatory function, en-
ergy homeostasis, and intermediarymetabolism. It is essential
to adopt a physiological whole animal approach for investi-
gation of thyroid hormone action in vivo. By necessity, this
requires longitudinal studies of T3-responsive biological pa-
rameters and/or biochemical markers.
Studies generally focus on the transition from hypothy-
roidism to euthyroidism and thyrotoxicosis. Two comple-
mentary strategies can be adopted: (i) collect sequential
biological measurements from the same animals at baseline
and intervals during the period of study, or (ii) run control
and experimental groups in parallel and collect biological
measurements at specific time points; this model has
the advantage that animals can be killed at different time
points and tissues harvested for structural or biochemical
analyses.
In general these studies are performed in common rat or
mouse strains. More advanced animal models include geneti-
cally modified mice in which thyroid hormone signaling has
been disrupted or modified by either global or tissue-specific
gene targeting. With such mouse models it is important to
ensure experiments are designed to avoid the confounding
influence of mixed genetic background if possible. Ideally,
mutant strains should be backcrossed to homogeneity onto a
suitable background such as C57BL/6. If this is unrealistic (e.g.,
if crossing CRE and FLOXED lines from different genetic
backgrounds), littermates should be compared and adequate
power calculations performed. Males and females may need to
be studied separately because responses to thyroid hormones
can be sexually dimorphic.
T3-dependent biological parameters can also be studied
using ex vivo preparations, such as freshly isolated cells, cul-
tures of primary cells or established cell lines. In general, such
in vitro systems have poor responsiveness to T3, with only a
few being well characterized. However, cell-based models
have been invaluable in the deconstruction and understand-
ing of molecular mechanisms underlying the complex bio-
logical effects of T3.
[J.1] Central nervous system
Background. Most effects of thyroid hormone in the brain
are observed during development. Endemic neurological
cretinism results from maternal iodine deficiency and the
consequent maternal hypothyroxinemia, in which circulating
T4 levels are low for the stage of pregnancy. Maternal hy-
pothyroxinemia causes neurological thyroid hormone defi-
ciency in the developing fetus resulting in mental retardation,
spastic diplegia, deaf-mutism, and squint in the absence of
general signs of hypothyroidism. Even though endemic cre-
tinism can be mitigated by iodine supplementation to prevent
or correct first trimester maternal hypothyroxinemia, iodine
deficiency remains the commonest cause of preventable
mental retardation. On the other hand, neurological features
of neonatal hypothyroidism may be less profound because
they are dependent on the severity of hypothyroidism. Ab-
normalities are largely preventable by immediate thyroid
hormone replacement, although deficits in memory and IQ
may persist. Nevertheless, untreated neonates have growth
retardation and general features of hypothyroidism with
mental retardation, tremor, spasticity, and speech and lan-
guage defects. The differences between endemic cretinism
and congenital hypothyroidism illustrate that the timing of
thyroid hormone action is fundamental for neurodevelop-
ment (470,471).
Developmental hypothyroidism also causes sensory im-
pairment, including permanent deafness, which in rodent
models has been shown to involve deformity in the inner ear
tectorial membrane and impaired maturation of the sensory
epithelium (247). There is also a visual phenotype since thy-
roid hormone affects the development of color vision. In
adults, thyroid hormone acts on mood, behavior, and cogni-
tive function, and sophisticated tests have been validated to
investigate the effects of thyroid hormones on behavior phe-
notypes in mice. Thyroid hormone also affects muscle
strength and fatigue as well as the motor and cerebellar sys-
tems. Individuals with hypothyroidism are sluggish and fa-
tigued with muscle weakness and slow-relaxing reflexes,
whereas in thyrotoxicosis there is tremor, muscle wasting,
hyper-reflexia, and fatigue.
FIG. 14. T3 signaling represented by b-galactosidase stain-
ing (blue) in coronal brain sections in postnatal day 5 mice
carrying the FINDT3 reporter transgene. (A, D) FINDT3
reporter on wild-type (WT/FINDT3) mice; (B, E) FINDT3
reporter in mice lacking type 3 deiodinase, a thyroid hor-
mone-inactivating enzyme (D3KO/FINDT3). (C, F) No b-
galactosidase staining was detected in sections from control
mice (WT) not carrying the transgene. S, septum; Pi, piriform
cortex; MCx, motor cortex; SCx, sensory cortex. Note in-
creased b-galactosidase activity in D3KO/FINDT3 mice in
the piriform, motor, and sensory cortex, consistent with in-
creased T3 exposure in mice lacking type 3 deiodinase.
Cryosections (50 lm thick) were stained using 1mg/mL of
X-gal (5-bromo-4-chloro-3-indolyl-d-galactopyranoside), a
colorigenic substrate for b-galactosidase. Reproduced and
adapted from Hernandez et al. (278) with permission. ª 2013,
The Endocrine Society.
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The adult brain is also responsive to thyroid hormone. A
standardized observational screening assessment of behavior
and function in rodents has been described (SHIRPA) that
allows a general and comprehensive neurological (muscle
and lower motor neuron, spinocerebellar, sensory, and auto-
nomic function) and neuropsychiatric (activity, learning,
arousal, fear, aggression, feeding, irritability, etc.) analysis to
be performed prior to more detailed investigation of abnor-
mal parameters and neurological pathways (472). A modified
and standardized SHIRPA assessment has been adopted by
the International Mouse Phenotyping Consortium as part of
the initial characterization primary phenotype screen of
mouse mutants generated by the International Knockout
Mouse Consortium (473,474). Such an approach is being
adopted to include phenotype analysis of all physiological
systems and facilitate standardization and eventual genera-
tion of comprehensive and large repositories of phenotype
data.
& RECOMMENDATION 42
Rodent models can be used to study how thyroid hormone
affects brain development and function. The correlation
between the time of onset of fetal thyroid function and the
chronologic age is different in rodents than in humans;
the stage of neurobiological development rather than the
chronological age of the animal should be considered.
Commentary. Congenital hypothyroidism promotes
profound impairment of brain development and function. For
example, selective and persistent cognitive problems may be
seen in children that were born with congenital hypothy-
roidism. Sophisticated imaging, such as magnetic resonance
imaging (MRI), has shown that children and adolescents with
congenital hypothyroidism have reduced hippocampal size
and abnormal hippocampal growth patterns relative to peers.
More importantly, reduced hippocampal volumes predict
poor memory performance (475).
Rodent models of congenital hypothyroidism have been
studied extensively, given that most anatomical and func-
tional components of the mammalian brain are similar be-
tween man and other mammalian species (476). However, in
many respects they do not constitute an ideal animal model
for study of fetal maternal thyroid economy during gestation.
The main differences involve the onset of fetal thyroid func-
tion and timing of neurodevelopmental events in relation to
birth. The issue is how much different species vary in relation
to man according to the proportion of the brain growth spurt
that is postnatal (476). In this respect, thyroid hormones do
not influence very early events such as neural induction and
the establishment of polarity during brain development. In-
stead, they modulate later processes, including neurogenesis
and dendrite proliferation, myelination, and synapse forma-
tion. The timing of onset of thyroid hormone action in the
developing brain is thus crucial and physiologically impor-
tant. Alternatively, sheep have been extensively used as an
animal model. The guinea pig is of potential interest as well
because its in utero thyroidmaturation ismuch closer to that of
the human (477).
Many rodent studies have focused on the rat cerebellum
because its neurobiological development is predominantly
postnatal and thus more easily exposed to experimental ma-
nipulation (476). However, other regions including the cere-
bral cortex, basal ganglia, cerebellum, and hippocampus have
also been studied using standard histological approaches.
These techniques have also been adapted to study the spinal
cord and dorsal and ventral nerve roots (478). For example,
the Purkinje cell neurons and their spatial organization are
central to the function of the cerebellum. They are formed just
before birth in the rat and their number is not affect by hy-
pothyroidism at birth but their migration and maturation is
severely impaired (476). The effect of thyroid hormone defi-
ciency on maturation of the rat cerebellar cortex may still
be observed if hypothyroidism is induced up to the second
postnatal week (476). Similarly, most rat forebrain neurogenesis
is completed at birth. However, the structural analysis indicates
that there is marked hypoplasia of the neuropil (476). Thus, it
seems clear that thyroid hormone affects direct brainmaturation
through specific effects on cell differentiation. Thyroid hormone
slows down cell division while concomitantly stimulating the
onset of cell differentiation.
& RECOMMENDATION 43
Given the functional diversity and structural complexity of
the CNS studies of T3-responsive genes in the brain are
greatly enhanced if studied via in situ hybridization or IHC.
Commentary. Microarray analysis, Northern blotting,
RT-qPCR, next-generation RNA sequencing, and in situ hy-
bridization have all been used to study T3-regulated gene
expression in the brain (392,401,479). Protocols for in situ
hybridization and IHC have been described (445,480–484).
These may be performed on paraffin-embedded sections or
fixed frozen tissue if preservation of detailed histological
architecture is of significant importance (485). However,
paraffin embedding interferes with RNA quality, thus better
signal-to-noise ratio and analysis of gene expression are
obtained using fixed frozen tissue. For example, in situ
hybridization has been used to define TRH as a negatively T3-
regulated gene in the hypothalamus (486–489) and to study
the cortex/dentate gyrus expression of RC3/neurogranin,
which is positively regulated by T3 (396).
When using quantitative methods, careful sample dissec-
tion is needed given the highly compartmentalized nature of
the brain. In some cases, pooled samples from 5–10 mice are
required to obtain sufficient RNA for such studies (485). A
more appropriate way of obtaining brain samples is through
laser-capture microdissection, which allows accurate isolation
of specific cell-types embedded in a heterogeneous tissue mi-
croenvironment. Laser-capture microdissection works under
micromanipulator-assisted direct microscopic visualization
and the samples obtained can then be processed for RNA
isolation (491).
A microarray analysis of hypothyroid mouse cerebral cor-
tex identified 316 genes positively regulated and 318 genes
negatively regulated by T3 (127). The responsiveness of sub-
sets of these genes to T3was confirmed by RT-qPCR in a brain-
specific, severely hypothyroid mouse model, the double
Mct8/D2 KO mouse (127) and in the brain of systemically
thyrotoxic mice or D3 KO mice (492). Through the study of
systemic hypothyroidism or thyrotoxicosis, T3-regulated
genes have also been identified in specific regions of the brain
(e.g., cerebellum, cortex, hippocampus). In the developing
cerebellum, systemic hypothyroidism resulted in altered ex-
pression of 2940 genes, of which 1357 were up-regulated and
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1583 down-regulated as assessed by microarray analysis
(493). However, the number of cerebellar genes directly reg-
ulated by T3 is likely to be much smaller as evidenced in
primary cultures of cerebellar neuronal cells studied via mi-
croarray RNA hybridization (494). In any such screen, strin-
gent statistical criteria should be used to narrow down the
number of candidate T3-regulated genes for further confir-
matory analyses.
Brain protein expression is typically analyzed by Western
blotting or IHC of fixative-perfused brains (post-fixed over-
night at 4C and cryoprotected in 30% sucrose). IHC is suit-
able for quantitative approaches only if the detection system is
kept unsaturated; quantification of secreted proteins and
peptides by this method is not recommended. Studies can be
performed on free-floating cryostat sections of specific brain
regions (478). The approach was used to study the effects
of congenital hypothyroidism on microtubule-associated
protein-2 expression in the cerebellum of the rat (495) and the
expression of thyroid hormone transporters in the cochlea
(496). In addition, IHC was also used to study the regulation
of reelin and dab1 by thyroid hormone in different brain re-
gions (497), whereas Western blotting and in situ hybridiza-
tion were used to study tenascin-c (498). These techniques
have differing advantages and disadvantages. Thus, immu-
nocytochemistry provides the ability to identify precisely
where in the CNS the antigen is located in individual cells or
at the subcellular level in the nucleus or cytoplasm or even
more precisely if electron microscopy is used. It also provides
an excellent method to verify loss or re-expression of a par-
ticular antigen in transgenic mouse models or following an-
atomical manipulation such as electrolytic lesioning or
transection. Because the content of an antigen in any partic-
ular cell can be influenced by its rate of synthesis, transport,
degradation, and secretion, in situ hybridization histochem-
istry tends to be a much better quantitative approach than
IHC. Alternatively, specialist microdialysis techniques can be
used to measure secreted protein concentrations. Western
analysis also can be subject to some of the same concerns with
respect to quantitation as immunocytochemistry, but has the
advantage of being able to identify the size of the antigen(s)
being identified.
& RECOMMENDATION 44a
Functional hearing deficits resulting from thyroid hormone
deficiency may be studied by measuring auditory evoked
brainstem responses to determine stimulus intensity
thresholds.
Commentary. Analysis of middle ear anatomy involves
histological inspection of the ossicle for deformities (499).
Assessment of ossification requires staining with alcian blue
and van Gieson to visualize cartilage and bone formation.
Cochlear anatomy is examined on inner ear sections. Metha-
crylate plastic-embedded samples of paraformaldehyde/
glutaraldehyde-fixed cochlear tissue yield good preservation
of cellular structure; 3- to 4-lm-thick sections can be stained
with toluidine blue (448,501) or thionin (499,502) or aqueous
hematoxylin (277).
A relatively rapid, noninvasive means of assessing auditory
function is the measurement of the auditory-evoked brainstem
response (277,448,501,502). Investigation of other features of
cochlear function or cochlear nerve function may include de-
termination of the endocochlear potential, compound action
potential, and other physiological parameters (277).
& RECOMMENDATION 44b
Deficits of visual function that result from thyroid hormone
deficiency may be studied by measuring visual evoked
responses in electroretinograms to determine wavelength
sensitivity and light intensity thresholds.
Commentary. Histological analysis of the retina is per-
formed on 2lm sections obtained from methacrylate plastic-
embedded samples. The dorso-ventral axis of the globe is
marked. In situ hybridization and immunohistochemistry are
used to assess expression of candidate target genes and are
typically performed on 10–16 lm paraformaldehyde-fixed
cryosections (279,398,503,504). Protein expression analyses
can be performed on protein extracts prepared from dissected
retina to investigate various opsin and rhodopsin proteins
using Western blot and immunohistochemical studies
(279,398,503,504,506).
Cone and rod photoreceptor functions can be assessed by
analysis of the electroretinogram, which is typically recorded
in young adult mice. Given the critical functions of thyroid
hormone in different cone types, it is important to analyze
photopic (light-adapted) cone responses in response to spe-
cific light wavelengths that are selective for the different cone
populations, namely, those with peak sensitivity to medium-
long (M, or ‘‘green’’ *520 nm) and short (S, or ‘‘blue’’
*367 nm) wavelengths of light. Scotopic (dark-adapted) rod
responses should also be determined (279,398).
& RECOMMENDATION 45
Thyroid hormone effects on neuron ion channels and nerve
conduction can be investigated by patch-clamp analysis or
microelectrode recording.
Commentary. Detailed analysis of neuronal function re-
quires specialist techniques best performed in collaboration
with established neuroscience laboratories. For example,
patch-clamp analysis of whole neurons in tissue slices or
microelectrode recording from tissue slices have been used
to study the effects of thyroid hormones on neuron function
(478).Whole-cell patch-clamp recordings of individual neurons
can be performed using specialist instruments on 300lm para-
sagittal brain slices obtained from mice. Neurons are visual-
ized by infrared-differential interference contrast microscopy
to allow selection of cells to be recorded (478). Advanced re-
cording procedures can measure hypothyroidism-induced
changes in long-term potentiation in hippocampal neuron
populations, a cellular mechanism of synaptic plasticity that is
thought to be involved in memory (507–510).
& RECOMMENDATION 46a
Standardized neurological tests can be used to investigate
how thyroid hormone affects neuromuscular control at
both motor and cerebellar levels. The use of complemen-
tary methods is recommended.
Commentary. Open-field testing protocols have been
used to quantitate locomotor activity for distance travelled
and speed over a defined period (187,483,511) in order to in-
vestigate both behavioral and stamina aspects of
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neuromuscular function in response to alterations in thyroid
status. Motor and muscle function can be investigated by
standardized tests of strength, including grip strength deter-
mined using an automated grip strength meter, an electronic
pull strain gauge, or a hanging wire test (478). Accelerating
rotarod testing of balance and motor coordination is per-
formed by determining the time an individual mouse is able
to stay on the rod during its rotation following a defined
training period prior to testing (187,483). Beam walk testing
using a series of elevated beams of differing widths may be
used to determine balance by measurement of foot slippage
and time to cross the length of the beam (478). Alternatively,
vertical pole tests are used to investigate agility and balance
by determining the time taken for amouse to invert and run to
the base of a pole when placed near the top (187). Footprint
analysis of gait can be assessed inmice trained to walk along a
filter paper with their feet painted with different color non-
toxic paints applied to forelimbs and hindlimbs. Determina-
tion of stride length, front and hind base width, interstep
distance, heel usage, and hind paw angle can be used to assess
balance and coordination (478).
& RECOMMENDATION 46b
Mood, behavior, learning, and memory are responsive to
thyroid hormone and can be investigated using established
behavioral tests. The use of complementary methods is
recommended.
Commentary. Features of depression are investigated by
learned helplessness testing. In this situation, an operant
learning system, comprising a conditioning chamber with a
shock generator, allows analysis of ‘‘active avoidance’’ be-
havior by discriminating avoidance from escape (511). In
order to investigate anxiety a ‘‘passive avoidance’’ system
should be used. A light/dark box is employed to determine
the time spent in light versus dark during a defined total time
period (511–513). An elevated plus sign–shaped maze, con-
sisting of two opposed open arms and two opposed enclosed
arms, can be used as an alternative assessment. In this situa-
tion, the time spent in exploratory behavior in the open arms
versus nonexploratory behavior time in enclosed arms is de-
termined (187,483). Startle responses as further indicators of
anxiety and restlessness may also be investigated (511).
To investigate the effects of altered thyroid status on
learning and to measure effects on recognition memory,
studies in an open field with familiar and novel objects can be
employed in novel object recognition tasks (187,483). Open-
field testing can also be used to investigate features of de-
pression because it evaluates the tendency of mice to explore
openly or stay frozen at the edges of the field or to present
rearing behavior. Additional tests to investigate learning and
memory involve the use of a Morris water maze filled with
opaque water and containing a small platform located in one
quadrant just below thewater surface. Themouse is placed on
the small platform for 10 seconds and then placed in the
water. The time taken to find and climb onto the platform is
recorded. The task is repeated on sequential days to investi-
gate learning and memory. The visible cue test replicates the
experiment except that the platform is clearly visible (187).
The water escape test investigates visual awareness by plac-
ing a visible escape ladder on the side of the vessel and re-
cording the time taken to climb on to the ladder (187).
& RECOMMENDATION 47
The hypothalamic effects of thyroid hormone on behav-
ioral andmetabolic parameters can be studied directly after
intra-cerebro-ventricular (ICV) administration of T3.
Commentary. Thyroid hormone exhibits a number of ef-
fects that are mediated directly at the medial basal hypo-
thalamus. An example is the increase in food intake that
rapidly follows administration of T3 directly into the ventro-
medial nucleus (514–516). A related approach is to implant T3
crystals stereotaxically into discrete hypothalamic areas. This
method has been used to define the direct role played by T3 in
the TRH negative feedbackmechanism (487,488) and to study
the photoperiod-mediated regulation of seasonal energy bal-
ance and reproduction in the Siberian hamster (517). Fur-
thermore, the direct role played by a number of neuropeptides
on the HPT axis has been studied using the ICV route; for
example, aMHS, neuropeptide-Y, and agouti-related protein
(518–522).
& RECOMMENDATION 48a
Brain cell models that respond to thyroid hormone in vitro
can be used to model T3 effects in the CNS.
Commentary. Primary cultures of hippocampal neurons
and neuronal cell lines respond to T3 in vitro. In cultured
neurons, exposure to T3 significantly increases the neurite size
and length, as well as acetylcholinesterase activity (523). In
addition, T3 directly affects the development of cultured cer-
ebellar Purkinje cell dendritic processes through activation of
TRa1 (524). T3 can also enhance neuronal differentiation in-
duced by retinoic acid treatment of embryonic stem cells
(525). Glial cells are also responsive to T3 (526). For example,
the activity of the cell maturation marker glutamine synthe-
tase increases in cultured cerebellar astrocytes in response to
T3 (527). Notably, thyroid hormone–evoked changes in neu-
ronal function often involve glia-mediated actions (526). For
example, thyroid hormone up-regulates voltage-activated
sodium current in cultured postnatal hippocampal neurons
through T3-dependent secretion of basic fibroblast growth
factor from hippocampal astrocytes (528). Oligodendrocytes
are also responsive to T3 and myelination is probably the best
characterized T3-mediated effect on glial cell function (529),
with T3 stimulating myelin basic protein gene expression in
cultures of oligodendrocytes (530).
Cultured brain cells often exhibit substantial deiodinase ac-
tivity, D2 and/orD3, and thus the type and concentration of the
thyroid hormone applied in treatment groups should be con-
sidered and experiments planned accordingly. Frequent media
changes may be required to ensure stable iodothyronine con-
centration throughout the experiment. Adding tracer amounts
of radiolabeled T4 or T3 with subsequent analysis of the me-
tabolites in the media indicates their metabolic rate (173). In
coculture models, T3 produced by D2 in H4 glioma cells affects
gene expression in neighboring SK-N-AS neuroblastoma cells
(173). In this system, concentrations of T4 as low as 20pM
evoked T3-mediated gene expression in the neuronal cells.
& RECOMMENDATION 48b
Pituitary cell models respond to thyroid hormone in vitro
and can be used to study T3 effects in the anterior pituitary
gland.
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Commentary. Pituitary cell lines are typically responsive
to thyroid hormone given the high TR expression in the gland
(101). The GH1 somatotroph cell line was among the first cell
models shown to respond to physiological levels of thyroid
hormone as monitored by cell growth and glucose utilization
(531). In the GH3 somatotroph cell line, exposure to T3 in-
creases growth hormone expression in a TRb2-mediated
manner (532), while in GH-secreting GC cells, T3 decreases D2
mRNA levels (143). The thyrotroph-derived cell line TaT1 also
responds to physiological levels of T3 by decreasing TSHb and
D2 expression (259,533).
[J.2] Heart and cardiovascular system
Background. Development of the heart and transition of a
fetal to adult cardiac gene expression program is to a large
extent dependent on thyroid hormone (534). The heart re-
mains a major target organ of thyroid hormone in adult life
and cardiovascular effects are among the most pronounced
clinical manifestations of hypothyroidism and thyrotoxicosis
in man (535). Rodent hearts are equally responsive, and vir-
tually every aspect of cardiac biology is affected by thyroid
hormone, including electrophysiology, ion homeostasis, con-
traction, energy metabolism, and adrenergic signaling (402).
The sum of these effects is evident in the increases in heart rate
and rates of contraction and relaxation in the transition from
low to high thyroid-hormone states. Together with the reduc-
tion of peripheral resistance induced by thyroid hormone, this
results in the higher cardiac output required by the hyper-
metabolic organism. Ventricular growth is also stimulated by
thyroid hormone, almost doubling heart weight in the transi-
tion from hypothyroidism to thyrotoxicosis. However, thyroid
hormone has little direct effect on cardiomyocyte growth and
the ventricular hypertrophy is almost entirely in response to the
increase in cardiac workload induced by thyroid hormone
(537). Therefore, although the functional consequences of al-
tered thyroid-hormone levels are relatively straightforward
and well documented, separating the direct effects from the
secondary ones may be challenging. This even applies to those
cardiac genes that have been identified as direct targets of T3,
because they are inmany cases transcriptionally coregulated by
factors that are themselves influenced by the thyroid status
(e.g., through load-dependent signal-transduction routes).
Understanding the mechanisms of thyroid-hormone action
in the heart and assessing cardiac T3 activity is relevant,
particularly given the suspected role of impaired cardiac
thyroid-hormone signaling in the progression of heart disease
and the potential therapeutic use of thyroid hormone. This is
related to the low serum thyroid-hormone levels seen in heart
failure (i.e, the NTI syndrome) as well as to changes in cardiac
thyroid-hormone metabolism and TR expression in various
forms of heart disease. The recommendations in this section
describe approaches andmethods that are used to determine
the effect of the thyroid status on cardiac parameters. These
methodologies are also used to assess the role of cardiac
thyroid-hormone signaling in genetically modified mice,
such as TR knock-out models (451), and in models of path-
ological cardiac remodeling and heart failure. Models for
LV remodeling include the spontaneously hypertensive rat
model (539); surgical induction of myocardial infarction by
transient or permanent ligation of the left descending coro-
nary artery (238,540); LV pressure overload by surgical
banding of the aorta (transverse aortic constriction) (541–
544); and isoproterenol-induced LV hypertrophy in the
context of the D3 knock-out mouse model (64). Involvement
of thyroid-hormone signaling in right-ventricular (RV)
remodeling has been studied in rat using the model of pul-
monary arterial hypertension induced by a single injection of
monocrotaline (62, 63). The methods for inducing LV re-
modeling are used in rats and mice, but monocrotaline
cannot be used for inducing RV remodeling in mice.
& RECOMMENDATION 49
The effects of thyroid hormone on cardiac function and mor-
phology can be assessed noninvasively by ultrasound orMRI.
Commentary. Noninvasive methods are used to study the
effects of thyroid hormone on cardiac function and morphol-
ogy (540,545,546). These methods are ideally suited for longi-
tudinal analyses of individual animals. Echocardiography is
the most widely used, allowing assessment of a range of
functional heart parameters (heart rate, stroke volume, cardiac
output, fractional shortening, ejection fraction) as well as ven-
tricular volumes and wall thickness during the cardiac cycle
(540,546). Ultrasonic devices with high spatial and temporal
resolution are required to image the mouse heart accurately
because of its small size and high heart rates (i.e., > 400bpm).
With proper handling it is possible to analyze awake animals,
but echocardiography is typically done on lightly sedated an-
imals using isoflurane or tribromoethanol as anesthetics. These
compounds have minimal cardiodepressant effects, unlike
other commonly used anesthetics. Maintenance of body tem-
perature during the procedure is essential.
Certain aspects of fetal cardiac function can be assessed
using color Doppler–guided spectral Doppler ultrasound
(534). This specialized technique has been used in TR-mutant
mice to study the effects of disruption of T3 action on func-
tional cardiac development in utero (534).
When the resolution of echocardiography is insufficient to
detect effects, MRI provides superior delineation of structures
throughout the cardiac cycle with high time resolution
(546,547). The same considerations with respect to anesthesia
and temperature control apply as for ultrasound analysis.
Image collection is triggered by the electrocardiogram (ECG)
and processing of acquired images allows reconstruction of
the heart through a complete cycle. From these data, func-
tional and structural cardiac parameters can be calculated
with greater accuracy.
& RECOMMENDATION 50a
Analysis of the effects of thyroid hormone on heart rate
and blood pressure requires longitudinal analysis in free-
moving animals.
Commentary. Telemetry is required to monitor changes in
vital parameters accurately without interference from stress.
This method has been used in the analysis of thyroid-hormone
treatment of rats followingmyocardial infarction (540), in wild-
type mice (548), and in transgenic mice carrying TR mutations
(451,549). Heart rate, ECG, body temperature, arterial blood
pressure (550), and physical activity are simultaneously re-
corded by probes connected to a transmitter implanted into
the peritoneal cavity with a telemetry receiver located beneath
the cage. Continuous telemetry read out is possible for up to
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3 months. Key issues are cost and skills required to perform
surgical implantation. A telemeter pre-implantation service is
available from suppliers including The Jackson Laboratories
(http://jaxmice.jax.org/preconditioned/surgical/telemetry.html)
and Charles River (www.criver.com/products-services/basic-
research/rodent-surgery/device-implants).
& RECOMMENDATION 50b
The effects of thyroid hormone on LV contractile function
can be assessed by in vivo recording of LV pressures.
Commentary. Hemodynamic parameters are determined
in terminal experiments in anesthetized and ventilated mice
(238,551) or rats (540) by advancing a micro-tipped pressure
transducer or a combined pressure-volume catheter through
the right common carotid artery into the ascending aorta
and subsequently into the LV. The positive and negative
rates of pressure development and the systolic and end-
diastolic pressures may be used as sensitive indicators of
thyroid hormone–dependent changes in expression of con-
tractile proteins and proteins involved in intracellular cal-
cium homeostasis.
& RECOMMENDATION 51a
Analysis of the effects of thyroid hormone on cardiac con-
tractile function requires ex vivo experiments using isolated
intact hearts or tissue preparations.
Commentary. The perfused heart preparation (Langen-
dorff method) is used to analyze a wide range of cardiac
function parameters, with the advantage of being able to
control experimental conditions (e.g., stimulus frequency, cor-
onary perfusion, ventricular volume, and pressure). A fluid-
filled PVC balloon is inserted into the LV cavity and attached to
a pressure sensor and data acquisition system, allowing re-
cording and manipulation of LV pressures and volumes. The
method can be applied to assess the cardiac effects of thyroid
hormone in both rat (552–554) andmousemodels (555,556). An
additional advantage of this heart model is that it allows
analysis of the important effects of thyroid hormone on cardiac
substrate metabolism and mitochondrial function (552,556,
557). Labeled fatty acids and glucose are used to analyze oxi-
dative and glycolytic metabolism by standard techniques (3H-
labeled substrates) (552) or by NMR spectroscopy (13C-labeled
substrates) (556). This may be complemented by subsequent
tissue analysis of key metabolic enzymes and respiratory
function of isolated mitochondria (552,556).
More detailed analysis of the effects of thyroid hormone on
contractile and mechanical properties of cardiac tissue is
achieved using isolated trabeculae (558,559) or papillary mus-
cles (560). Force and shortening velocities of the electrically
stimulatedmuscles are recorded using a strain gauge. Papillary
preparations have also been used to record the effect of thyroid
hormone on electrophysiological properties (e.g., the shorten-
ing of action potential duration) (561). Thin preparations and/
or reduced temperatures are required to prevent tissue hypoxia
of the superfused preparations during repetitive stimulation
such as when determining force-frequency relationships. For
this reason small trabeculae are preferred, which are more
readily obtained from the RV than from the LV.
Right atrial preparations containing the sino-atrial node
can be used for recording isometric force and frequency of
spontaneous beating. This has been done to assess the effect of
a TRa1 mutation on the autonomic control of heart rate in
mice (549).
& RECOMMENDATION 51b
The effects of thyroid hormone on cardiac Ca2+ homeo-
stasis can be assessed in trabeculae or papillary muscles as
well as in isolated single cardiomyocytes.
Commentary. The positive inotropic and lusitropic effects
of thyroid hormone detected using trabeculae or papillary
muscles reflect changes in expression of myosin heavy chain
isoforms, as well as changes in expression of calcium-han-
dling proteins. The latter include the ryanodine Ca2+ channel,
the sarcoplasmic/endoplasmic reticulum Ca2+ -ATPase
(SERCA2a or Atp2a2) and its regulatory protein phospho-
lamban (536). The effect on beat-to-beat intracellular Ca2+
fluxes can be assessed in trabeculae or papillarymuscles using
Ca2+ indicators (560,562,563). FURA2 is the most widely used
fluorescent indicator that allows determination of intracellu-
lar free Ca2+ concentrations by a dual wavelength approach.
However, recording of Ca2+ transients with millisecond time
resolution requires sophisticated high-speed optics. Dedi-
cated setups are available for combined analysis of contractile
properties and Ca2+ fluxes (563).
The same experimental approach can be used to analyze
the effects of thyroid hormone on Ca2+ homeostasis in indi-
vidual, electrically stimulated cardiomyocytes isolated from
mouse (564) or rat hearts (565,566). Analysis of single cultured
cells has obvious advantages, but the yield of viable, rod-
shaped cardiomyocytes is variable. It is particularly low in the
case of hypothyroid hearts, creating the risk of selection bias.
& RECOMMENDATION 52a
The cardiac tissue response to thyroid hormone can be as-
sessed using histological methods and by studies of thyroid
hormone–responsive gene expression.
Commentary. The weight of the whole heart or individ-
ual ventricles should preferably be determined as a ratio to
tibia length, since body weight may vary considerably as a
function of the thyroid status. H&E staining of paraffin sec-
tions is typically used for measurement of cardiomyocyte
cross-sectional area (238,567). It should be noted that the
conditions of fixing cardiac tissue can affect cardiomyocyte
morphology and additional methods have been developed to
determine accurately myocyte cross-sectional area as well as
length (539). Masson’s trichrome staining of sections is used to
assess fibrosis in combination with cardiomyocyte morphol-
ogy (542), and the collagen volume fractionmay be quantified
by picrosirius-red staining and polarized-light microscopy
(568). Expression of T3 target genes, including Hcn2, Kcne1,
Kcnb1, Kcna1, Kcnq1, Thra, Thrb (534), Atp2a2, Myh6, Myh7
(62,238), andNppa (238), is performed by RT-qPCR onmRNA
extracted either from whole heart or from individual cham-
bers or regions (see Section I.2 for technical considerations).
Expression of major cardiac myosin heavy chain isoforms
MHCa and MHCb (i.e.,Myh6 andMyh7, respectively) can be
determined in tissue homogenates by Western blotting using
commercially available polyclonal (238) or monoclonal (542)
antibodies. IHC of T3-responsive genes is rarely done on the
assumption that all cardiomyocytes respond similarly to
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thyroid hormone or stress. However, recent studies have
shown an unexpected heterogeneity of regulated expression
of Myh7 (569,570), and this needs to be taken into account
when assessing effects of T3.
It is also important to realize that no cardiac protein is ex-
clusively regulated by thyroid hormone. The effectiveness of
T3 treatment may be apparent from changes in expression of
the above mentioned genes—in particular the reciprocal
changes in Myh6 and Myh7 expression—but changes in ex-
pression of these genes in pathological situations does not
necessarily imply altered T3 signaling. For instance, many of
the signal transduction routes involved in pathological ven-
tricular remodeling and heart failure also converge on the T3-
responsive genes, with effects opposite to those of T3. As a
result, the phenotype of the failing heart resembles that of a
hypothyroid heart, at least for a number of proteins (535).
However, assessment of tissue T3 levels (63,238) (see Section
B.2, Recommendation 8) and levels of TRs (571), or ideally,
determination of T3-dependent transcription (63,238) is re-
quired to establish changes in cardiac T3 signaling.
& RECOMMENDATION 52b
Contracting myocardium takes up plasmid DNA encoding
T3-responsive reporter genes, allowing cardiomyocyte-
specific T3-dependent transcription activity to be deter-
mined in vivo.
Commentary. Cardiomyocytes in the beating heart have
the unique capacity to take up plasmid DNA injected into the
ventricular wall. The mechanism of uptake is unknown, but
because no other cells present in the myocardium are trans-
fected, cardiomyocyte-specific regulation of fluorescent re-
porter genes can be studied in vivo. The same considerations
outlined for in vitro analysis of reporter genes apply with re-
spect to normalization and controls for off-target effects of
thyroid hormone or other interventions (see Section I).
However, analysis of T3-regulated transcription does not re-
quire co-transfection of a TR-expressing plasmid. During
thoracotomy surgery the free wall of the LV (mouse) or LV
and/or RV (rat) is injected with a small volume of plasmid
solution (Fig. 15). Typically, several thousand cardiomyocytes
are transfected, and expression lasts for several weeks. Ana-
lysis of reporter and normalization luciferase expression
(usually firefly and Renilla luciferase) is done on tissue ho-
mogenates. This methodology has been used to investigate
the T3-dependent regulation of the Myh7 promoter (572) and
to assess the T3-dependent transcriptional activity in rat and
mouse models of heart failure (63,238). Because in the latter
approach a minimal promoter containing only a T3RE as cis-
acting element is used, it yields the net result of all factors
potentially contributing to the altered T3 signaling in the
cardiomyocyte (e.g., thyroid-hormone uptake, metabolism,
and expression of TRs and cofactors).
& RECOMMENDATION 53
Primary cultures of rat and mouse cardiomyocytes, as well
as the cell line H9C2, can be used to study the effects of
thyroid hormone.
Commentary. Primary cultures of adult rat or cardio-
myocytes are obtained by Langendorff perfusion of the iso-
lated heart with a collagen-digesting solution. Rod-shaped,
viable cardiomyocytes are separated from permeabilized,
rounded cardiomyocytes and other cells and plated. The
FIG. 15. In vivo transfection of rat
cardiomyocytes by direct DNA in-
jection. The animal is anesthetized
with a mixture of N2O (0.2 L/min),
O2 (0.2 L/min), and sevoflurane (2%–
3%), and the heart is exposed
through a right-lateral thoracotomy.
The free wall of the right and/or the
left ventricle is injected three to four
times each, delivering a total of 20lg
of reporter plasmid(s)/ventricle in
100lL of saline. In this example in-
jection of the right ventricle is shown,
with the 29-gauge needle bent at the
tip at an almost right angle to allow
easy injection of the thin right ventri-
cle wall. The thorax is then closed and
the animal is sacrificed 5 days later.
Expression of luciferase reporter and
normalization genes is determined in
ventricle homogenates. Courtesy of
Dr. Warner Simonides.
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yield of viable cardiomyocytes varies, but it may be as high
as 80%. This depends primarily on the quality of the collage-
nase preparation used, and several batches of the enzyme may
need to be tested. Although primary culturesmay last formore
than 1 week, the cardiomyocytes start to gradually dediffer-
entiate from the moment of isolation. Consequently, analyses
of the effects of altered thyroid status on cell parameters, such
as recording of action potentials (573) andCa2+ transients (564–
566), as well as in vitro effects of thyroid hormone (574), are
typically done on freshly prepared cultures.
Because of the limitations of adult primary cultures, most
studies of the effects of thyroid hormone on cardiomyocytes
in vitro are performed using primary neonatal rat (541,575–
577) or mouse (578) cultures. One- to three-day-old pups are
used and cells are plated following collagenase digestion of
minced ventricles. Neonatal primary cultures show sponta-
neous and synchronous contractions and cultures can be
maintained for more than 1 week. The interaction of thyroid
hormone and contractile activity can be analyzed either by
inhibiting spontaneous contractions (576) or by electrically
stimulating the cells (575). The cell lineH9C2, derived from rat
embryonic heart tissue, is used as an alternative to primary
cardiomyocyte cultures and various aspects of thyroid-
hormone action and metabolism have been studied in H9C2
cells (579–581). Although this cell line has retained a number
of cardiomyocyte characteristics, it exhibits many of the key
properties of skeletal muscle. Notably, H9C2 myoblasts will
readily fuse to formmultinucleated myotubes and respond to
acetylcholine stimulation. Care should therefore be taken
when extrapolating data to normal cardiomyocytes.
& RECOMMENDATION 54
The effects of thyroid hormone on vascular function can be
assessed by analysis of arterial rings and cultured vascular
smooth muscle cells.
Commentary. The mechanism of thyroid hormone–
dependent reduction in systemic vascular resistance is
investigated by ex vivo determination of the vasomotor prop-
erties of rat arteries. Vascular rings are prepared from ex-
planted aortas or resistance arteries of hypothyroid, euthyroid,
or thyrotoxic rats and mounted in a myograph (582–585). The
contractile response to vasodilating or vasoconstricting agents
is recorded, allowing differentiation between changes in en-
dothelium-mediated effects and changes intrinsic to the vas-
cular smooth muscle cells (VSMCs). Primary cultures of
VSMCs are used to study the rapid effects of thyroid hormone
on VSMC relaxation (586) and the signal-transduction pro-
cesses involved (587).
[J.3] Intermediary metabolism and energy homeostasis
Background. All major metabolically relevant organs and
tissues (e.g., brain, adipose tissue, liver, and skeletal muscle)
are targeted by thyroid hormone. In most tissues, thyroid
hormone activates multiple metabolic pathways, leading to a
faster ATP turnover (ATP breakdown and synthesis) and
accelerated oxygen consumption (588,589). Energy transfer is
an inherently thermodynamically inefficient process; that is,
heat is an obligatory byproduct when energy is transferred (i)
from the oxidation of substrates into ATP and (ii) from ATP
into biological work. Thus, acceleration in ATP turnover leads
to heat production (thermogenesis), which is the accepted
pathway by which thyroid hormone activates thermogenesis.
Specifically, thyroid hormone accelerates turnover of a num-
ber of ATP-requiring ionic or substrate cycles including Na/K
ATPase, Ca ATPase, lipogenesis and lipolysis, and Cory cycle
(590). Both basal metabolic rate (i.e., energy spent to sustain
life in a resting state) and adaptive energy expenditure (e.g.,
cold-induced) are up-regulated by thyroid hormone. Direct
activation of the UCP1 gene transcription in BAT is the un-
derlying mechanism by which thyroid hormone accelerates
cold-induced thermogenesis (267,269,592); it is less clear that
thyroid hormone plays a role in diet-induced adaptive energy
expenditure (211,593). In addition to these direct actions in
energy homeostasis, thyroid hormone also acts in the CNS
(e.g., hypothalamus) influencing major homeostatic path-
ways; for example, sympathetic activity, appetite, and food
intake (594,595). Thus, studies of the metabolic effects of
thyroid hormone may also require strict control of food and
fluid intake, motor activity, respiration, and heart rate.
& RECOMMENDATION 55a
Systemic thyrotoxicosis and hypothyroidism can be mod-
eled in rats; experimental endpoints to consider include
oxygen consumption (VO2), respiratory quotient (RQ),
feeding behavior, food and water intake, and movement/
activity.
Commentary. There is an approximately fourfold accel-
eration in the rate of energy expenditure during the transition
from hypothyroidism to thyrotoxicosis in rats (596,597). VO2
is reduced to *50% once systemic hypothyroidism is
achieved (597). Administration of thyroid hormone rapidly
accelerates VO2 in euthyroid or hypothyroid rats, with sig-
nificant changes observed as soon as 18–24 hours of the ad-
ministration (597,598). A significant drop in RQ of *10% is
observed within 2 days of the administration of thyroid hor-
mone to rats (599). The administration of T3 to euthyroid rats
also results in rapid acceleration in VO2 (*60%), which starts
at 24 hours and plateaus at 7 days (600).
The energetic cost of living for the mouse is about twofold
higher than for the rat (601). Thus, substantial differences exist
between mice and rats with respect to their metabolic re-
sponsiveness to thyroid hormone. Hypothyroid mice do not
exhibit a decrease in VO2 at room temperature, only after
acclimatization at thermoneutrality (211). However, the total
daily energy expenditure is decreased in the hypothyroid
mouse acclimatized at room temperature, a parameter that
takes into account the VO2 and the RQ. The sustained total
daily energy expenditure in the hypothyroid mouse is due to
enhanced sympathetic stimulation of BAT (211,602). This in-
dicates that the reduction in thyroid hormone signaling is
compensated for by an increase in sympathetic activity, sus-
taining VO2 at room temperature (211).
Indirect calorimetry can be studied over 30–120 minutes
with reliable results (597,598,603,604). Stress might be a sig-
nificant factor in these short-term studies and care should be
taken to avoid or at least control for such a variable. In some
settings animals are anesthetized to minimize movements
and stress (597), but anesthetic agents can interfere with
thermoregulation and energy homeostasis. A state-of-the-art
methodology involves admitting mice to an integrated con-
tinuous monitoring system that can house animals for days or
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weeks at controlled temperature (Fig. 16) (232). This mini-
mizes the effects of stress in addition to allowing for acquisi-
tion of 24 hour data profiles. Another major advantage is
obtaining data points during the day (which reflect basal
metabolic rate) and night (which include acceleration of the
metabolic rate caused by feeding).
Ideally, VO2 is expressed as a function of lean body mass
determined at or around the time of indirect calorimetry. Fat
and lean body masses can be measured by destructive car-
cass composition analysis or by more recent noninvasive
imaging techniques including dual energy x-ray absorptio-
metry or quantitative MRI. These methods have been com-
pared and may yield differing results, further indicating the
importance of careful experimental design and the use of
complementary methods for analysis of metabolic pheno-
types (606,607).
FIG. 16. Use of the Comprehensive Laboratory Animal Monitoring System to perform continuous indirect calorimetry in
mice. (A) Two independent metabolic cages that are connected to a computer for recording and data analyses; (B) VO2 during
a 24 hour time period showing the nocturnal (shaded area) increase in metabolism; (C) respiratory quotient (RQ) during the
same period of time, depicting the nocturnal (shaded area) increase in RQ when animals are kept on a carbohydrate-enriched
diet; (D) dramatic increase in VO2 during 48 hours cold exposure (shaded area); (E) decreased VO2 in hypothyroid mice that
were kept on 0.1% MMI for 60 days; (F) RQ in the animals shown in (E). Courtesy of Drs. Antonio Bianco and Tatiana
Fonseca.
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Core temperature in rodents can be measured via a rectal
thermal probe connected to a digital thermometer (608).
However, state-of-the-art technology involves surgically im-
planting radio transmitters into the abdominal cavity to
monitor core temperature (609,610). Administration of anti-
thyroid drugs to rats results in rapid reduction of core tem-
perature that is evident after 3 days of treatment; by the end of
the first week of treatment, there is an approximately 0.5C
reduction in core temperature that is sustained during all day
and night (609). At the same time, rats treated with thyroid
hormone for 1 week exhibit an increase of about 1C in core
temperature as assessed with a rectal probe (611).
& RECOMMENDATION 55b
The effects of systemic hypothyroidism or thyrotoxicosis
on a particular tissue can be studied via tissue or cell iso-
lation from appropriately treated animals.
Commentary. Thyroid hormone is well known to influ-
ence the metabolic rate of intact organisms; however, the
distribution of the effect among various tissues is not as well
understood. The liver is clearly established as an important
mediator of themetabolic effects of thyroid hormone based on
a series of studies utilizing hepatocytes isolated from rats with
experimentally induced hypothyroidism or thyrotoxicosis
(612), reviewed by Harper and Brand (613). Hepatocyte oxy-
gen consumption was positively correlated with thyroid
hormone status of the animal; analysis of respiration indi-
cates that basal mitochondrial proton leak is also positively
correlated with oxygen consumption (614). At the same time,
other cellular mechanisms differ in their response to hypo-
thyroidism and thyrotoxicosis: in hypothyroid cells, non-
mitochondrial oxygen consumption decreases, whereas in
thyrotoxic cells reactions involving ATP turnover are in-
creased (613). It should be noted that because the hepatocytes
were made hypothyroid or thyrotoxic in vivo (while still part
of an intact liver in a pharmacologically treated animal), these
effects on respiration cannot be assumed to be directly related
to effects of T3 on hepatocytes but may include hepatic effects
caused by second messengers arising from extrahepatic
sources such as the sympathetic nervous system (SNS).
Historically, energy expenditure of isolated cells has been
quantified by measuring oxygen consumption using a Clark
electrode or similar apparatus (234). Alternatively, oxygen
consumption and media acidification can be measured non-
destructively in 24- or 96-well format using modern instru-
ments based on solid state fluorophore/optical sensors
(Fig. 17) (615,616).
& RECOMMENDATION 55c
To isolate the direct effects of thyroid hormone on cellular
energy expenditure andmetabolic pathways on a given cell
type, in vitro studies should be performed with thyroid
hormone treatment of cultured cells.
Commentary. Studies in which cultured cells are exposed
to varying concentrations of thyroid hormones in themedium
exclude the possibility of second messengers arising from
FIG. 17. Measuring O2 consumption and
the rate of medium acidification in cultured
cells. Extracellular flux analysis is per-
formed using XF Analyzers (Seahorse
Bioscience, Billerica, MA). Cells are plated in
monolayer 24- or 96-well format. Oxygen
consumption rate (OCR) and extracellular
acidification rate (ECAR) are measured via
chemiluminescent sensors applied to dis-
posable cartridge-based probes that are
lowered over the cells and a few microliters
of media (lower picture), creating a tran-
siently sealed micro-environment. As oxy-
gen is depleted from the media and protons
accumulate in the media, the device plots
the concentration of O2 and pH in real time
(upper picture). The OCR and ECAR are
calculated as the slopes of the O2 and pH
versus time curves. Modified with permis-
sion from a web posting by Seahorse
Bioscience; courtesy of Dr. Brian Kim.
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other tissues, and thus may reveal ‘‘direct’’ effects of thyroid
hormone on a given cell type. For example, gene expression
analysis of hepatocellular carcinoma cells (HepG2) exposed to
pharmacologic concentrations of T3 has demonstrated chan-
ges in metabolically relevant genes (617). Alternatively, pri-
mary hepatocyte cultures from rats or mice may be used for
such studies because they represent excellent models of thy-
roid hormone effects on the liver (618,619). In addition, D3
activity has been shown to be inversely correlated with oxy-
gen consumption in cultured cells, suggesting a direct effect of
T3 on energy expenditure (though T3 concentrations were not
measured in the intracellular compartment) (63).
& RECOMMENDATION 55d
Studies utilizing isolated mitochondria can be used to in-
vestigate the effects of T3 on mitochondrial biology.
Commentary. The effects of systemic, pharmacologic al-
teration of thyroid status in rats on hepatic mitochondria have
been investigated following their isolation from treated ani-
mals; mitochondrial proton leak and the respiratory chain
were identified as important sites of T3 control (620,621).
While such studies present advantages in that mitochondria
can been interrogated apart from other cellular mechanisms,
the respiratory phenotype is different from that observed in
isolated cells because the physiologic context is lost; for ex-
ample, the increase in ATP-consuming reactions induced by
thyrotoxicosis is not seen given the lack of extramitochondrial
ATP-consuming pathways (613).
& RECOMMENDATION 56a
Acute and chronic responsiveness to cold exposure (4C–
5C) can be used to study the thermogenic effects of thyroid
hormone.
Commentary. Defending core temperature during cold
exposure depends on a series of adaptive mechanisms mostly
initiated by the SNS. However, because of modifications in
the adrenergic signal transduction system, hypothyroid ani-
mals respondmuch less to catecholamines, and the opposite is
observed in thyrotoxic animals (622–624). Thus, hypothyroid
rodents exhibit profound hypothermia and succumb in a
matter of hours when exposed to cold (4C–5C) (625,626). By
2 hours of being moved to cold all rodents exhibit a transient
drop in rectal temperature (about 1C) but recover to baseline
values by 4 hours of continued cold exposure (610). In hy-
pothyroid rats and mice, rectal temperature continues to de-
crease, and to avoid the animals’ death the experiment should
be interrupted at core temperatures of about 30C.
& RECOMMENDATION 56b
BAT thermogenesis is positively regulated by thyroid
hormone and can be studied in the interscapular BAT
(iBAT) pad during infusion with adrenergic agonists in rats
or mice.
Commentary. BAT is an important site of thermogenesis
and has been used extensively as a model to study thyroid
hormone signaling and its synergism with the SNS. Heat
production in the BAT is initiated by SNS stimulation. Thus,
the ultimate assessment of BAT thermogenesis should include
measurement of BAT temperature in response to adrenergic
stimulation. This can be obtained by measuring the thermal
response of iBAT to stimulation with an adrenergic agonist
(e.g., norepinephrine) in a dose- and time-dependent fashion
(627). The setup includes surgical placement of a small
thermistor under the iBAT (Fig. 18). Due to the small body
size, mice should be kept on a thermal bed set to 30C at all
times (311). The jugular or femoral veins are cannulated and
connected to a pump and used as ports for drug infusion. A
second thermistor should be inserted in the rectum tomonitor
core temperature. iBAT thermal response can be observed
within minutes of the start of the infusion. The increase in
iBAT temperature is usually 1C–2C in the first hour and can
reach up to 4C depending on whether the animals were
previously fed a high-fat diet or chronically exposed to cold
(593). The core temperature should increase less markedly
and at later times as an indication that the BAT is warming up
the body and not the other way around. This setup allows for
direct assessment of the thyroid hormone effects in the BAT,
bypassing indirect effects. For example, the hypothyroid iBAT
is only minimally responsive to an infusion with norepi-
nephrine (627,629).
& RECOMMENDATION 57a
Studies of metabolic effects of thyroid hormone may need
to be performed under conditions of thermoneutrality; that
is, the ambient temperature at which core temperature is
maintained by obligatory thermogenesis (thermogenesis
produced by the animals at its basal metabolic rate).
Commentary. Room temperature (21C) is a significant
thermal stress for small rodents, especiallymice. Thus, even in
animals acclimatized to room temperature, the metabolic ef-
fects of thyroid hormone are influenced by a significant syn-
ergism with sympathetic activity. Acclimatization at 30C
minimizes the sympathetic activity and thus interference in
metabolism. Most sympathetic effects on metabolism are
minimized within the first 24–48 hours of acclimatization at
30C (232). However, it may take up to several weeks for a full
sympathetic shut down and investigators may need to de-
termine this experimentally depending on the parameters to
be studied (232,608). This is particularly important if the
studies involve hypothyroid or thyrotoxic animals given that
the activity of the SNS is inversely correlated with thyroid
status (630,631); it is increased during hypothyroidism and
minimized during thyrotoxicosis (632,633).
& RECOMMENDATION 57b
The use of diet-induced obesity as a model to study the
thermogenic effect of thyroid hormone must take into
account additional thyroid hormone-dependent variables;
for example, growth hormone secretion and linear
growth, appetite, sympathetic activity, and environment
temperature.
Commentary. BAT is also a main site of diet-induced
thermogenesis in small rodents, which can be triggered by
feeding a high-fat diet (634). However, contrary to cold-
induced thermogenesis, the role played by thyroid hormone
in diet-induced thermogenesis is less clear. Hypothyroid rats
or mice are not obese when kept on a chow diet (211,593),
but when they are placed on a high-fat diet, the response is
different between rats and mice and depends on the
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environmental temperature (211,593). At room temperature,
hypothyroid rats placed on a high-fat diet become just as
obese as euthyroid control rats (593), whereas mice are pro-
tected against diet-induced obesity (211). Only at thermo-
neutrality do hypothyroid mice become obese when placed
on a high-fat diet (211). For these types of studies, commer-
cially available diets are preferred for consistency and may
contain anywhere from 20% to 50% fat. Such diets contain
approximately 4.73 kcal/g in which 45% of energy is derived
from fat and can be compared to responses in mice fed a
standard diet consisting of 3.85 kcal/g inwhich 10% of energy
is derived from fat (608). In general, animals are exposed to
different dietary regimens for periods that vary between 30
and 60 days.
& RECOMMENDATION 58
Thyroid hormone–dependent metabolic processes in adi-
pose tissue can be investigated in tissue preparations, in
freshly isolated white or brown adipocytes, and in white or
brown adipocytes differentiated in vitro.
Commentary. The structural or biochemical analysis of
fat pads in hypothyroid or thyrotoxic mice or rats constitutes
a basic approach to study the effects of thyroid hormone
in adipose tissue. Thyroid hormone affects the weight of
specific fat pad deposits (e.g., epididymal, inguinal, and in-
terscapular) (635), which should always be expressed as a
function of total body weight or femoral length (464). Lipo-
genesis is stimulated by thyroid hormone in white and brown
adipose tissues (237,268,637). At the same time, thyroid hor-
mone also promotes lipolysis via amplification of the adren-
ergic signaling pathway. The net balance of these antagonistic
pathways is a reduction in adiposity, reaching *50% in 6
days (600). Although one would intuitively speculate that in
hypothyroid animals there should be an increase in adiposity,
body fat in hypothyroid rats remains unaffected (593),
whereas it is decreased in hypothyroid mice (211).
In the white adipose tissue and BAT thyroid hormone
stimulates lipogenesis and lipolysis; only in BAT does T3
stimulate thermogenesis. UCP-1 gene expression (mRNA and
protein) is the critical marker for BAT thermogenesis, and it
is highly responsive to thyroid hormone (267,269,592,638).
Other thyroid hormone–responsive pathways exist in the
adipose tissue that can be assessed by measuring the Vmax of
key rate limiting enzymes (268,269,640). Examples include
the assays of acetyl CoA carboxylase activity by an NADH-
coupled assay (237), malonyl CoA decarboxylase activity
using a carnitine acetyltransferase-linked assay (641), and the
activity of a-GPD in mitochondria preparations using a L-a-
glycerophosphate as substrate (464), although investigators
should be aware that a-GPD activity may not be thyroid
hormone dependent in all mammalian species. Lipogenesis is
particularly sensitive to thyroid hormone and can be assessed
by measuring de novo fatty acid synthesis in fat pad depots
after intraperitoneal or intravenous injection of 3H2O fol-
lowed by lipid extraction at different time points (600,642).
Isolated white or brown adipocytes prepared from colla-
genase digestion of specific fat pads can be studied in
FIG. 18. Study of the interscapular
brown adipose tissue (iBAT) thermal
response to norepinephrine (NE) infu-
sion. (A, B) A rat (or mouse) is an-
esthetized, and the iBAT pad is
exposed through a surgical incision. A
thermistor is placed under the iBAT
pad and secured with a stitch; a rectal
thermistor is inserted in the colon for
measurement of core temperature (not
shown). The right jugular vein is can-
nulated and connected to an infusion
pump for infusion of catecholamines
or other molecules. Temperatures are
measured continuously before and
during infusion. Courtesy of Dr. Mir-
iam O. Ribeiro. (C) Plasma NE levels
during infusion in intact and Tx rats;
(D) iBAT temperature during infusion
in intact and Tx rats. Infusion lasted
for 60 minutes, and the temperature
data points indicate the difference be-
tween baseline and maximum peak
achieved during infusion. Reproduced
with permission from Ribeiro et al.
(627).
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suspension for a few hours only, given that prolonged incu-
bations are hardly stable (237,622,643). An advantage of this
approach is that cellular metabolism can be studied under
defined conditions of substrate availability; for example, low/
high glucose, fatty acids, and carnitine (644). The results ob-
tained reflect the state of these cells immediately before being
harvested. Specific metabolic pathways can be studied by
measuring the Vmax of key rate-limiting enzymes under basal
conditions and in response to provocative agents such as
norepinephrine, forskolin (activating adenylate cyclase), di-
butyryl cAMP (a phosphodiesterase-resistant cAMP ana-
logue), terbutaline (b2-selective adrenergic agonist), and
dobutamine (b1-selective adrenergic agonist) (464). Examples
include measuring the rate of energy expenditure (VO2), li-
pogenesis, lipolysis, or beta-oxidation, all thyroid hormone-
sensitive pathways (237). Lipogenesis can also be studied
after a pulse with 3H2O and lipid extraction (237). Lipolysis is
also studied by measuring catecholamine-stimulated glycerol
release (645–647).
Isolated adipocytes have limited in vitro responsiveness to
thyroid hormone (237,648,649). In contrast, primary cultures
of white or brown adipocytes are responsive to thyroid hor-
mone and thus constitute an advantageous alternative system
(69,651). Obviously primary cultures of adipocytes do not
reflect the metabolic status of an animal, but they have the
advantage of generating cells that are stable and thus suitable
for prolonged experiments. Mature adipocytes are obtained
after white or brown pre-adipocytes are pushed in vitro to-
wards differentiation by exposure to different cocktails and
strategies during an 8–12 day period (652). Lines of white or
brown pre-adipocytes have also been established and used
successfully (653).
& RECOMMENDATION 59a
Simultaneous induction of lipogenesis and fatty acid oxi-
dation are important effects of thyroid hormone in the liver.
Studying expression of key rate-limiting enzymes aswell as
estimating the rates of both of these processes in animal and
cell models can be used to gauge the extent of thyroid
hormone signaling in the liver.
Commentary. With the second highest density of TRs in
the body, the liver is highly responsive to thyroid hormone
(654). Eighteen thyroid hormone–responsive proteins were
identified several years ago in the analysis of a translational
assay of hepatic mRNA of euthyroid and hypothyroid
(655). As with the fat tissue, thyroid hormone stimulates
lipogenesis in the liver by activating the expression of key
enzymes involved in the synthesis of fatty acids (596), such
as malic enzyme (656), glucose-6P-dehydrogenase (both
enzymes generatingNADPH), fatty acid synthase, and acetyl-
CoA carboxylase (657–659). At the same time, thyroid hor-
mone rapidly accelerates fatty acid oxidation in the liver (660).
There is an approximately fivefold reduction in fatty acid
oxidation in the isolated hepatocytes of hypothyroid rats. In
contrast, the administration of thyroid hormone to euthyroid
rats accelerates the rate of fatty acid oxidation (661). This ex-
plains in part the reduction in RQ seen during the transition
between hypothyroidism and thyrotoxicosis (599). However,
the net result of thyroid hormone action in liver triglycerides
tends to be neutral given the combined effects on lipolysis,
lipogenesis, and fatty acid oxidation (211).
& RECOMMENDATION 59b
Serum cholesterol levels and liver cholesterol content can
be used as biological markers of the metabolic effects of
thyroid hormone in the liver.
Commentary. Hypothyroid rats typically have high
plasma cholesterol with normal, reduced, or marginally ele-
vated triglycerides (662–665). The hypercholesterolemia is
largely caused by an increase in cholesterol concentration in
low-density lipoprotein (LDL) that results from decreased
receptor-mediated catabolism of the lipoprotein, primarily in
the liver. This is intensified by feeding rodents with a high
cholesterol diet. A widely utilized model is feeding a high-fat
diet, such as 10% corn oil containing 2% cholesterol (choles-
terol diet) or 10% corn oil, 2% cholesterol, and 0.5% cholic acid
(cholic acid diet). Hypothyroid rats kept on such diets exhibit
marked hypercholesterolemia (665) and hepatic secretion of
cholesteryl ester and apoE-rich very low density lipoprotein
and LDL (666,667). In contrast, thyrotoxic rats have reduced
cholesterol levels in association with reduced LDL turnover.
Thyroid hormone administration affects cholesterol metabo-
lism as early as 1 week after treatment (668). This has fostered
considerable interest in the potential for thyroid hormone
analogs in the treatment of hyperlipidemic disorders
(310,315,669,670).
[J.4] Skeletal muscle
Background. The contractile and metabolic properties of
skeletal muscles are determined by the properties of the dif-
ferent fiber types that make up the muscle. Groups of fibers
innervated by a single motor neuron form a motor unit. The
type of innervation and thyroid hormone are the principal
modulators of the phenotype of muscle fibers, both during
development and in the adult (671). The dynamic interaction
between these modulators, together with the developmental
origin of the fibers, results in various phenotypes ranging
from slow-twitch, oxidative fibers (Type I) to fast-twitch,
glycolytic fibers (Type IIB) (671). Skeletal muscle fibers are
typically identified by the major type of MHC that is ex-
pressed; that is, MHC I, IIa, IIx/d, and IIb (note that MHC I is
identical to cardiac MHCb, but that the other MHC isoforms
are not expressed in heart). These isoforms have increasing
catalytic turnover rates, with MHC IIb being five times faster
than MHC I, and largely determine the rate of contraction.
Multiple isoforms also exist for other key proteins that make
up the muscle fiber, such as the myosin light chains (MLCs)
and the sarcoplasmic/endoplasmic reticulum Ca2+-ATPases
SERCA2a (Atp2A2) and SERCA1a (Atp2A1). These SERCA
isoforms are responsible for the re-uptake of cytosolic Ca2+,
determining the rate of relaxation, and are typically associated
with slow (SERCA2a) or fast fibers (SERCA1a) (672). Apart
from obvious differences in mitochondrial density between
primarily oxidative and glycolytic fibers, marked qualitative
differences also exist in composition and function of the mi-
tochondria in these fibers (673).
The fiber composition of different muscles in the body
varies considerably, matching their specific tasks. Develop-
ment of slow characteristics is dependent on innervation by
slow motor neurons, whereas development of fast character-
istics is much less dependent on neural input (674). Expres-
sion of the fast phenotype is, however, co-regulated by
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thyroid hormone (671,674). For example, the postnatal ex-
pression of SERCA1a is completely dependent on thyroid
hormone (675,676) and the transition from fetal to adult fast
MHC isoforms is delayed in hypothyroidism (677–679). In the
adult animal this responsiveness of fast muscles is greatly
diminished, in contrast to slow muscles, which are highly
sensitive to changes in the thyroid status. The reason for this is
that, generally speaking, thyroid hormone opposes the effect
of slow-type innervation; that is, it stimulates expression of
fast characteristics, while suppressing slow characteristics,
and it increases the overall ATP-generating capacity of the
muscle. Fast muscle fibers are energetically less efficient and
the increase in speed induced by thyroid hormone is associ-
ated with higher energy turnover and concomitant heat pro-
duction. Because of the total mass of skeletal muscle, these
effects of thyroid hormone have an impact on whole body
substrate metabolism and thermogenesis (671).
The basis of muscle plasticity is the fairly coordinated
regulation of expression of genes governing contractile
properties and energy metabolism in response to changes in
external cues, such as use or thyroid status. Although the
overall effects of thyroid hormone on muscle physiology are
relatively straightforward, the effects on gene expression at
the level of individual muscle fibers are complex and may be
diametrically opposed, depending on the context (676,680).
For instance, expression of MHCIIa is strongly stimulated by
thyroid hormone in predominantly slowmuscles, but equally
strongly repressed in fast muscles (674,680). Furthermore,
expression of both SERCA1a and SERCA2a is transcription-
ally stimulated by T3. However, in thyrotoxic slowmuscle the
expression of SERCA2a is shut off in themajority of fibers and
replaced by SERCA1a (676), but at the same time they are co-
expressed at high levels in other fibers. This primarily reflects
subtle differences in the various motor units that make up the
muscle. Consequently, whole muscle analysis of gene expres-
sion may not provide an accurate picture of the effects of thy-
roid hormone, particularly when working with mixed fiber
typemuscles. Such studies should therefore include analyses of
tissue sections to determine effects in individual fibers.
In larger mammals, all skeletal muscles contain a variable
mix of fast and slow fibers. However, in rodents some hind
limb muscles are primarily composed of slow type I and in-
termediate type IIA fibers, such as the slow-twitch soleus
(SOL) muscle, or fast type IIB fibers, such as the fast-twitch
extensor digitorum longus (EDL) muscle (681,682). These
muscle are therefore often used as models to study the effects
of thyroid hormone on slow and fast muscle properties.
& RECOMMENDATION 60
The effects of thyroid hormone on muscle energy metabo-
lism and contractile properties can be assessed by analysis
of perfused hind limb preparations.
Commentary. In the pump-perfused muscle model a
single hind limb of the rat is perfused following catheteriza-
tion of the femoral artery and vein (683). Contraction of a
group of muscles or a single muscle is triggered either by
stimulating the innervating nerve or by using electrodes
placed on the muscle. Contraction parameters are recorded
using a force-transducer connected to the Achilles tendon.
Control of the rate and composition of the perfusion medium
allows manipulation of substrate and oxygen delivery. Ana-
lysis of the venous perfusate yields information on the met-
abolic response during different stimulus protocols and
allows calculation of the efficiency of contraction. Blood flow
distribution over the various perfused muscles can be deter-
mined using radiolabeled microspheres, and histochemical
and biochemical analyses can complement the analyses of
muscle function (684). Although there are some limitations,
notably the absence of normal vasomotor regulation (683),
this model best approximates the in vivo situation of active
skeletal muscles and has been used to study the functional
and metabolic consequences of thyrotoxicosis (685) and hy-
pothyroidism (684,686). This methodology has so far not been
described for mouse models.
& RECOMMENDATION 61
The interaction between thyroid hormone and neuromus-
cular activity in regulating muscle properties can be stud-
ied in vivo by direct electrical stimulation of muscles.
Commentary. Slow-twitch muscles like the SOL muscle
are typically activated by motor neurons generating long
trains of low-frequency impulses, whereas fast-twitch mus-
cles are activated intermittently by short bursts of high
frequency impulses. The counteracting effects of thyroid hor-
mone and slow-type innervation on muscle gene expression
(674) can be studied by imposing a chronic low-frequency
stimulation pattern on fast-twitch hind limb muscles. In this
model the peroneal nerve of the hind limb is continuously
stimulated in vivo at 10Hz for up to 20 days through implanted
electrodes. Gene expression and fiber type composition of fast-
twitch tibialis anterior and EDL muscles from the stimulated
and contralateral hind limb can then be compared. This
method has been used to assess the combined effects of thyroid
hormone and slow-type innervation on the expression of
myogenic regulatory factors (687) and MHC isoforms (688).
& RECOMMENDATION 62
The effects of thyroid hormone on contractile properties
can be assessed by ex vivo analysis of intact muscles and
isolated muscle fibers.
Commentary. Detailed analysis of the contractile prop-
erties of rat and mouse skeletal muscles requires ex vivo ana-
lyses. The slow-twitch SOL muscle has typically been used in
studies involving thyroid hormone (689–692) because of the
greater responsiveness when compared to the fast-twitch EDL
(693). Although contractile properties can be recorded with
the muscle left in situ, analysis of isolated muscles in a stim-
ulation chamber allows for greater experimental flexibility
(690). The EDL and SOL muscles are relatively thin and su-
perfusion provides sufficient delivery of oxygen and sub-
strates, although reduced temperatures (21C–30C) may be
required to prevent hypoxia during prolonged stimulation.
Contralateral muscles are kept in oxygenated superfusion
medium to serve as controls in subsequent biochemical ana-
lyses. Typical parameters analyzed include twitch and tetanic
contractile response, force-frequency relationships, post-rest
potentiation of force development, and fatigue-recovery re-
sponses. Dedicated equipment and software is now available
for these kinds of analyses (694).
Although technically challenging, single muscle fibers can
be isolated from skeletal muscles such as the SOL and EDL
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muscles (692,695) and the diaphragm (696). In the latter,
thyroid hormone also induces a shift in fiber phenotype type
from slow to fast (697) and ex vivo analysis of the contractile
properties of this muscle requires single fibers or bundles of
fibers (698). Isolated fibers are chemically skinned and
mounted between a force transducer and a motor, allowing
measurement of isometric and isotonic contractions. Con-
traction or relaxation is achieved by immersion of the fibers in
solutions containing high or low concentrations of calcium,
respectively. Subsequent single-fiber analysis of contractile
protein composition allows for a detailed assessment of the
effects of thyroid hormone on fiber phenotype and contractile
properties (692).
& RECOMMENDATION 63
The skeletal muscle tissue response to thyroid hormone can
be assessed by analysis of gene expression and enzyme
assays.
Commentary. Analysis of muscle gene expression is
performed by RT-qPCR (92,699,700) (see Section I.2,
Recommendation 35 for technical considerations) and by
analysis of protein levels using polyacrylamide gel electro-
phoresis, followed by quantification of stained bands or Wes-
tern blot analysis where appropriate. The MHC isoforms, as
well as the MLC isoforms, can be separated by high-resolution
gel electrophoresis. Silver staining and subsequent densito-
metric analysis allows accurate determination of the relative
expression levels of the various isoforms in samples as small
as single fibers (679,692,699,701,702). Antibodies forWestern
analysis are available for a large number of skeletal muscle
proteins encoded by genes which are directly or indirectly
regulated by thyroid hormone, including MyoD, myogenin,
MHC isoforms, SERCA1a, SERCA2a, myoglobin, PGC-1a,
RYR, and Na+-K+-ATPase subunits (92,691,701,703,704).
The sarcoplasmic reticulum (SR) is responsible for up to
50% of the energy consumption in active muscle. The effect of
thyroid hormone on this ATPase activity can be assessed
spectrophotometrically in homogenates of whole muscles or
single fibers (701,705). SR membrane fragments in muscle
homogenates reseal into vesicles that retain the ability to take
up and store Ca2 + . Using assay conditions that selectively
stimulate this capacity, it is possible to determine the ATPase-
coupled Ca2 + -uptake rate and maximal Ca2 + -storage capac-
ity (675,704,705). The latter provides an estimate of the degree
of proliferation of the SR membrane network, which is in part
dependent on the thyroid status. The Ca2 + -ATPase and Ca2 + -
uptake assays determine the total SERCA activities, but do
not allow discrimination between the SERCA1a and SER-
CA2a isoforms.
Standard assays are used to determine activities of en-
zymes involved in aerobic and anaerobic energy metabolism
such as cytochrome c oxidase, citrate synthase, succinate de-
hydrogenase, lactate dehydrogenase, and creatine kinase
(675,703). Mitochondria can be isolated by differential cen-
trifugation for measurements of respiratory rate, membrane
potential and other enzymatic assays (706,707).
& RECOMMENDATION 64
Assessment of the effects of thyroid hormone on the fiber
type composition of skeletal muscle requires histochemical
analysis of tissue sections.
Commentary. Skeletal muscle fiber types are primarily
distinguished on the basis of the MHC isoform expressed; i.e.,
the slow MHC I and fast MHC IIa, IIx/d, or IIb isoforms.
Antibodies discriminating between these isoforms have been
described (708) and although some caution is warranted
when using currently available commercial antibodies (709),
multicolor immunofluorescence analysis has been described
for the simultaneous assessment of expression of all
MHC isoforms in rat and mouse skeletal muscle using these
antibodies (710). More typically, a histochemical method
for myofibrillar ATPase expression is widely used which
distinguishes between Type I fibers (MHC I), Type IIB fibers
(MHC IIb), and intermediate fibers (MHC IIa, MHC IIx/d)
(684,692,700,702,711). Muscles are clamped at their approxi-
mate in situ length and frozen in liquid N2-cooled freon or
isopentane. Series of cryosections are then cut for various
histochemical analyses. It should be noted that not all fibers
necessarily run the length of the muscle. This is for example
the case in SOL muscle, which should preferably be sectioned
at the motor point to include all fibers (682,702).
Additional analyses of fiber-specific gene expression con-
cern the expression and activity of the SR Ca2 + -ATPase
enzymes. Serial cryosections can be used to correlate MHC-
based fiber typing with immunohistochemistry of SERCA1a
and SERCA2a (676,682), as well as with isoform-specific
mRNAs by in situ hybridization (676). Fiber-specific differ-
ences in total SR Ca2 + -ATPase activity can also be determined
histochemically (676). The effects of thyroid-hormone treat-
ment on fiber characteristics are dynamic and in some cases
transient over a period of several days (676). This should be
taken into account when studying animals treated for less
than 14 days.
& RECOMMENDATION 65
Primary cultures of skeletal muscle cells as well as various
cell lines can be used to study thyroid hormone–regulated
gene expression and its interactionwith contractile activity.
Commentary. Primary cultures of muscle myoblasts can
be obtained from neonatal rat or mouse skeletal muscles
(92,712–715). Depending on the composition of the culture
medium, myoblasts can be maintained in a proliferative
state, or they can be induced to fuse and form spontane-
ously contracting myotubes. The interaction of thyroid
hormones and contractile activity on myotube properties
can be studied by inhibiting contractions (715) or by direct
electrical stimulation of the myotubes in culture (712). Al-
though primary cultures provide a versatile model to study
different aspects of muscle gene regulation, it should be
noted that myotubes do not fully develop adult phenotypic
characteristics.
The mouse C2C12 (704,716–718) and the rat L6 (704,717,
719–721) myoblast cell lines are used as alternatives for pri-
mary cultures in studies of thyroid-hormone action. Standard
techniques for cell transfection can be used to analyze regu-
lation of gene-expression (see Section I.4). Subclones of the L6
cell line with slightly different properties have been isolated
by various groups (704,721). Notably, the L6AM subclone (721)
shows increased responsiveness to thyroid hormone in com-
parison to the original L6 cell line. Similar to primary cultures,
confluent myoblast cultures of both cell lines can be induced
to form myotubes, but only C2C12 myotubes can be induced
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to contract by electrical stimulation. Methods have been de-
veloped to stimulate C2C12 myotubes chronically or inter-
mittently for up to 4 days using stimulus electrodes integrated
in standard culture dishes (718,723). This technique allows a
more detailed analysis of the interaction between thyroid
hormone and contractile activity on muscle gene expression
(718).
[J.5] Skeleton
Background. Bone strength in adults is determined by
the acquisition of bone mass and mineral during growth and
the subsequent rate of bone loss throughout adulthood.
Normal euthyroid status is essential for skeletal develop-
ment, growth, and mineralization and is a key determinant
of peak bone mass. T3 also regulates bone remodeling in
adults, and thyroid status is an important determinant of the
rate of bone loss (724). Hypothyroidism results in a state of
reduced bone turnover, which if prolonged may result in to
accumulation of bone mass and mineral. By contrast, thy-
rotoxicosis accelerates bone turnover and loss resulting in
osteoporosis.
& RECOMMENDATION 66
Thyroid hormones effects on postnatal linear growth and
bone maturation are best determined ex vivo by using
samples from animals harvested at defined ages.
Commentary. Mice should be genotyped and identified
at young postnatal ages while preserving their tail so that
linear growth velocity can be determined by weekly mea-
surement of tail length between postnatal days P7 to P70.
Maximum growth velocity occurs between P14 and P42 in
mice, and comparison of growth curves provides an accurate
indication of developmental delay. Neonatal P1 mice and
limbs from animals aged between P21 and P42 should be
stained with alizarin red (bone) and alcian blue (cartilage)
to investigate intrauterine skeletal development and the
progress of postnatal bone formation. Measurement of skull
dimensions, fontanelles, and suture areas provide an assess-
ment of intramembranous ossification; measures of bone
length and growth plate histomorphometry are accurate and
sensitive indicators of the progression of endochondral ossi-
fication (725–731).
& RECOMMENDATION 67
The structural andmineralization response of adult bone to
alterations in thyroid status or disruption of thyroid hor-
mone action can be assessed using complementary imaging
techniques at different levels of resolution.
Commentary. Analysis of the skeleton in mice requires
collection of bone samples ex vivo. It is not possible to de-
termine structural parameters accurately in vivo because
imaging modalities do not have sufficient resolution to dis-
criminate features of trabecular bone accurately and much
more information can be obtained from ex vivo samples using
complementary approaches and methods (Fig. 19). Bone
mineral content, bone length, and cortical bone measure-
ments are determined in long bones and vertebrae from
adults aged 12 weeks onwards by Faxitron digital point
projection x-ray microradiography (725). Bone micro-
architecture and volumetric parameters require sophisti-
cated imaging and can be obtained by high resolution micro-
CT (to a maximum nominal resolution of 0.5–2 lm). Cortical
and trabecular bone volumes as proportions of tissue vol-
ume, trabecular thickness, trabecular separation, and tra-
becular number can be determined. Such parameters in the
mouse are at the limits of spatial resolution by micro-CT.
Detailed analysis of bone microarchitecture and micro-
mineralization density can be analyzed using specialist back
scattered electron-scanning electron microscopy (BSE-SEM)
techniques (725–727,729–731). The effects of altered thyroid
status on linear growth and bone structural parameters are
significant and readily determined using these methods, al-
though specialist equipment and data analysis methods are
required.
& RECOMMENDATION 68
The thyroid hormone–induced changes in bone structure
and mineralization are reflected by functional abnormali-
ties, which can be investigated by determination of bio-
mechanical properties under loading.
Commentary. The strength of bone is determined using
appropriate mechanical loading equipment (Fig. 20). Destruc-
tive three-point bend tests are performed on long bones from
adult mice to determine cortical bone biomechanical variables
from load displacement curves, including stiffness, maximum
load, fracture load, and energies dissipated at maximum load
and fracture. Trabecular bone compression strength can be
determined similarly in vertebrae. Cross-sectional area mea-
surements are obtained from Faxitron and micro-CT data and
usedwith biomechanical data to calculate ultimate stress, yield
stress, and modulus parameters (725). More detailed and spe-
cialist studies of material properties of bone at various resolu-
tion scales can be obtained using highly sophisticated
techniques and equipment in collaboration with engineering
and other specialist laboratories (732–734). Suchmeasurements
provide accurate determination of bone strength together with
assessment of its material properties (brittleness or ductility)
that are affected significantly, for example, by loss of bonemass
and mineral content in thyrotoxicosis.
& RECOMMENDATION 69a
Metabolic responses and changes in bone resorption and
formation in response to altered thyroid status can be as-
sessed indirectly by measurement of serum parameters.
Commentary. Biochemical analysis of mineral metabo-
lism and bone turnover should include measurement of
serum Ca2 + , Mg2 + , PO4
3 - , and alkaline phosphatase,
which can be determined using standard auto-analyzers. In
addition to determination of thyroid status, other hormones
affecting bone can be assayed using commercial assays,
including corticosterone, vitamin D, parathyroid hormone,
and insulin-like growth factor-1. In addition, sex hormone
and gonadotropin status can be determined if required
(735). Indirect analysis of bone turnover can be obtained by
measurement of bone resorption and formation markers
using commercially available kits (725). C-terminal cross-
linked telopeptide of type I collagen and tartrate-resistant
acid phosphatase (TRAcP) 5b are measured by ELISA and
solid-phase immuno-fixed enzyme activity assay as
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indicators of bone resorption. N-terminal propeptide of
type 1 procollagen and osteocalcin are also measured by
ELISA and IRMA as markers of bone formation. Assess-
ment of bone turnover markers should ideally be per-
formed ideally in the morning on fasted animals to mitigate
the confounding diurnal and dietary effects on bone turn-
over. Older rodents have low levels of bone turnover in the
basal state and determination cannot be performed reliably
after about 12–16 weeks of age as levels of markers will be
close to the limits of detection. It is important to note there
are sex- and strain-specific differences in bone mass and
turnover and care in experimental design should be taken
to ensure littermates are compared where possible. Never-
theless, measurement of bone turnover using surrogate
bone markers is an established method in the field that
provides additional information to support imaging and
histomorphometry data.
& RECOMMENDATION 69b
The effects of thyroid hormone on bone turnover might in-
volve effects on osteoclastic bone resorption, osteoblastic bone
formation, or a combination of both. Biochemical analysis of
markers of bone turnover in response to thyroid hormone
provides indirect crude assessment of these parameters, but
this must also be investigated directly in the bone tissue.
Commentary. Hypothyroidism results in reduced bone
turnover affecting both bone formation and resorption.
FIG. 20. Instron5534 load frame apparatus for destructive
three-point bend testing of bone strength. Custom mounts
incorporate rounded supports and loading pins that mini-
mize cutting and shear forces, thus enabling biomechanical
parameters of bone strength to be determined accurately.
Courtesy of Dr. Graham Williams.
FIG. 19. Scheme for collection of bone samples, tissue fixation, and methods of analysis. The usage of this chart can
maximize phenotype information obtained from juvenile and adult mice. qBSE-SEM, quantitative back-scattered electron-
scanning electron microscopy. Courtesy of Dr. Graham Williams.
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Thyrotoxicosis accelerates both parameters with a greater
effect on bone resorption resulting in bone loss. To inves-
tigate and quantify the cellular basis for altered bone
turnover, dynamic measurements by histomorphometry
are required. Mice are given two intraperitoneal injections
of the fluorochrome calcein (15mg/kg in saline with 2%
sodium bicarbonate) approximately 7 and 4 days prior to
sacrifice, although the precise interval can be varied and
should be determined empirically depending on the locally
available analysis techniques. Dynamic bone histomor-
phometry parameters should be determined according to
the standard system of nomenclature (736). Bone resorp-
tion is investigated in bone sections stained for TRAcP,
and osteoclast numbers and surface determined by light
microscopy and normalized to total bone surface. Cortical
and trabecular bone resorption surfaces in vivo can also
be determined using specialized BSE-SEM techniques
(725,727,729), although such methods are not routinely or
widely available. Bone formation should be quantified
in dual calcein-labeled bone by standard histomorpho-
metry and indices of bone formation determined using
ImageJ (http://rsbweb.nih.gov/ij) according to the Amer-
ican Society for Bone and Mineral Research standard sys-
tem of nomenclature (736). Alternative high resolution
methods using confocal microscopy can be performed in
specialist laboratories (725,737). Gene expression studies
can be performed in paraffin-embedded decalcified sec-
tions of bone and cartilage (in situ hybridization and IHC),
using RNA extracted from tissue samples (mRNA expres-
sion and profiling) and in skeletal tissue extracts (protein
expression and enzyme activity assays) (726,727,729–
731,738–740).
& RECOMMENDATION 70a
Themechanisms of thyroid hormone action in cartilage can
be studied in chondrocyte cultures prepared from limbs or
rib cages of neonatal mice.
Commentary. Bone is a complex organ and the cellular
responses to thyroid hormone can be determined by in vivo
and tissue studies. A deeper understanding of the molec-
ular mechanisms of T3 action and the signaling pathways
involved in mediating T3 responses in bone cell lineages can
be obtained by studying thyroid hormone effects in pri-
mary cell cultures of skeletal cells. Primary chondrocytes
are prepared from neonatal mice (741,742) and prolifera-
tion, differentiation (collagen X mRNA expression, alkaline
phosphatase activity, alcian blue staining), apoptosis, and
gene expression responses (Ihh, PTHrP, Sox9 by RT-qPCR)
to T3 treatment determined after 7, 14, and 28 days. It
should be noted that chondrocytes are difficult to study
in vitro because they tend to de-differentiate and acquire a
fibroblast-like phenotype in monolayer culture after a few
days. This does not pose a problem for gene expression
studies if investigation of acute responses to T3 treatment is
limited to analysis of freshly cultured cells within the first
48 hours. However, in studies to investigate effects of thy-
roid hormone on chondrogenesis and cell proliferation over
longer periods of time as already indicated, 3D cultures
should be performed in agarose suspension to prevent the
tendency for de-differentiation of chondrocytes when cul-
tured for prolonged periods in monolayers (653).
& RECOMMENDATION 70b
Osteoblast cultures can be employed to investigate the
mechanisms of thyroid hormone action on cell differenti-
ation, as well as on functional bone mineralization assays
in vitro. Such cultures are usually prepared by collagenase
digestion of calvariae obtained from neonatal mice using
standard techniques.
Commentary. Osteoblasts express TRs and, like chon-
drocytes, respond directly to the actions of T3. Primary
calvarial osteoblasts are prepared from P4 pups and prolif-
eration, differentiation (osteocalcin and osterix mRNA ex-
pression, alkaline phosphatase activity, alizarin red and von
Kossa mineralization assays), and gene expression (Runx-2,
OPG, receptor activator of nuclear factor kappa B-ligand
[RANKL] by RT-qPCR) responses are usually determined
after 7, 14, and 28 days (738–740,743).
& RECOMMENDATION 70c
The effects of thyroid hormone on osteoclastogenesis and
function can be determined in osteoclast cultures prepared
from 6-week-old mouse long bones. The protocols used
include treating extracted bone marrow cells with mono-
cyte colony stimulating factor and RANKL to induce os-
teoclast formation in vitro.
Commentary. Bone marrow is isolated from long bones of
P42 mice and primary cultures treated with monocyte colony
stimulating factor and RANKL to induce osteoclast formation
in vitro (725,729,740). Osteoclast numbers (following TRAP
staining) and cell differentiation (TRAP activity, calcitonin re-
ceptor, cathepsin K mRNA expression) are determined after
days 0, 3, 6, and 9 days. Osteoclast activity can also be deter-
mined by dentine resorption assay using standard techniques
employed previously in studies of T3 action (725,729). The
mechanism of thyroid hormone action on osteoclast function is
currently unclear, and it is uncertain whether the major re-
sponse to increase osteoclastic bone resorption represents a
direct effect of T3 in osteoclasts or whether the response is a
secondary effect mediated via the actions of T3 in osteoblasts,
bone marrow stromal cells, or other factors.
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Abbreviations Used
2D¼ two-dimensional
3D¼ three-dimensional
5¢D¼ 5¢-deiodination
5D¼ 5-deiodination
ATA¼American Thyroid Association
BAT¼ brown adipose tissue
BSA¼ bovine serum albumin
BSE-SEM¼ back scattered electron-scanning electron
microscopy
bTSH¼ bovine TSH
Abbreviations Used (Cont.)
BW¼ body weight
CAR¼ constitutive androstane receptor
ChIP¼ chromatin immunoprecipitation
CNS¼ central nervous system
CT¼ computerized tomography
Ct¼ critical threshold
D1¼ type I deiodinase
D2¼ type II deiodinase
D3¼ type III deiodinase
DITPA¼ 3,5-diiodothyropropionic acid
DTT¼dithiothreitol
DUOX2¼dual oxidase 2
ECG¼ electrocardiogram
EDL¼ extensor digitorum longus
EDTA¼ ethylenediaminetetraacetic acid
ELISA¼ enzyme-linked immunosorbent assay
EMSA¼ electromobility shift assays
EYFP¼ enhanced yellow fluorescent protein
FBS¼ fetal bovine serum
FT3I¼ free T3 index
FT4I¼ free T4 index
GFP¼ green fluorescent protein
GPD¼ glycerophosphate dehydrogenase
H&E¼hematoxylin and eosin
HFUS¼high frequency ultrasound
HPLC¼high performance liquid chromatography
HPT¼hypothalamus-pituitary-thyroid axis
iBAT¼ interscapular BAT
ICV¼ intra-cerebro-ventricular
IHC¼ immunohistochemistry
IRMA¼ immune radiometric assay
KClO4¼potassium perchlorate
KO¼ knock-out
LDL¼ low-density lipoprotein
LID¼ low-iodine diet
LPS¼ lipopolysaccharide
L-T4¼ levothyroxine
LV¼ left ventricle (ventricular)
MCT¼monocarboxylate transporter
MHC¼myosin heavy chain
MLC¼myosin light chain
MMI¼methimazole
MRI¼magnetic resonance imaging
NaClO4¼ sodium perchlorate
NIS¼ sodium iodine symporter
NTI¼nonthyroidal illness
OATP¼ organic anion transporting polypeptide
PAPS¼ 3¢-phosphoadenosine-5¢-phosphosulfate
PBS¼phosphate-buffered saline
PCR¼polymerase chain reaction
PET¼positron emission tomography
PTU¼ 6-n-propyl-2-thiouracil
PXR¼pregnane X receptor
RAIU¼ radioactive iodide uptake
RANKL¼ receptor activator of nuclear factor
kappa B-ligand
rhTSH¼ recombinant human TSH
RIA¼ radioimmunoassay
RNAseq¼RNA sequences
RQ¼ respiratory quotient
rT3¼ 3,3¢,5¢-triiodothyronine
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Abbreviations Used (Cont.)
RT-qPCR¼ reverse transcriptase quantitative PCR
RV¼ right ventricle (ventricular)
SR¼ sarcoplasmic reticulum
SERCA1 and 2¼ sarcoplasmic/endoplasmic reticulum
Ca + +ATPase 1 and 2
SIMS¼ secondary ion mass spectrometry
SLC26A4/PDS¼pendrin
SNS¼ sympathetic nervous system
SOL¼ soleus
SPECT¼ single photon emission computed
tomography
SR¼ sarcoplasmic reticulum
SULT¼ sulfotranferase
T2¼ 3,3¢-diiodothyronine
T3¼ 3,3¢,5-triiodothyronine
T3RE¼T3 responsive element
T3S¼T3 sulfate
T4¼ thyroxine
TBG¼ thyroxine binding globulin
Abbreviations Used (Cont.)
TCA¼ trichloroacetic acid
T/ebp¼ thyroid-specific enhancer-binding
protein
Tetrac¼ tetraiodothyroacetic acid
Tm¼ equilibrium time point
TR¼ thyroid hormone receptor
TRAcP¼ tartrate-resistant acid phosphatase
TRH¼ thyrotropin releasing hormone
TRIAC¼ tiratricol (3,5,3¢-triiodothyroacetic acid)
Tris-HCl¼ 2-amino-2-hydroxymethyl-1,
3-propanediol hydrochloride
TSH¼ thyrotropin
TSHR¼TSH receptor
UDPGA¼UDP-glucuronic acid
UGT¼UDP-glucuronyltransferase
UPLC¼ultrahigh performance liquid
chromatography
VO2¼ oxygen consumption
VSMC¼vascular smooth muscle cell
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